<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004289.pub5" GROUP_ID="RENAL" ID="069202111212583074" MERGED_FROM="" MODIFIED="2014-05-12 05:47:13 +0100" MODIFIED_BY="Narelle Willis" REVIEW_NO="083" REVMAN_SUB_VERSION="5.2.11 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2014-05-12 14:46:07 +1000" MODIFIED_BY="[Empty name]">
<TITLE>HMG CoA reductase inhibitors (statins) for dialysis patients</TITLE>
<CONTACT>
<PERSON ID="16154" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Giovanni</FIRST_NAME>
<MIDDLE_INITIALS>FM</MIDDLE_INITIALS>
<LAST_NAME>Strippoli</LAST_NAME>
<SUFFIX/>
<POSITION>Editor and Regional Coordinator</POSITION>
<EMAIL_1>strippoli@negrisud.it</EMAIL_1>
<EMAIL_2>gfmstrippoli@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Renal Group, Centre for Kidney Research</DEPARTMENT>
<ORGANISATION>The Children's Hospital at Westmead</ORGANISATION>
<ADDRESS_1>Locked Bag 4001</ADDRESS_1>
<ADDRESS_2/>
<CITY>Westmead</CITY>
<ZIP>2145</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+39 080 5580776</PHONE_1>
<PHONE_2>+39 349 5705884</PHONE_2>
<FAX_1>+39 080 5580776</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2014-05-12 14:45:36 +1000" MODIFIED_BY="Narelle Willis">
<PERSON ID="19787" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Suetonia</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Palmer</LAST_NAME>
<SUFFIX>MBChB</SUFFIX>
<POSITION/>
<EMAIL_1>suetonia.palmer@otago.ac.nz</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine</DEPARTMENT>
<ORGANISATION>University of Otago Christchurch</ORGANISATION>
<ADDRESS_1>2 Riccarton Ave</ADDRESS_1>
<ADDRESS_2>PO Box 4345</ADDRESS_2>
<CITY>Christchurch</CITY>
<ZIP>8140</ZIP>
<REGION/>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<PHONE_1>+64 21626008</PHONE_1>
<PHONE_2/>
<FAX_1>+64 3 3253368</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16132" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Sankar</FIRST_NAME>
<MIDDLE_INITIALS>D</MIDDLE_INITIALS>
<LAST_NAME>Navaneethan</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>navanes@ccf.org</EMAIL_1>
<EMAIL_2>sankardass@hotmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Nephrology and Hypertension</DEPARTMENT>
<ORGANISATION>Glickman Urological and Kidney Institute, Cleveland Clinic</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Cleveland</CITY>
<ZIP>44195</ZIP>
<REGION>OH</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 216 6369230</PHONE_1>
<PHONE_2/>
<FAX_1>+1 216 4449378</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="4552" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Jonathan</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Craig</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>jonathan.craig@sydney.edu.au</EMAIL_1>
<EMAIL_2>JonC@health.usyd.edu.au</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Sydney School of Public Health</DEPARTMENT>
<ORGANISATION>The University of Sydney</ORGANISATION>
<ADDRESS_1>Edward Ford Building A27</ADDRESS_1>
<ADDRESS_2/>
<CITY>Sydney</CITY>
<ZIP>2006</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16113" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>David</FIRST_NAME>
<MIDDLE_INITIALS>W</MIDDLE_INITIALS>
<LAST_NAME>Johnson</LAST_NAME>
<SUFFIX/>
<POSITION>Nephrologist</POSITION>
<EMAIL_1>david_johnson@health.qld.gov.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Nephrology</DEPARTMENT>
<ORGANISATION>Princess Alexandra Hospital</ORGANISATION>
<ADDRESS_1>Ipswich Rd</ADDRESS_1>
<ADDRESS_2/>
<CITY>Woolloongabba</CITY>
<ZIP>4102</ZIP>
<REGION>Queensland</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 7 3240 5080</PHONE_1>
<PHONE_2/>
<FAX_1>+61 7 3240 5480</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19789" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Vlado</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Perkovic</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>vperkovic@georgeinstitute.org.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Renal and Metabolic Division</DEPARTMENT>
<ORGANISATION>The George Institute for Global Health</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Camperdown</CITY>
<ZIP/>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 2 99934551</PHONE_1>
<PHONE_2/>
<FAX_1>+61 2 99934502</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="60A7CD7482E26AA20029B8549EA567DA" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Sagar</FIRST_NAME>
<MIDDLE_INITIALS>U</MIDDLE_INITIALS>
<LAST_NAME>Nigwekar</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION/>
<EMAIL_1>sagarnigs@gmail.com</EMAIL_1>
<EMAIL_2>snigwekar@partners.org</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Brigham and Women's Hospital, Massachusetts General Hospital, Scholars in Clinical Sciences Program</DEPARTMENT>
<ORGANISATION>Harvard Medical School</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Boston</CITY>
<ZIP/>
<REGION>MA</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="50537534288058682062110419044257" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Jorgen</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Hegbrant</LAST_NAME>
<SUFFIX/>
<POSITION>Chief Medical Officer</POSITION>
<EMAIL_1>Jorgen.Hegbrant@diaverum.com</EMAIL_1>
<EMAIL_2>rs07@diaverum.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Medical Office</DEPARTMENT>
<ORGANISATION>Diaverum Renal Services Group</ORGANISATION>
<ADDRESS_1>PO Box 4167</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lund</CITY>
<ZIP>SE-227 22</ZIP>
<REGION/>
<COUNTRY CODE="SE">Sweden</COUNTRY>
<PHONE_1>+46 708 11 93 44</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16154" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Giovanni</FIRST_NAME>
<MIDDLE_INITIALS>FM</MIDDLE_INITIALS>
<LAST_NAME>Strippoli</LAST_NAME>
<SUFFIX/>
<POSITION>Editor and Regional Coordinator</POSITION>
<EMAIL_1>strippoli@negrisud.it</EMAIL_1>
<EMAIL_2>gfmstrippoli@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Renal Group, Centre for Kidney Research</DEPARTMENT>
<ORGANISATION>The Children's Hospital at Westmead</ORGANISATION>
<ADDRESS_1>Locked Bag 4001</ADDRESS_1>
<ADDRESS_2/>
<CITY>Westmead</CITY>
<ZIP>2145</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+39 080 5580776</PHONE_1>
<PHONE_2>+39 349 5705884</PHONE_2>
<FAX_1>+39 080 5580776</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2013-11-26 10:25:42 +1100" MODIFIED_BY="Sagar Nigwekar">
<UP_TO_DATE>
<DATE DAY="29" MONTH="2" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="29" MONTH="2" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="29" MONTH="11" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="9" YEAR="2013"/>
</DATES>
<WHATS_NEW MODIFIED="2014-05-12 14:46:07 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-05-12 14:42:49 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="5" YEAR="2014"/>
<DESCRIPTION>
<P>Minor copy edit made to study names</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-05-12 14:46:07 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2014-05-12 14:46:07 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="7" YEAR="2013"/>
<DESCRIPTION>
<P>14 new studies have been included</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-05-12 14:46:04 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="11" MONTH="5" YEAR="2012"/>
<DESCRIPTION>
<P>Author added: Jorgen Hegbrandt; Suetonia Palmer</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-05-12 14:46:01 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="3" YEAR="2012"/>
<DESCRIPTION>
<P>Updated search to February 2012. Ten new trials added including AURORA and SHARP. Results and conclusions updated. Conclusions generally unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2013-05-22 08:30:07 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="1" YEAR="2009"/>
<DESCRIPTION>
<P>New studies included, additional outcomes now available.</P>
<P>New authors for this update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-07-01 16:01:17 +1000" MODIFIED_BY="Narelle S Willis">
<DATE DAY="1" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2012-03-01 12:19:09 +1100" MODIFIED_BY="Suetonia Palmer">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2012-03-01 12:19:09 +1100" MODIFIED_BY="Suetonia Palmer">
<SOURCE MODIFIED="2012-03-01 12:19:09 +1100" MODIFIED_BY="Suetonia Palmer">
<NAME>SP receives a Fellowship from the Consorzio Mario Negri Sud from an unrestricted grant from Amgen Dompe</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-05-07 11:10:10 +1000" MODIFIED_BY="Gail Y Higgins">
<SUMMARY MODIFIED="2013-07-30 18:34:59 +1000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2013-05-09 16:36:18 +1000" MODIFIED_BY="[Empty name]">Does statin therapy improve survival or reduce risk of heart disease in people on dialysis?</TITLE>
<SUMMARY_BODY MODIFIED="2013-07-30 18:34:59 +1000" MODIFIED_BY="[Empty name]">
<P>Adults with severe kidney disease who are treated with dialysis have high risks of developing heart disease. Statin treatment reduces risks of death and complications of heart disease in the general population.</P>
<P>In 2009 we identified 14 studies, enrolling 2086 patients, and found that while statins were generally safe and reduced cholesterol levels, they did not prevent death or clinical cardiac events in people treated with dialysis. This latest update analysed a total or 25 studies (8289 patients), and included the results from two new large studies. We found that statins lowered cholesterol in people treated with dialysis but did not prevent death, heart attack, or stroke.</P>
<P>Evidence for side-effects was incomplete, and potential harms from statin therapy remain uncertain. Current study data did not address whether statin treatment should be stopped when a person starts dialysis, although the benefits associated with continued treatment are likely to be small. Limited information was available for people treated with peritoneal dialysis, suggesting that more research is needed in this setting.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-09-02 11:24:39 +1000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-07-24 16:22:43 +1000" MODIFIED_BY="Narelle S Willis">
<P>People with advanced kidney disease treated with dialysis experience mortality rates from cardiovascular disease that are substantially higher than for the general population. Studies that have assessed the benefits of statins (HMG CoA reductase inhibitors) report conflicting conclusions for people on dialysis and existing meta-analyses have not had sufficient power to determine whether the effects of statins vary with severity of kidney disease. Recently, additional data for the effects of statins in dialysis patients have become available. This is an update of a review first published in 2004 and last updated in 2009.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-07-29 16:42:36 +1000" MODIFIED_BY="[Empty name]">
<P>To assess the benefits and harms of statin use in adults who require dialysis (haemodialysis or peritoneal dialysis).</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-05-21 11:41:50 +1000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Renal Group's Specialised Register to 29 February 2012 through contact with the Trials' Search Co-ordinator using search terms relevant to this review.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-05-31 09:14:31 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) and quasi-RCTs that compared the effects of statins with placebo, no treatment, standard care or other statins on mortality, cardiovascular events and treatment-related toxicity in adults treated with dialysis were sought for inclusion.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-05-21 11:43:10 +1000" MODIFIED_BY="[Empty name]">
<P>Two or more authors independently extracted data and assessed study risk of bias. Treatment effects were summarised using a random-effects model and subgroup analyses were conducted to explore sources of heterogeneity. Treatment effects were expressed as mean difference (MD) for continuous outcomes and risk ratios (RR) for dichotomous outcomes together with 95% confidence intervals (CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-09-02 11:24:39 +1000" MODIFIED_BY="[Empty name]">
<P>The risk of bias was high in many of the included studies. Random sequence generation and allocation concealment was reported in three (12%) and four studies (16%), respectively. Participants and personnel were blinded in 13 studies (52%), and outcome assessors were blinded in five studies (20%). Complete outcome reporting occurred in nine studies (36%). Adverse events were only reported in nine studies (36%); 11 studies (44%) reported industry funding.</P>
<P>We included 25 studies (8289 participants) in this latest update; 23 studies (24 comparisons, 8166 participants) compared statins with placebo or no treatment, and two studies (123 participants) compared statins directly with one or more other statins. Statins had little or no effect on major cardiovascular events (4 studies, 7084 participants: RR 0.95, 95% CI 0.88 to 1.03), all-cause mortality (13 studies, 4705 participants: RR 0.96, 95% CI 0.90 to 1.02), cardiovascular mortality (13 studies, 4627 participants: RR 0.94, 95% CI 0.84 to 1.06) and myocardial infarction (3 studies, 4047 participants: RR 0.87, 95% CI 0.71 to 1.07); and uncertain effects on stroke (2 studies, 4018 participants: RR 1.29, 95% CI 0.96 to 1.72).</P>
<P>Risks of adverse events from statin therapy were uncertain; these included effects on elevated creatine kinase (5 studies, 3067 participants: RR 1.25, 95% CI 0.55 to 2.83) or liver function enzymes (4 studies, 3044 participants; RR 1.09, 95% CI 0.41 to 1.25), withdrawal due to adverse events (9 studies, 1832 participants: RR 1.04, 95% CI 0.87 to 1.25) or cancer (2 studies, 4012 participants: RR 0.90, 95% CI 0.72 to 1.11). Statins reduced total serum cholesterol (14 studies, 1803 participants; MD -44.86 mg/dL, 95% CI -55.19 to -34.53) and low-density lipoprotein cholesterol (12 studies, 1747 participants: MD -39.99 mg/dL, 95% CI -52.46 to -27.52) levels. Data comparing statin therapy directly with another statin were sparse.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-05-21 11:38:55 +1000" MODIFIED_BY="[Empty name]">
<P>Statins have little or no beneficial effects on mortality or cardiovascular events and uncertain adverse effects in adults treated with dialysis despite clinically relevant reductions in serum cholesterol levels.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-05-07 11:10:10 +1000" MODIFIED_BY="Gail Y Higgins">
<BACKGROUND MODIFIED="2014-05-07 11:10:10 +1000" MODIFIED_BY="Gail Y Higgins">
<CONDITION MODIFIED="2013-05-31 09:25:23 +1000" MODIFIED_BY="[Empty name]">
<P>Although cardiovascular mortality is decreasing, events among dialysis patients remains 20- to 30-times higher than for the general population (<LINK REF="REF-Foley-2007" TYPE="REFERENCE">Foley 2007</LINK>; <LINK REF="REF-Herzog-2011" TYPE="REFERENCE">Herzog 2011</LINK>; <LINK REF="REF-USRDS-2011" TYPE="REFERENCE">USRDS 2011</LINK>). Elevated circulating lipid levels is one of several factors, that also include hypertension, diabetes, and smoking, that have been implicated in the increased cardiovascular risk associated with chronic kidney disease (CKD) (<LINK REF="REF-Ganesh-2001" TYPE="REFERENCE">Ganesh 2001</LINK>; <LINK REF="REF-Jungers-1997" TYPE="REFERENCE">Jungers 1997</LINK>; <LINK REF="REF-Mallamaci-2002" TYPE="REFERENCE">Mallamaci 2002)</LINK>.</P>
</CONDITION>
<THEORY MODIFIED="2013-07-29 16:20:59 +1000" MODIFIED_BY="[Empty name]">
<P>Clinical studies conducted in the general population, and in people with established cardiovascular disease, have found a strong, consistent and independent association between lipid lowering, primarily low-density lipoprotein (LDL) cholesterol, and the risk of all-cause and cardiovascular mortality (<LINK REF="REF-Law-1994" TYPE="REFERENCE">Law 1994</LINK>; <LINK REF="REF-Rossouw-1990" TYPE="REFERENCE">Rossouw 1990</LINK>). A linear proportional reduction in the risk of major vascular events equal to approximately 20% per 1 mmol/L (39 mg/dL) reduction in LDL cholesterol has been reported (<LINK REF="REF-Baigent-2005" TYPE="REFERENCE">Baigent 2005</LINK>). Optimal lowering of serum lipid levels has been anticipated to lower cardiovascular and overall mortality for people treated with dialysis.</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-05-07 11:10:10 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Study data for the benefits of lipid lowering in people on dialysis are increasingly conflicted. Our previous review (<LINK REF="REF-Navaneethan-2009a" TYPE="REFERENCE">Navaneethan 2009a</LINK>) identified little or no benefit from statin therapy on mortality, although one study reported fewer major cardiovascular events in people with diabetes on dialysis (<LINK REF="STD-_x0034_D-Study-2004" TYPE="STUDY">4D Study 2004</LINK>). The Study for Heart and Renal Protection (<LINK REF="STD-SHARP-Study-2010" TYPE="STUDY">SHARP Study 2010</LINK>, completed since our last review update), which included 3023 people on dialysis, reported that benefits for lipid-lowering therapy extended to people with advanced kidney disease on dialysis, whereas the <LINK REF="STD-AURORA-Study-2005" TYPE="STUDY">AURORA Study 2005</LINK> (A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events) conducted with 2776 adults on haemodialysis, found no clear benefit for statin therapy in this population. An advisory committee to the US Food and Drug Administration that considered <LINK REF="STD-SHARP-Study-2010" TYPE="STUDY">SHARP Study 2010</LINK> study data did not recommend lipid-lowering using simvastatin/ezetimibe in people on dialysis, citing insufficient evidence (<LINK REF="REF-FDA-2011" TYPE="REFERENCE">FDA 2011</LINK>).</P>
<P>In light of conflicting information on the benefits of statin therapy to inform clinical practice and policy in people on dialysis, together with new study data, we conducted an update of our earlier review (<LINK REF="REF-Navaneethan-2009a" TYPE="REFERENCE">Navaneethan 2009a</LINK>) to evaluate the benefits and harms of statin therapy in people on dialysis.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-04-24 14:30:19 +1000" MODIFIED_BY="[Empty name]">
<P>To evaluate the benefits (reductions in all-cause mortality, cardiovascular mortality, major cardiovascular events, myocardial infarction and stroke) and harms (liver or muscle damage, or cancer) of statins compared with placebo, no treatment, or another statin in adults who require dialysis.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-09-02 13:15:44 +1000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-09-02 13:15:44 +1000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-07-28 17:30:57 +1000" MODIFIED_BY="[Empty name]">
<P>All randomised controlled trials (RCT) and quasi-RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable method) of at least 8 weeks' duration that evaluated the benefits and harms of statins in adults treated with haemodialysis or peritoneal dialysis were included. The first periods of randomised cross-over studies were also included. Studies of fewer than eight weeks' duration were excluded because they were unlikely to enable detection of mortality or cardiovascular outcomes related to statin therapy (<LINK REF="REF-Briel-2006" TYPE="REFERENCE">Briel 2006</LINK>).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-09-02 13:15:44 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<P>Adults treated with dialysis (haemodialysis and peritoneal dialysis) irrespective of pre-existing cardiovascular disease or statin therapy were included.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<P>Studies in children were excluded. Studies including adults with CKD not treated with dialysis and recipients of a kidney transplant are the subject of other related reviews (<LINK REF="REF-Navaneethan-2009b" TYPE="REFERENCE">Navaneethan 2009b</LINK>; <LINK REF="REF-Navaneethan-2009c" TYPE="REFERENCE">Navaneethan 2009c</LINK>; updates in press (<LINK REF="REF-Palmer-2013a" TYPE="REFERENCE">Palmer 2013a</LINK>; <LINK REF="REF-Palmer-2013b" TYPE="REFERENCE">Palmer 2013b</LINK>)).</P>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-05-30 11:26:24 +1000" MODIFIED_BY="[Empty name]">
<P>We included studies that compared statins with placebo, no treatment or standard care, or another statin. We excluded studies that compared a statin with a second non-statin regimen, including fibrate therapy.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-09-02 12:05:09 +1000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-04-24 14:34:38 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Major cardiovascular events</LI>
<LI>All-cause mortality</LI>
<LI>Cardiovascular mortality</LI>
<LI>Fatal and non-fatal myocardial infarction</LI>
<LI>Fatal and non-fatal stroke</LI>
<LI>Adverse events attributable to interventions</LI>
<OL>
<LI>Elevated creatine kinase</LI>
<LI>Elevated liver function enzymes</LI>
<LI>Withdrawal due to adverse events</LI>
<LI>Cancer.</LI>
</OL>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-09-02 12:05:09 +1000" MODIFIED_BY="[Empty name]">
<P>Lipid parameters (mg/dL)</P>
<OL>
<LI>Serum lipid levels</LI>
<OL>
<LI>Total cholesterol</LI>
<LI>LDL cholesterol</LI>
<LI>Triglycerides</LI>
<LI>High-density lipoprotein (HDL) cholesterol</LI>
</OL>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-09-02 12:05:40 +1000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2013-09-02 12:05:40 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">2013 update</HEADING>
<P>We searched the Cochrane Renal Group's Specialised Register to 29 February 2012 through contact with the Trials' Search Co-ordinator using search terms relevant to this review.</P>
<P>The Cochrane Renal Group&#8217;s Specialised Register contains studies identified from the following sources.</P>
<OL>
<LI>Quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</LI>
<LI>Weekly searches of MEDLINE OVID SP</LI>
<LI>Handsearching of renal-related journals and the proceedings of major renal conferences</LI>
<LI>Searching of the current year of EMBASE OVID SP</LI>
<LI>Weekly current awareness alerts for selected renal journals</LI>
<LI>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</LI>
</OL>
<P>Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of the Cochrane Renal Group. Details of these strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts are available in the Specialised Register section of information about the <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html">Cochrane Renal Group</A>.</P>
<P>See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for search terms used in strategies for this review.</P>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-07-30 15:52:44 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Reference lists of relevant clinical practice guidelines, review articles and studies.</LI>
<LI>Letters seeking information about unpublished or incomplete RCTs to investigators known to be involved in previous studies.</LI>
</OL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-07-30 18:45:43 +1000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2013-07-30 18:45:06 +1000" MODIFIED_BY="[Empty name]">
<P>Two authors independently screened all abstracts retrieved by electronic searches to identify potentially relevant citations for detailed study in full text format. Studies that might have included relevant data or information on studies involving HMG Co-A reductase inhibitors were retained initially. Studies published in non-English language journals were translated before assessment for inclusion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-07-30 18:45:43 +1000" MODIFIED_BY="[Empty name]">
<P>Two authors independently extracted data from the eligible studies using standard data extraction forms. Where more than one publication of one study existed, reports were grouped together and the publication with the most complete data was included. Any further information required from the original author was requested and any relevant information obtained was included in the review. Disagreements were resolved in consultation with a third author.</P>
<P>Data entry was carried out by the same two authors. Treatment effects were summarised using the random-effects model but the fixed effects model was also analysed to ensure robustness of the model chosen and susceptibility to outliers. For dichotomous outcomes (cardiovascular events, mortality, and adverse events) treatment effects were summarised as relative risk (RR) with 95% confidence intervals (CI). Where continuous scales of measurement were used (lipid parameters), treatment effects were summarised using the mean difference (MD).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-04-24 15:31:16 +1000" MODIFIED_BY="[Empty name]">
<P>The following items were independently assessed by two authors using the risk of bias assessment tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</P>
<UL>
<LI>Was there adequate sequence generation (selection bias)?</LI>
<LI>Was allocation adequately concealed (selection bias)?</LI>
<LI>Was knowledge of the allocated interventions adequately prevented during the study (detection bias)?</LI>
<UL>
<LI>Participants and personnel</LI>
<LI>Outcome assessors</LI>
</UL>
<LI>Were incomplete outcome data adequately addressed (attrition bias)?</LI>
<LI>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)?</LI>
<LI>Was the study apparently free of other problems that could put it at a risk of bias?</LI>
</UL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-05-08 11:42:03 +1000" MODIFIED_BY="[Empty name]">
<P>Dichotomous outcomes (e.g. fatal and non-fatal heart attack and stroke) were expressed as risk ratios (RR) with 95% confidence intervals (CI). Risk differences (RD) with 95% confidence intervals were calculated for adverse effects. Continuous outcomes were calculated as mean differences (MD) with 95% CI.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2013-04-24 15:34:55 +1000" MODIFIED_BY="[Empty name]">
<P>Where applicable, study authors were contacted for further information or missing data. Data obtained in this manner were included in our analyses. </P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-05-08 11:47:06 +1000" MODIFIED_BY="[Empty name]">
<P>Heterogeneity was analysed using a Chi² test on N-1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I² test (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). I² values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-06-04 09:56:07 +1000" MODIFIED_BY="[Empty name]">
<P>This update included all studies identified in the Cochrane Renal Group's Specialised Register, which is updated regularly with published and unpublished reports identified in congress proceedings. This reduces the risk of publication bias. All reports of a single study were reviewed to ensure that all outcomes were reported to reduce the risk of selection bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-05-15 14:08:31 +1000" MODIFIED_BY="[Empty name]">
<P>We summarised evidence quality together with absolute treatment effects for mortality and cardiovascular events based on estimated baseline risks using Grading of Recommendations Assessment Development and Evaluation (GRADE) guidelines (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>). Absolute numbers of people on dialysis with cardiovascular events or adverse events avoided or incurred were estimated using the risk estimate for the outcome (and associated 95% confidence interval) obtained from the corresponding meta-analysis together with the absolute population risk estimated from previously published observational studies (<LINK REF="REF-Herzog-1998" TYPE="REFERENCE">Herzog 1998</LINK>; <LINK REF="REF-Trivedi-2009" TYPE="REFERENCE">Trivedi 2009</LINK>; <LINK REF="REF-Weiner-2006" TYPE="REFERENCE">Weiner 2006</LINK>; <LINK REF="REF-Wetmore-2009" TYPE="REFERENCE">Wetmore 2009</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-07-30 18:08:02 +1000" MODIFIED_BY="[Empty name]">
<P>We conducted subgroup analyses to explore potential sources of heterogeneity in modifying estimates of the effects of statins in the studies. We planned subgroup analyses according to participant type, intervention, or study-related characteristics, when subgroups contained four or more independent studies: dialysis type (peritoneal or haemodialysis); statin type; statin dose (equivalent to simvastatin); baseline cholesterol (&lt; 230 mg/dL versus &#8805; 230 mg/dL); age (&#8804; 55 years versus &gt; 56 years); proportion with diabetes (&gt; 20% versus &lt; 20%); adequacy of allocation concealment. Insufficient numbers of studies reporting one or more events were available to explore for publication bias using visual inspection of an inverted funnel plot or formal statistical analysis.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-04-24 15:40:05 +1000" MODIFIED_BY="[Empty name]">
<P>Where a study's results differed considerably from other studies in a meta-analysis, exclusion of the study was investigated to determine whether this altered the result of the meta-analysis.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-05-07 11:10:10 +1000" MODIFIED_BY="Gail Y Higgins">
<STUDY_DESCRIPTION MODIFIED="2014-05-07 11:10:10 +1000" MODIFIED_BY="Gail Y Higgins">
<SEARCH_RESULTS MODIFIED="2014-05-07 11:10:10 +1000" MODIFIED_BY="Gail Y Higgins">
<SUBSECTION>
<HEADING LEVEL="4">Initial review (2004) and first update (2009)</HEADING>
<P>The searches identified 88 reports in 2004 and 115 reports in 2009. After title and abstract screening 67 (2004) and 97 (2009) reports were excluded. Full text assessment resulted in six studies (7 reports, 357 participants) included in our initial 2004 review and 14 studies (32 reports, 2086 participants) included in the 2009 update. Two studies reported as ongoing in 2004 and 2009 (<LINK REF="STD-AURORA-Study-2005" TYPE="STUDY">AURORA Study 2005</LINK>; <LINK REF="STD-SHARP-Study-2010" TYPE="STUDY">SHARP Study 2010</LINK>) have been included in our 2013 update.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2013 review update</HEADING>
<P>Electronic searching to February 2012 identified 71 additional records. Of these, 33 were duplicate reports of existing studies and four were ongoing studies. After full-text assessment, a study by Joy 2008 included in our 2009 review update was considered to be a part of <LINK REF="STD-Dornbrook_x002d_Lavender-2005" TYPE="STUDY">Dornbrook-Lavender 2005</LINK>. We also removed <LINK REF="STD-Fiorini-1994" TYPE="STUDY">Fiorini 1994</LINK> because it did not evaluate a statin versus another statin, placebo, or no treatment; and <LINK REF="STD-Dogra-2007" TYPE="STUDY">Dogra 2007</LINK>, because treatment duration was only six weeks. This meant that 11 unique studies were retained from the 2009 published review (<LINK REF="REF-Navaneethan-2009a" TYPE="REFERENCE">Navaneethan 2009a</LINK>).</P>
<P>After detailed assessment of the remaining reports, 25 studies (14 new eligible studies) were identified. The flow chart for the review process is shown in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SUBSECTION>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-05-07 11:10:10 +1000" MODIFIED_BY="Gail Y Higgins">
<P>This review included 25 studies that involved 8289 participants. One study included relevant subsets of haemodialysis and peritoneal dialysis patient data and for purpose of the analyses have been identified as <LINK REF="STD-Saltissi-HD-2002" TYPE="STUDY">Saltissi HD 2002</LINK> and <LINK REF="STD-Saltissi-PD-2002" TYPE="STUDY">Saltissi PD 2002</LINK> respectively.</P>
<P>There were 14 new studies included in this update (<LINK REF="STD-Ahmadi-2005" TYPE="STUDY">Ahmadi 2005</LINK>; <LINK REF="STD-Angel-2007" TYPE="STUDY">Angel 2007</LINK>; <LINK REF="STD-Arabul-2008" TYPE="STUDY">Arabul 2008</LINK>; <LINK REF="STD-AURORA-Study-2005" TYPE="STUDY">AURORA Study 2005</LINK>; <LINK REF="STD-Burmeister-2006" TYPE="STUDY">Burmeister 2006</LINK>; <LINK REF="STD-Han-2011" TYPE="STUDY">Han 2011</LINK>; <LINK REF="STD-SHARP-Study-2010" TYPE="STUDY">SHARP Study 2010</LINK>; <LINK REF="STD-Soliemani-2011" TYPE="STUDY">Soliemani 2011</LINK>; <LINK REF="STD-Tse-2008" TYPE="STUDY">Tse 2008</LINK>; <LINK REF="STD-van-den-Akker-2003" TYPE="STUDY">van den Akker 2003</LINK>; <LINK REF="STD-Vareesangthip-2005" TYPE="STUDY">Vareesangthip 2005</LINK>; <LINK REF="STD-Velickovic-1997" TYPE="STUDY">Velickovic 1997</LINK>; <LINK REF="STD-Vernaglione-2003" TYPE="STUDY">Vernaglione 2003</LINK>; <LINK REF="STD-Yu-2007" TYPE="STUDY">Yu 2007</LINK>). Of these, two (<LINK REF="STD-AURORA-Study-2005" TYPE="STUDY">AURORA Study 2005</LINK>; <LINK REF="STD-SHARP-Study-2010" TYPE="STUDY">SHARP Study 2010</LINK>) were identified as ongoing studies in our 2009 review.</P>
<P>There were 23 studies (8166 participants) that compared statins with placebo or no treatment (<LINK REF="STD-_x0034_D-Study-2004" TYPE="STUDY">4D Study 2004</LINK>; <LINK REF="STD-Ahmadi-2005" TYPE="STUDY">Ahmadi 2005</LINK>; <LINK REF="STD-Angel-2007" TYPE="STUDY">Angel 2007</LINK>; <LINK REF="STD-Arabul-2008" TYPE="STUDY">Arabul 2008</LINK>; <LINK REF="STD-AURORA-Study-2005" TYPE="STUDY">AURORA Study 2005</LINK>; <LINK REF="STD-Burmeister-2006" TYPE="STUDY">Burmeister 2006</LINK>; <LINK REF="STD-Chang-2002" TYPE="STUDY">Chang 2002</LINK>; <LINK REF="STD-Diepeveen-2005" TYPE="STUDY">Diepeveen 2005</LINK>; <LINK REF="STD-Dornbrook_x002d_Lavender-2005" TYPE="STUDY">Dornbrook-Lavender 2005</LINK>; <LINK REF="STD-Han-2011" TYPE="STUDY">Han 2011</LINK>; <LINK REF="STD-Harris-2002" TYPE="STUDY">Harris 2002</LINK>; <LINK REF="STD-Ichihara-2002" TYPE="STUDY">Ichihara 2002</LINK>; <LINK REF="STD-Lins-2004" TYPE="STUDY">Lins 2004</LINK>; <LINK REF="STD-PERFECT-Study-1997" TYPE="STUDY">PERFECT Study 1997</LINK>; <LINK REF="STD-Saltissi-HD-2002" TYPE="STUDY">Saltissi HD 2002</LINK>-<LINK REF="STD-Saltissi-PD-2002" TYPE="STUDY">Saltissi PD 2002</LINK>; <LINK REF="STD-SHARP-Study-2010" TYPE="STUDY">SHARP Study 2010</LINK>; <LINK REF="STD-Stegmayr-2005" TYPE="STUDY">Stegmayr 2005</LINK>; <LINK REF="STD-Tse-2008" TYPE="STUDY">Tse 2008</LINK>; <LINK REF="STD-UK_x002d_HARP_x002d_I-2005" TYPE="STUDY">UK-HARP-I 2005</LINK>; <LINK REF="STD-Vareesangthip-2005" TYPE="STUDY">Vareesangthip 2005</LINK>; <LINK REF="STD-Velickovic-1997" TYPE="STUDY">Velickovic 1997</LINK>; <LINK REF="STD-Vernaglione-2003" TYPE="STUDY">Vernaglione 2003</LINK>;<LINK REF="STD-Yu-2007" TYPE="STUDY">Yu 2007</LINK>), and two (123 participants) directly compared two or more statins (<LINK REF="STD-Soliemani-2011" TYPE="STUDY">Soliemani 2011</LINK>; <LINK REF="STD-van-den-Akker-2003" TYPE="STUDY">van den Akker 2003</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Study design</HEADING>
<P>All included studies were RCTs; two were two-by-two factorial design with aspirin (<LINK REF="STD-UK_x002d_HARP_x002d_I-2005" TYPE="STUDY">UK-HARP-I 2005</LINK>) and enalapril (<LINK REF="STD-PERFECT-Study-1997" TYPE="STUDY">PERFECT Study 1997</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>All participants were undergoing dialysis.</P>
<UL>
<LI>Twelve studies only included participants undergoing haemodialysis (<LINK REF="STD-_x0034_D-Study-2004" TYPE="STUDY">4D Study 2004</LINK>; <LINK REF="STD-Ahmadi-2005" TYPE="STUDY">Ahmadi 2005</LINK>; <LINK REF="STD-AURORA-Study-2005" TYPE="STUDY">AURORA Study 2005</LINK>; <LINK REF="STD-Burmeister-2006" TYPE="STUDY">Burmeister 2006</LINK>; <LINK REF="STD-Chang-2002" TYPE="STUDY">Chang 2002</LINK>; <LINK REF="STD-Dornbrook_x002d_Lavender-2005" TYPE="STUDY">Dornbrook-Lavender 2005</LINK>; <LINK REF="STD-Ichihara-2002" TYPE="STUDY">Ichihara 2002</LINK>; <LINK REF="STD-Lins-2004" TYPE="STUDY">Lins 2004</LINK>; <LINK REF="STD-Soliemani-2011" TYPE="STUDY">Soliemani 2011</LINK>; <LINK REF="STD-UK_x002d_HARP_x002d_I-2005" TYPE="STUDY">UK-HARP-I 2005</LINK>; <LINK REF="STD-Vareesangthip-2005" TYPE="STUDY">Vareesangthip 2005</LINK>; <LINK REF="STD-Vernaglione-2003" TYPE="STUDY">Vernaglione 2003</LINK>);</LI>
<LI>Eight studies included participants treated with either haemodialysis or peritoneal dialysis (<LINK REF="STD-Arabul-2008" TYPE="STUDY">Arabul 2008</LINK>; <LINK REF="STD-Diepeveen-2005" TYPE="STUDY">Diepeveen 2005</LINK>; <LINK REF="STD-UK_x002d_HARP_x002d_I-2005" TYPE="STUDY">UK-HARP-I 2005</LINK>; <LINK REF="STD-PERFECT-Study-1997" TYPE="STUDY">PERFECT Study 1997</LINK>; <LINK REF="STD-Saltissi-HD-2002" TYPE="STUDY">Saltissi HD 2002</LINK>-<LINK REF="STD-Saltissi-PD-2002" TYPE="STUDY">Saltissi PD 2002</LINK>; <LINK REF="STD-SHARP-Study-2010" TYPE="STUDY">SHARP Study 2010</LINK>; <LINK REF="STD-Stegmayr-2005" TYPE="STUDY">Stegmayr 2005</LINK>; <LINK REF="STD-Yu-2007" TYPE="STUDY">Yu 2007</LINK>)</LI>
<LI>Five studies only included peritoneal dialysis patients (<LINK REF="STD-Angel-2007" TYPE="STUDY">Angel 2007</LINK>; <LINK REF="STD-Harris-2002" TYPE="STUDY">Harris 2002</LINK>; <LINK REF="STD-Han-2011" TYPE="STUDY">Han 2011</LINK>; <LINK REF="STD-Tse-2008" TYPE="STUDY">Tse 2008</LINK>; <LINK REF="STD-Velickovic-1997" TYPE="STUDY">Velickovic 1997</LINK>).</LI>
<LI>Median baseline serum LDL cholesterol was 190 mg/dL (range 150 to 254 mg/dL).</LI>
<LI>Two studies only included participants with diabetes at baseline (<LINK REF="STD-_x0034_D-Study-2004" TYPE="STUDY">4D Study 2004</LINK>; <LINK REF="STD-Ichihara-2002" TYPE="STUDY">Ichihara 2002</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>Five studies reported follow-up of more than six months (<LINK REF="STD-_x0034_D-Study-2004" TYPE="STUDY">4D Study 2004</LINK>; <LINK REF="STD-AURORA-Study-2005" TYPE="STUDY">AURORA Study 2005</LINK>; <LINK REF="STD-SHARP-Study-2010" TYPE="STUDY">SHARP Study 2010</LINK>; <LINK REF="STD-Stegmayr-2005" TYPE="STUDY">Stegmayr 2005</LINK>; <LINK REF="STD-UK_x002d_HARP_x002d_I-2005" TYPE="STUDY">UK-HARP-I 2005</LINK>). Generally, studies were small (median 42 participants; range 13 to 3023 participants); three studies enrolled more than 1000 participants undergoing dialysis (<LINK REF="STD-_x0034_D-Study-2004" TYPE="STUDY">4D Study 2004</LINK>; <LINK REF="STD-AURORA-Study-2005" TYPE="STUDY">AURORA Study 2005</LINK>; <LINK REF="STD-SHARP-Study-2010" TYPE="STUDY">SHARP Study 2010</LINK>).</P>
<P>Doses of statin (equivalent to simvastatin) were generally 20 mg (5 to 80 mg) with a median follow-up of six months (2 to 59 months) including studies reporting mortality and cardiovascular events. Non-randomised co-interventions included diet in three comparisons (<LINK REF="STD-Ichihara-2002" TYPE="STUDY">Ichihara 2002</LINK>; <LINK REF="STD-Saltissi-HD-2002" TYPE="STUDY">Saltissi HD 2002</LINK>; <LINK REF="STD-Saltissi-PD-2002" TYPE="STUDY">Saltissi PD 2002</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-07-30 13:55:34 +1000" MODIFIED_BY="[Empty name]">
<P>We excluded 28 studies: 13 were not randomised; seven did not include an appropriate intervention (other active treatment); one was a discontinued study; five were short durations (&lt; 8 weeks); two were not conducted in dialysis populations (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-05-07 11:10:10 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Risk of bias in included studies is summarised in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. The risk of bias was high in many of the included studies. Random sequence generation and allocation concealment was reported in three (12%) and four studies (16%), respectively. Participants and personnel were blinded in 13 studies (52%), and outcome assessors were blinded in five studies (20%). Complete outcome reporting occurred in nine studies (36%). Adverse events were only reported in nine studies (36%); 11 studies (44%) reported industry funding.The risk of bias was high in many included studies.</P>
<ALLOCATION MODIFIED="2014-05-07 11:10:10 +1000" MODIFIED_BY="Gail Y Higgins">
<SUBSECTION>
<HEADING LEVEL="4">Random sequence generation</HEADING>
<P>Random sequence generation was only reported in 3/25 studies (<LINK REF="STD-_x0034_D-Study-2004" TYPE="STUDY">4D Study 2004</LINK>; <LINK REF="STD-SHARP-Study-2010" TYPE="STUDY">SHARP Study 2010</LINK>; <LINK REF="STD-UK_x002d_HARP_x002d_I-2005" TYPE="STUDY">UK-HARP-I 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>Allocation to randomised groups was not reported adequately: only 4/25 included studies reported allocation methodology in detail (<LINK REF="STD-_x0034_D-Study-2004" TYPE="STUDY">4D Study 2004</LINK>; <LINK REF="STD-SHARP-Study-2010" TYPE="STUDY">SHARP Study 2010</LINK>; <LINK REF="STD-Stegmayr-2005" TYPE="STUDY">Stegmayr 2005</LINK>; <LINK REF="STD-UK_x002d_HARP_x002d_I-2005" TYPE="STUDY">UK-HARP-I 2005</LINK>).</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2014-05-07 11:10:10 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Blinding methodology was well reported: 13 provided adequate details (<LINK REF="STD-_x0034_D-Study-2004" TYPE="STUDY">4D Study 2004</LINK>; <LINK REF="STD-Angel-2007" TYPE="STUDY">Angel 2007</LINK>; <LINK REF="STD-Arabul-2008" TYPE="STUDY">Arabul 2008</LINK>; <LINK REF="STD-AURORA-Study-2005" TYPE="STUDY">AURORA Study 2005</LINK>; <LINK REF="STD-Burmeister-2006" TYPE="STUDY">Burmeister 2006</LINK>; <LINK REF="STD-Diepeveen-2005" TYPE="STUDY">Diepeveen 2005</LINK>; <LINK REF="STD-Harris-2002" TYPE="STUDY">Harris 2002</LINK>; <LINK REF="STD-Ichihara-2002" TYPE="STUDY">Ichihara 2002</LINK>; <LINK REF="STD-Lins-2004" TYPE="STUDY">Lins 2004</LINK>; <LINK REF="STD-PERFECT-Study-1997" TYPE="STUDY">PERFECT Study 1997</LINK>; <LINK REF="STD-Saltissi-HD-2002" TYPE="STUDY">Saltissi HD 2002</LINK>-<LINK REF="STD-Saltissi-PD-2002" TYPE="STUDY">Saltissi PD 2002</LINK>; <LINK REF="STD-SHARP-Study-2010" TYPE="STUDY">SHARP Study 2010</LINK>; <LINK REF="STD-UK_x002d_HARP_x002d_I-2005" TYPE="STUDY">UK-HARP-I 2005</LINK>); six did not indicate blinding (<LINK REF="STD-Han-2011" TYPE="STUDY">Han 2011</LINK>; <LINK REF="STD-SHARP-Study-2010" TYPE="STUDY">SHARP Study 2010</LINK>; <LINK REF="STD-Tse-2008" TYPE="STUDY">Tse 2008</LINK>; <LINK REF="STD-van-den-Akker-2003" TYPE="STUDY">van den Akker 2003</LINK>; <LINK REF="STD-Vareesangthip-2005" TYPE="STUDY">Vareesangthip 2005</LINK>; <LINK REF="STD-Vernaglione-2003" TYPE="STUDY">Vernaglione 2003</LINK>); and six did not blind participants (<LINK REF="STD-Ahmadi-2005" TYPE="STUDY">Ahmadi 2005</LINK>; <LINK REF="STD-Chang-2002" TYPE="STUDY">Chang 2002</LINK>; <LINK REF="STD-Dornbrook_x002d_Lavender-2005" TYPE="STUDY">Dornbrook-Lavender 2005</LINK>; <LINK REF="STD-Stegmayr-2005" TYPE="STUDY">Stegmayr 2005</LINK>; <LINK REF="STD-Velickovic-1997" TYPE="STUDY">Velickovic 1997</LINK>; <LINK REF="STD-Yu-2007" TYPE="STUDY">Yu 2007</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-05-07 11:10:10 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Drop-outs and losses to follow-up ranged for 0% to 32%. Seven studies were judged to be at low risk of bias (<LINK REF="STD-_x0034_D-Study-2004" TYPE="STUDY">4D Study 2004</LINK>; <LINK REF="STD-Arabul-2008" TYPE="STUDY">Arabul 2008</LINK>; <LINK REF="STD-AURORA-Study-2005" TYPE="STUDY">AURORA Study 2005</LINK>; <LINK REF="STD-Diepeveen-2005" TYPE="STUDY">Diepeveen 2005</LINK>; <LINK REF="STD-SHARP-Study-2010" TYPE="STUDY">SHARP Study 2010</LINK>; <LINK REF="STD-Stegmayr-2005" TYPE="STUDY">Stegmayr 2005</LINK>; <LINK REF="STD-UK_x002d_HARP_x002d_I-2005" TYPE="STUDY">UK-HARP-I 2005</LINK>), six were at high risk (<LINK REF="STD-Burmeister-2006" TYPE="STUDY">Burmeister 2006</LINK>; <LINK REF="STD-Chang-2002" TYPE="STUDY">Chang 2002</LINK>; <LINK REF="STD-Dornbrook_x002d_Lavender-2005" TYPE="STUDY">Dornbrook-Lavender 2005</LINK>; <LINK REF="STD-Harris-2002" TYPE="STUDY">Harris 2002</LINK>; <LINK REF="STD-Saltissi-HD-2002" TYPE="STUDY">Saltissi HD 2002</LINK>-<LINK REF="STD-Saltissi-PD-2002" TYPE="STUDY">Saltissi PD 2002</LINK>; <LINK REF="STD-van-den-Akker-2003" TYPE="STUDY">van den Akker 2003</LINK>), and the remaining 12 studies were unclear.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-05-07 11:10:10 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Overall, nine studies (36%) reported all expected outcomes (<LINK REF="STD-_x0034_D-Study-2004" TYPE="STUDY">4D Study 2004</LINK>; <LINK REF="STD-Arabul-2008" TYPE="STUDY">Arabul 2008</LINK>; <LINK REF="STD-AURORA-Study-2005" TYPE="STUDY">AURORA Study 2005</LINK>; <LINK REF="STD-Burmeister-2006" TYPE="STUDY">Burmeister 2006</LINK>; <LINK REF="STD-Lins-2004" TYPE="STUDY">Lins 2004</LINK>; <LINK REF="STD-Saltissi-HD-2002" TYPE="STUDY">Saltissi HD 2002</LINK>-<LINK REF="STD-Saltissi-PD-2002" TYPE="STUDY">Saltissi PD 2002</LINK>; <LINK REF="STD-SHARP-Study-2010" TYPE="STUDY">SHARP Study 2010</LINK>; <LINK REF="STD-Stegmayr-2005" TYPE="STUDY">Stegmayr 2005</LINK>; <LINK REF="STD-UK_x002d_HARP_x002d_I-2005" TYPE="STUDY">UK-HARP-I 2005</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-05-07 11:10:10 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Eleven studies (44%) reported industry funding (<LINK REF="STD-_x0034_D-Study-2004" TYPE="STUDY">4D Study 2004</LINK>; <LINK REF="STD-AURORA-Study-2005" TYPE="STUDY">AURORA Study 2005</LINK>; <LINK REF="STD-Burmeister-2006" TYPE="STUDY">Burmeister 2006</LINK>; <LINK REF="STD-Chang-2002" TYPE="STUDY">Chang 2002</LINK>; <LINK REF="STD-Diepeveen-2005" TYPE="STUDY">Diepeveen 2005</LINK>; <LINK REF="STD-Dornbrook_x002d_Lavender-2005" TYPE="STUDY">Dornbrook-Lavender 2005</LINK>; <LINK REF="STD-Lins-2004" TYPE="STUDY">Lins 2004</LINK>; <LINK REF="STD-PERFECT-Study-1997" TYPE="STUDY">PERFECT Study 1997</LINK>; <LINK REF="STD-Saltissi-HD-2002" TYPE="STUDY">Saltissi HD 2002</LINK>-<LINK REF="STD-Saltissi-PD-2002" TYPE="STUDY">Saltissi PD 2002</LINK>; <LINK REF="STD-SHARP-Study-2010" TYPE="STUDY">SHARP Study 2010</LINK>; <LINK REF="STD-UK_x002d_HARP_x002d_I-2005" TYPE="STUDY">UK-HARP-I 2005</LINK>)</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-05-07 11:06:29 +1000" MODIFIED_BY="Gail Y Higgins">
<SUBSECTION>
<HEADING LEVEL="3">Statins versus placebo or no treatment</HEADING>
<P>We found moderate-to-high quality evidence to indicate that statin therapy had little or no effect on risks of major cardiovascular events (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> (4 studies, 7084 participants): RR 0.95, 95% CI 0.88 to 1.03), all-cause mortality (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK> (13 studies, 4705 participants): RR 0.96, 95% CI 0.90 to 1.02) and cardiovascular mortality (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK> (13 studies, 4627 participants): RR 0.94, 95% CI 0.84 to 1.06) (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). Statins had little or no effect on risks of fatal or non-fatal myocardial infarction (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK> (3 studies, 4047 participants): RR 0.87, 95% CI 0.71 to 1.07) and had uncertain effects on fatal or non-fatal stroke (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK> (2 studies, 4018 participants): RR 1.29, 95% CI 0.96 to 1.72). There was no evidence of heterogeneity in these analyses (I² = 0%).</P>
<P>Statins had uncertain effects on adverse events, including elevation of creatine kinase (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK> (5 studies, 3067 participants): RR 1.25, 95% CI 0.55 to 2.83), elevated liver enzymes (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK> (4 studies, 3044 participants): RR 1.09, 95% CI 0.41 to 2.91), withdrawal due to adverse events (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK> (9 studies, 1832 participants): RR 1.04, 95% CI 0.87 to 1.25) and cancer (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK> (2 studies, 4012 participants): RR 0.90, 95% CI 0.72 to 1.11) (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). There was no evidence of heterogeneity in these analyses (I² = 0%).</P>
<P>Statins significantly reduced total cholesterol (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK> (14 studies, 1803 participants): MD -44.86 mg/dL, 95% CI -55.19 to -34.53), LDL cholesterol (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK> (12 studies, 1747 participants): MD -39.99 mg/dL, 95% CI -52.46 to -27.52) and triglycerides (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK> (13 studies, 1692 participants): MD -18.02 mg/dL, 95% CI -33.00 to -3.04), but had uncertain effects on HDL cholesterol (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK> (13 studies, 1769 participants): MD 2.57 mg/dL, 95% CI -0.39 to 5.52).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Analysis of heterogeneity</HEADING>
<P>We did not identify any sources of heterogeneity in the analyses for total or LDL cholesterol using prespecified subgroup analyses (dialysis type or statin type or dose, age, proportion with diabetes, baseline serum cholesterol, risk of bias (allocation concealment)). The lack of specific populations with or without cardiovascular disease at baseline in the available studies prevented subgroup analysis for the effect of statins by the presence or absence of cardiovascular disease.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Statin versus other statin</HEADING>
<P>
<LINK REF="STD-van-den-Akker-2003" TYPE="STUDY">van den Akker 2003</LINK> (28 participants) compared atorvastatin (10 to 40 mg/d) with simvastatin (10 to 40 mg/d), and <LINK REF="STD-Soliemani-2011" TYPE="STUDY">Soliemani 2011</LINK> compared atorvastatin, simvastatin and lovastatin directly (95 participants). Compared to simvastatin, atorvastatin treatment had uncertain effects on elevation of liver enzymes (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK> (1 study, 28 participants): RR 5.71, 95% CI 0.30 to 109.22), withdrawal from treatment due to adverse events (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK> (1 study, 63 participants): RR 2.06, 95% CI 0.20 to 21.63), total cholesterol (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK> (1 study, 28 participants): MD 0.23 mg/dL, 95% CI -0.35 to 0.81), LDL cholesterol (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK> (1 study, 28 participants): MD 0.06 mg/dL, 95% CI -0.40 to 0.52), triglycerides (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK> ((1 study, 28 participants): MD -0.02 mg/dL, 95% CI -0.58 to 0.54), and HDL cholesterol (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK> (1 study, 28 participants): 0.10 mg/dL, 95% CI -0.13 to 0.33). Data for other outcomes were not available in extractable format.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analyses</HEADING>
<P>When analyses were restricted to studies in which follow-up data were provided for six months or more, the results were unchanged (major cardiovascular events, unchanged from primary result; all-cause mortality (7 studies, 4328 participants): RR 0.96, 95% CI 0.90 to 1.02) (<LINK REF="STD-_x0034_D-Study-2004" TYPE="STUDY">4D Study 2004</LINK>; <LINK REF="STD-AURORA-Study-2005" TYPE="STUDY">AURORA Study 2005</LINK>; <LINK REF="STD-Ichihara-2002" TYPE="STUDY">Ichihara 2002</LINK>; <LINK REF="STD-Han-2011" TYPE="STUDY">Han 2011</LINK>; <LINK REF="STD-PERFECT-Study-1997" TYPE="STUDY">PERFECT Study 1997</LINK>; <LINK REF="STD-Saltissi-HD-2002" TYPE="STUDY">Saltissi HD 2002</LINK>-<LINK REF="STD-Saltissi-PD-2002" TYPE="STUDY">Saltissi PD 2002</LINK>); cardiovascular mortality ((7 studies, 4247 participants): RR 0.94, 95% CI 0.84 to 1.06) (<LINK REF="STD-_x0034_D-Study-2004" TYPE="STUDY">4D Study 2004</LINK>; <LINK REF="STD-AURORA-Study-2005" TYPE="STUDY">AURORA Study 2005</LINK>; <LINK REF="STD-Ichihara-2002" TYPE="STUDY">Ichihara 2002</LINK>; <LINK REF="STD-Han-2011" TYPE="STUDY">Han 2011</LINK>; <LINK REF="STD-PERFECT-Study-1997" TYPE="STUDY">PERFECT Study 1997</LINK>; <LINK REF="STD-Saltissi-HD-2002" TYPE="STUDY">Saltissi HD 2002</LINK>-<LINK REF="STD-Saltissi-PD-2002" TYPE="STUDY">Saltissi PD 2002</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-05-07 11:10:10 +1000" MODIFIED_BY="Gail Y Higgins">
<SUMMARY_OF_RESULTS MODIFIED="2013-09-02 11:35:53 +1000" MODIFIED_BY="Suetonia Palmer">
<P>This review update on the benefits and harms of statins in people treated with dialysis found that data for mortality and cardiovascular events were generally moderate-to-high quality. Statin therapy (generally at doses equivalent to 20 mg of simvastatin) reduced total serum cholesterol levels by 46 mg/dL (1.2 mmol/L) in adult dialysis patients, but had little or no effect on major cardiovascular events or mortality. Statins were found to have little or no effect on myocardial infarction and uncertain effects on the risk of stroke. Statins were also found to have uncertain effects on risks of liver dysfunction, muscle damage or cancer in people on dialysis; and toxicity data were limited by a lack of systematic reporting in half the studies. Few data were available for people treated with peritoneal dialysis. Direct head-to-head studies of different statin agents were rare and estimated effects of atorvastatin versus simvastatin were imprecise.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-05-07 11:10:10 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Three large and well-conducted studies provided moderate-to-high quality data that showed consistent effects of statins on cardiovascular events in people treated with dialysis (<LINK REF="STD-_x0034_D-Study-2004" TYPE="STUDY">4D Study 2004</LINK>; <LINK REF="STD-AURORA-Study-2005" TYPE="STUDY">AURORA Study 2005</LINK>; <LINK REF="STD-SHARP-Study-2010" TYPE="STUDY">SHARP Study 2010</LINK>). Mortality data were assessed as moderate quality because information from <LINK REF="STD-SHARP-Study-2010" TYPE="STUDY">SHARP Study 2010</LINK> could not be included as these were not reported in the published study separately for dialysis patients and could not be obtained from the authors on request.</P>
<P>The strengths of this review include consistent results for primary outcomes among studies (no evidence of heterogeneity), comprehensive systematic searching for eligible studies, rigid inclusion criteria for RCTs, and data extraction and analysis by two independent investigators. Furthermore, the possibility of publication bias was minimised by including both published and unpublished studies (such as abstracts from meetings), although we could not formally test for evidence of publication bias or small study effects due to the small numbers of available studies.</P>
<P>Despite comprehensive inclusion of available studies, the current evidence for statins in people treated with dialysis has some significant limitations. Studies were generally small (median number of participants was 42) and, with the exception of three large well-conducted studies (<LINK REF="STD-_x0034_D-Study-2004" TYPE="STUDY">4D Study 2004</LINK>; <LINK REF="STD-AURORA-Study-2005" TYPE="STUDY">AURORA Study 2005</LINK>; <LINK REF="STD-SHARP-Study-2010" TYPE="STUDY">SHARP Study 2010</LINK>), were assessed to be at high risk of bias. Studies were also generally of short duration (six months) and may not have been sufficiently powered to identify the effects of statins on clinical end points such as mortality (<LINK REF="REF-Briel-2006" TYPE="REFERENCE">Briel 2006</LINK>) (although the larger studies that dominated analyses provided outcome data for three to five years of treatment).</P>
<P>Limited data were available for adverse events, which were not systematically captured in over half of the included studies, such that potential toxicities of statins in this population remain incompletely characterised. We were unable to determine whether treatment effects were different in people on peritoneal dialysis compared with those on haemodialysis. Eight studies enrolled both haemodialysis and peritoneal dialysis patients and only one presented separate outcome data for these two populations (<LINK REF="STD-Saltissi-HD-2002" TYPE="STUDY">Saltissi HD 2002</LINK>-<LINK REF="STD-Saltissi-PD-2002" TYPE="STUDY">Saltissi PD 2002</LINK>). In addition, the small number of available studies meant that we were unable to explore other sources of heterogeneity in the treatment effects among studies on serum cholesterol levels, although this was a secondary (and surrogate) outcome. We could not identify whether treatment effects differed between men and women. Furthermore, we were unable to analyse the relative benefits of primary versus secondary prevention of cardiovascular events in people on dialysis, because there were too few studies specifically designed to address this question. <LINK REF="STD-SHARP-Study-2010" TYPE="STUDY">SHARP Study 2010</LINK> evaluated a combination of simvastatin and ezetimibe, but it remains unclear whether there was an important difference in treatment effects compared with a statin alone, although it is unlikely because treatment effects were consistent among all studies for major cardiovascular events irrespective of the treatment used.</P>
<P>It was noteworthy that adverse mortality and cardiovascular events were not clearly prevented by statins in the dialysis population, despite clinically significant lowering of serum lipid levels. This finding is inconsistent with data from people with earlier stages of kidney disease not treated with dialysis, for which statins clearly reduce risks of death and major cardiovascular events (<LINK REF="REF-Palmer-2013a" TYPE="REFERENCE">Palmer 2013a</LINK>). It was possible that a lack of power in available studies for dialysis resulted in the small or no effects on all-cause mortality and cardiovascular events, although the inclusion of nearly 2000 events in each analysis makes this unlikely. It has previously been suggested that the choice of endpoints for major cardiovascular events in <LINK REF="STD-AURORA-Study-2005" TYPE="STUDY">AURORA Study 2005</LINK> and <LINK REF="STD-_x0034_D-Study-2004" TYPE="STUDY">4D Study 2004</LINK> (both showing no statistical effect on cardiovascular events) were a reason for negative studies of statins in dialysis, because definitions of endpoints included a smaller proportion of modifiable vascular events. While this is possible, even with the inclusion of <LINK REF="STD-SHARP-Study-2010" TYPE="STUDY">SHARP Study 2010</LINK> (in which cardiovascular events were predominantly occlusive vascular outcomes including revascularisation procedures), statins had little or no effect on cardiovascular outcomes. Finally, data comparing a statin with another statin regimen (different drug or different dose) were sparse for people treated with dialysis.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-08-30 12:11:44 +1000" MODIFIED_BY="[Empty name]">
<P>Overall, data evaluating the effects of statins on mortality and cardiovascular outcomes for dialysis patients is of moderate to high quality and suggests that additional studies are unlikely to change our confidence in the estimates of effect or our confidence in these results. The estimates of treatment effect for mortality, cardiovascular mortality and major cardiovascular events are derived from studies at generally low risks of bias, are consistent between studies, are precise, and are generalisable to dialysis populations outside the RCTs. Direct head-to-head data for different statin agents are sparse and inconclusive.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-05-07 11:10:10 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Although this review was conducted by two or more independent authors, used a comprehensive search of the literature designed by a specialist librarian that included grey literature, and examined all potentially relevant clinical outcomes, potential biases exist in the review process.</P>
<P>We were unable to include data for people treated with dialysis from <LINK REF="STD-SHARP-Study-2010" TYPE="STUDY">SHARP Study 2010</LINK> or <LINK REF="STD-Stegmayr-2005" TYPE="STUDY">Stegmayr 2005</LINK> for all-cause and cardiovascular mortality because reported data combined results for dialysis with earlier stages of kidney disease not treated with dialysis; separate unpublished data for dialysis populations were not available.</P>
<P>Many studies did not systematically report clinical outcomes: all but two either did not report or reported very few mortality events. Similarly, although meta-analyses for mortality and cardiovascular events had no discernible heterogeneity, effects of statins on serum cholesterol levels were markedly different among studies. Subgroup analyses did not identify reasons for differences, including type of dialysis or baseline serum cholesterol.</P>
<P>Adverse events and stroke data were limited by wider confidence intervals and treatment effects were uncertain.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-05-07 11:10:10 +1000" MODIFIED_BY="Gail Y Higgins">
<P>This review analysed current evidence on statin therapy in adults treated with dialysis, updating evidence from its previous two iterations in 2004 and 2009 (<LINK REF="REF-Navaneethan-2004" TYPE="REFERENCE">Navaneethan 2004</LINK>; <LINK REF="REF-Navaneethan-2009a" TYPE="REFERENCE">Navaneethan 2009a</LINK>). This update included 23 studies of statins versus placebo or no treatment in 8166 participants treated with dialysis and two head-to-head studies comparing two different statins.</P>
<P>Data from <LINK REF="STD-AURORA-Study-2005" TYPE="STUDY">AURORA Study 2005</LINK> were included in analyses for mortality and major cardiovascular events, and data from <LINK REF="STD-SHARP-Study-2010" TYPE="STUDY">SHARP Study 2010</LINK> informed analyses of major cardiovascular events. The effect estimates for statins on mortality and adverse events in this review were largely similar to our 2009 review (<LINK REF="REF-Navaneethan-2009a" TYPE="REFERENCE">Navaneethan 2009a</LINK>), finding little or no effect from statins among people treated with dialysis. The possible benefit from statins on non-fatal cardiovascular events in our 2009 review (which included one study of 1255 participants, <LINK REF="STD-_x0034_D-Study-2004" TYPE="STUDY">4D Study 2004</LINK>) was not confirmed following inclusion of three additional studies and more than 5000 participants.</P>
<P>The finding that statins had little or no effect on mortality and cardiovascular outcomes in people treated with dialysis contrasts with a similar systematic review and meta-analysis of studies in people with earlier stages of CKD (<LINK REF="REF-Palmer-2013a" TYPE="REFERENCE">Palmer 2013a</LINK>) and a prospective meta-analysis of data of more general populations <LINK REF="REF-Baigent-2005" TYPE="REFERENCE">Baigent 2005</LINK>. Statin therapy in people with less severe kidney disease proportionally reduced major cardiovascular events by 25% (RR 0.72, 95% CI 0.66 to 0.79) and all-cause mortality by 20% (RR 0.79, 95% CI 0.69 to 0.91) (<LINK REF="REF-Palmer-2013a" TYPE="REFERENCE">Palmer 2013a</LINK>
<U>),</U> and similarly reduced vascular events (RR 0.79, 95% CI 0.77 to 0.81) and all-cause mortality (RR 0.88, 95% CI 0.84 to 0.91) in people with or at risk of cardiovascular disease in the general population (<LINK REF="REF-Baigent-2005" TYPE="REFERENCE">Baigent 2005</LINK>).</P>
<P>In a recent analysis using the current data we showed that treatment effects of statins on mortality and cardiovascular events differ significantly based on stage of kidney disease (data not shown; <LINK REF="REF-Palmer-2012" TYPE="REFERENCE">Palmer 2012</LINK>). Although it is unclear why, despite equivalent lowering of serum cholesterol, statins have less effect in people treated with dialysis, reasons may relate to the competing causes of cardiovascular morbidity (known and unknown) in people treated with dialysis that cannot be modified significantly by the lipid-lowering or other pleiotropic effects of statins.</P>
<P>The smaller risk reductions from statins on death and cardiovascular disease in people treated with dialysis may reflect the competing mechanisms of cardiovascular disease in dialysis patients for whom vascular disease is dominated by vascular calcification, cardiomyopathy, hyperkalaemia, and sudden death, which might be modified to a lesser extent by statin therapy (<LINK REF="REF-ANZDATA-2009" TYPE="REFERENCE">ANZDATA 2009</LINK>). We note that reductions in mortality were small in this meta-analysis despite end of treatment LDL cholesterol lowering by 41 mg/dL (1.1 mmol/L) on average. This small relative effect of lipid-lowering contrasts with a 12% risk reduction (95% CI 9% to 16%) for each 1 mmol/L reduction in LDL cholesterol in a meta-analysis of studies in the general population (<LINK REF="REF-Baigent-2005" TYPE="REFERENCE">Baigent 2005</LINK>). However, because few studies in the current meta-analysis provided data for both all-cause mortality and end of treatment lipid levels, we could not be certain if larger reductions in cholesterol levels might reduce mortality to a greater extent in the dialysis population or whether more aggressive lipid-lowering approaches can be safely achieved with statin therapy.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-07-28 17:44:38 +1000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-05-08 14:14:38 +1000" MODIFIED_BY="[Empty name]">
<P>Statins have little or no effect on mortality or major cardiovascular outcomes in adults treated with dialysis and cannot be routinely recommended to prevent cardiovascular events in this population. The body of included evidence did not address whether statin treatment should be stopped when a person commences dialysis, although the benefits associated with continued treatment are likely to be small. Risks of adverse events for statins on muscle and liver dysfunction and cancer with statin treatment remain uncertain. Insufficient data are available to understand whether treatment effects differ in the clinical setting of haemodialysis compared to peritoneal dialysis or the effect of statin therapy in patients with established vascular disease or recent vascular event.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-07-28 17:44:38 +1000" MODIFIED_BY="[Empty name]">
<P>Statin therapy consistently provides little or no benefit for people treated with dialysis. Despite some limitations, the evidence is generally moderate to high quality according to GRADE recommendations (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>), indicating further large studies may have an important impact on our confidence in the estimate of effect. Additional data for people treated with peritoneal dialysis would improve our confidence in the effects of therapy in this clinical setting. Well-designed RCTs of other interventions to reduce cardiovascular morbidity and death in people on dialysis are now required.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-07-30 13:32:19 +1000" MODIFIED_BY="[Empty name]">
<P>We acknowledge the contribution of study authors (Drs Wanner, Baigent, Diepeveen, Harris) who provided data about their studies upon request. We also thank Narelle Willis, for her help in coordinating and editing this review and Ruth Mitchell and Gail Higgins for assistance in the development of search strategies. We also acknowledge Dr Rakesh Srivastava who contributed to a previous version of this review.</P>
<P>We wish to thank the referees for their comments and feedback during the preparation of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-07-30 18:11:16 +1000" MODIFIED_BY="[Empty name]">
<P>Vlado Perkovic is supported by a fellowship from the Heart Foundation of Australia and various grants from the Australian National Health and Medical Research Council. He has received speaker fees from Roche, Servier and Astra Zeneca, funding for a clinical trial from Baxter, and serves on Steering Committees for trials funded by Johnson and Johnson, Boehringer Ingelheim, Vitae and Abbott. His employer conducts clinical trials funded by Servier, Johnson and Johnson, Roche and Merck.</P>
<P>David Johnson is a consultant for Baxter Healthcare Pty Ltd and has previously received research funds from this company. He has also received speakers&#8217; honoraria and research grants from Fresenius Medical Care and is a current recipient of a Queensland Government Health Research Fellowship. He has also received speakers' honoraria and consultancy fees from Amgen, Janssen-Cilag, Shire, Lilley, Boehringer-Ingelheim and Merck Sharpe &amp; Dohme. He has received a research grant from Pfizer.</P>
<P>Suetonia Palmer received a fellowship administered by the Consorzio Mario Negri Sud from Amgen Dompe for assistance with travel for collaboration and supervision.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-07-31 14:10:13 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Sankar D Navaneethan: concept and design of the review, data extraction, analysis and interpretation of data, writing the final manuscript, final approval of version to be published</LI>
<LI>Suetonia Palmer: data extraction, analysis and interpretation of data, drafting the final manuscript, final approval of version to be published</LI>
<LI>Vlado Perkovic: critical revision for intellectual content, interpretation of data, assistance with writing of the final manuscript, final approval of the manuscript to be submitted for publication</LI>
<LI>Sagar Nigwekar: data extraction, analysis and interpretation of data, writing the final manuscript</LI>
<LI>David W Johnson: data extraction, analysis and interpretation of data, writing the final manuscript, final approval of version to be published</LI>
<LI>Jonathan Craig: concept and design, analysis and interpretation of data, writing the final manuscript, final approval of version to be published</LI>
<LI>Giovanni FM Strippoli: concept and design of the review, data extraction, analysis and interpretation of data, writing the final manuscript, final approval of version to be published</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-09-02 12:03:14 +1000" MODIFIED_BY="[Empty name]">
<P>The duration of treatment in included studies was reduced from 12 weeks to 8 weeks.</P>
<SUBSECTION>
<HEADING LEVEL="2">Differences between original review and review update</HEADING>
<P>The study by Joy 2008 (included in the 2009 update of this review) is now considered to be a report of <LINK REF="STD-Dornbrook_x002d_Lavender-2005" TYPE="STUDY">Dornbrook-Lavender 2005</LINK> and has been incorporated with the references for that study. <LINK REF="STD-Fiorini-1994" TYPE="STUDY">Fiorini 1994</LINK> has now been excluded from the review because the study did not compare a statin with either another statin, placebo, or no treatment. <LINK REF="STD-Dogra-2007" TYPE="STUDY">Dogra 2007</LINK> has now been excluded because the treatment duration was only six weeks.</P>
</SUBSECTION>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-05-12 14:43:36 +1000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-05-12 14:43:36 +1000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-05-12 14:43:36 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-_x0034_D-Study-2004" MODIFIED="2013-07-23 17:33:23 +1000" MODIFIED_BY="Gail Y Higgins" NAME="4D Study 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-10-23 11:56:36 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Drechsler C, Krane V, Grootendorst DC, Ritz E, Winkler K, Marz W, et al</AU>
<TI>The association between parathyroid hormone and mortality in dialysis patients is modified by wasting</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2009</YR>
<VL>24</VL>
<NO>10</NO>
<PG>3151-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19474272"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-10-23 11:56:39 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Drechsler C, Krane V, Ritz E, Marz W, Wanner C</AU>
<TI>Glycemic control and cardiovascular events in diabetic hemodialysis patients</TI>
<SO>Circulation</SO>
<YR>2009</YR>
<VL>120</VL>
<NO>24</NO>
<PG>2421-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19948978"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 17:31:21 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Drechsler C, Krane V, Winkler K, Dekker FW, Wanner C</AU>
<TI>Increasing adiponectin is associated with cardiovascular events and mortality in diabetic patients on hemodialysis [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2008</YR>
<VL>19</VL>
<NO>Abstracts Issue</NO>
<PG>727A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 17:32:38 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krane V, Berger M, Lilienthal J, Winkler K, Schambeck C, Wanner C, et al</AU>
<TI>Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes</TI>
<SO>Clinical Journal of The American Society of Nephrology: CJASN</SO>
<YR>2010</YR>
<VL>5</VL>
<NO>5</NO>
<PG>874-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20185595"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 17:32:29 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krane V, Heinrich F, Meesmann M, Olschewski M, Lilienthal J, Angermann C, et al</AU>
<TI>Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis</TI>
<SO>Clinical Journal of The American Society of Nephrology: CJASN</SO>
<YR>2009</YR>
<VL>4</VL>
<NO>2</NO>
<PG>394-400</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19158371"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-20 11:18:21 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krane V, Krieter DH, Olschewski M, Maerz W, Mann JFE, Ritz E et al</AU>
<TI>Impact of dialyzer membrane characteristics on outcome in type 2 diabetic patients on maintenance hemodialysis: results of the 4D study [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>Abstracts</NO>
<PG>22A</PG>
<IDENTIFIERS MODIFIED="2012-03-20 11:18:21 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 17:32:00 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krane V, Maerz W, Ruf G, Ritz E, Wanner C</AU>
<TI>Atorvastatin in Type 2 diabetic patients on hemodialysis (4D-study): baseline characteristics and 1st interim analysis [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Nov</NO>
<PG>496A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-10-23 11:56:53 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krane V, Winkler K, Drechsler C, Lilienthal J, Marz W, Wanner C, et al</AU>
<TI>Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2009</YR>
<VL>54</VL>
<NO>5</NO>
<PG>902-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19781835"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-10-23 11:56:56 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krane V, Winkler K, Drechsler C, Lilienthal J, Marz W, Wanner C, et al</AU>
<TI>Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis</TI>
<SO>Kidney International</SO>
<YR>2008</YR>
<VL>74</VL>
<NO>11</NO>
<PG>1461-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="18818679"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-19 16:29:54 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marz W, Genser B, Drechsler C, Krane V, Grammer TB, Ritz E, et al</AU>
<TI>Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis</TI>
<SO>Clinical Journal of the American Society of Nephrology: CJASN</SO>
<YR>2011</YR>
<VL>6</VL>
<NO>6</NO>
<PG>1316-25</PG>
<IDENTIFIERS MODIFIED="2011-12-19 16:29:54 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="21493741"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 17:33:17 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, et al</AU>
<TI>Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<NO>3</NO>
<PG>238-48</PG>
<IDENTIFIERS MODIFIED="2009-01-20 11:42:18 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-20 11:42:18 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16034009"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 17:33:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wanner C, Krane V, Marz W, Olschewski M, Asmus HG, Kramer W, et al</AU>
<TI>Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics</TI>
<SO>Kidney &amp; Blood Pressure Research</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>4</NO>
<PG>259-66</PG>
<IDENTIFIERS MODIFIED="2009-01-30 10:43:15 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="15316128"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-30 10:42:39 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wanner C, Krane V, Ruf G, Marz W, Ritz E</AU>
<TI>Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators</TI>
<SO>Kidney International - Supplement</SO>
<YR>1999</YR>
<VL>56</VL>
<NO>Suppl 71</NO>
<PG>S222-6</PG>
<IDENTIFIERS MODIFIED="2009-01-30 10:42:31 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="10412782"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ahmadi-2005" MODIFIED="2013-07-23 17:34:02 +1000" MODIFIED_BY="[Empty name]" NAME="Ahmadi 2005" YEAR="2006">
<REFERENCE MODIFIED="2013-07-23 17:33:50 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ahmadi FI, Eslami K, Maziar S, Lessan-Pezeshki M, Khatami MR, Mahdavi-mazdeh M, et al</AU>
<TI>Effect of lovastatin on high-sensitivity C-reactive protein and hemoglobin in hemodialysis patients [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>Suppl 4</NO>
<PG>iv229</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 17:34:02 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ahmadi FL, Eslami K, Maziar S, Lessan-Pezeshki M, Reza-Khatami M, Mahdavi-mazdeh M, et al</AU>
<TI>Effect of lovastatin on C-reactive protein and hemoglobin in hemodialysis patients [abstract]</TI>
<SO>Nephrology</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>Suppl</NO>
<PG>A283-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Angel-2007" MODIFIED="2013-07-23 17:34:23 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Angel 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-07-23 17:34:13 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Angel JR, Rojas E, del Campo FM, Nava D, Cueto-Manzano A</AU>
<TI>Effect of pravastatin on inflammatory status of CAPD patients: a randomized, double-blinded, controlled and cross-over clinical trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>Abstracts</NO>
<PG>270A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 17:34:23 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zuniga J, Rojas-Campos E, del Campo FM, Nava D, Cueto-Manzano A</AU>
<TI>Effect of pravastatin on the inflammatory status of CAPD patients: a randomized, double-blinded, controlled and cross-over clinical trial [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>Suppl 6</NO>
<PG>vi301</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arabul-2008" MODIFIED="2013-05-30 11:38:34 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Arabul 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-05-30 11:38:34 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arabul M, Gullulu M, Yilmaz Y, Akdag I, Kahvecioglu S, Eren MA, et al</AU>
<TI>Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease</TI>
<SO>Clinical Biochemistry</SO>
<YR>2008</YR>
<VL>41</VL>
<NO>13</NO>
<PG>1055-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="18571502"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-AURORA-Study-2005" MODIFIED="2014-05-12 14:43:29 +1000" MODIFIED_BY="[Empty name]" NAME="AURORA Study 2005" YEAR="2003">
<REFERENCE MODIFIED="2011-10-22 03:23:11 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fellstrom B, Holdaas H, Jardine AG, Rose H, Schmieder R, Wilpshaar W, et al</AU>
<TI>Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study</TI>
<SO>Kidney &amp; Blood Pressure Research</SO>
<YR>2007</YR>
<VL>30</VL>
<NO>5</NO>
<PG>314-22</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17671394"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 17:34:59 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fellstrom B, Holdaas H, Jardine AG, Schmieder RE, Holme I, Zannad F</AU>
<TI>Normalisation of CRP and LDL-C levels is related to reduction of cardiovascular morbidity and mortality in haemodialysis patients on rosuvastatin treatment - a posthoc analysis of the AURORA trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2010</YR>
<VL>21</VL>
<PG>218a</PG>
<IDENTIFIERS MODIFIED="2012-03-20 11:18:34 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 17:36:25 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Fellstrom B, Jardine AG, Holdaas H, Schmieder R, Gottlow M, Johnsson E, et al</AU>
<TI>Effect of rosuvastatin versus placebo on cardiovascular outcomes in patients with end-stage renal disease on hemodialysis - results of the Aurora Study [abstract]</TI>
<SO>World Congress of Nephrology; 2009 May 22-26; Milan (Italy)</SO>
<YR>2009</YR>
<IDENTIFIERS MODIFIED="2012-03-20 11:18:42 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 17:36:36 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fellstrom B, Zannad F, Schmieder R, Holdaas H, Jardine A, Armstrong J, et al</AU>
<TI>A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events - the AURORA study [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>Suppl 4</NO>
<PG>713</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-10-22 03:23:11 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fellstrom B, Zannad F, Schmieder R, Holdaas H, Jardine A, Rose H, et al</AU>
<TI>Effect of rosuvastatin on outcomes in chronic haemodialysis patients - Design and rationale of the AURORA study</TI>
<SO>Current Controlled Trials in Cardiovascular Medicine</SO>
<YR>2005</YR>
<VL>6</VL>
<PG>9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="EMBASE" VALUE="2005487466"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 17:45:02 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al</AU>
<TI>Rosuvastatin and cardiovascular events in patients undergoing hemodialysis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>14</NO>
<PG>1395-407</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19332456"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 17:45:19 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holdaas H, Fellstrom B, Holme I, Schmieder RE, Zannad F, Jardine AG</AU>
<TI>Rosuvastatin and LDL cholesterol in diabetic patients receiving hemodialysis - a posthoc analysis of the AURORA trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2010</YR>
<VL>21</VL>
<PG>12A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-20 11:18:58 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holdaas H, Holme I, Schmieder RE, Jardine AG, Zannad F, Norby GE, et al</AU>
<TI>Rosuvastatin in diabetic hemodialysis patients</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2011</YR>
<VL>22</VL>
<NO>7</NO>
<PG>1335-41</PG>
<IDENTIFIERS MODIFIED="2012-03-20 11:18:56 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="21566054"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 17:45:42 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Holdaas H, Jardine AG, Schmieder R, Gottlow M, Johnsson E, Zannad F, et al</AU>
<TI>Effect of rosuvastatin on cardiovascular outcomes in diabetic patients receiving hemodialysis - results from the Aurora Study [abstract]</TI>
<SO>World Congress of Nephrology; 2009 May 22-26; Milan (Italy)</SO>
<YR>2009</YR>
<IDENTIFIERS MODIFIED="2012-03-20 11:19:05 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 17:46:04 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jardine AG, Fellstrom B, Holdaas H, Gottlow M, Johnsson E, Zannad F, et al</AU>
<TI>Risk factors for cardiovascular events in patients receiving haemodialysis - post hoc analyses of the AURORA study [abstract]</TI>
<SO>World Congress of Nephrology; 2009 May 22-26; Milan (Italy)</SO>
<YR>2009</YR>
<IDENTIFIERS MODIFIED="2012-03-20 11:19:13 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="CTG" VALUE="NCT00240331"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burmeister-2006" MODIFIED="2013-07-23 17:48:06 +1000" MODIFIED_BY="[Empty name]" NAME="Burmeister 2006" YEAR="">
<REFERENCE MODIFIED="2013-07-23 17:48:02 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Burmeister JE, Miltersteiner DR, Campos BM</AU>
<TI>Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein</TI>
<SO>Journal of Nephrology</SO>
<YR>2009</YR>
<VL>22</VL>
<NO>1</NO>
<PG>83-89</PG>
<IDENTIFIERS MODIFIED="2013-07-23 17:48:02 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-23 17:48:02 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19229822"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 17:48:06 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burmeister JE, Miltersteiner DR, Costa MG, Campos BM</AU>
<TI>Short-term results of rosuvastatin therapy over lipid profile and hs-C-reactive protein in patients on regular hemodialysis [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>Suppl 4</NO>
<PG>iv472</PG>
<IDENTIFIERS MODIFIED="2012-03-19 16:54:35 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chang-2002" MODIFIED="2013-07-30 18:19:58 +1000" MODIFIED_BY="[Empty name]" NAME="Chang 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-07-30 18:19:58 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chang JW, Lee MS, Kin SB, Yang WS, Park SK, Lee SK et al</AU>
<TI>Simvastatin decreased high-sensitive c-reactive protein (hs-CRP) and increased serum albumin in hemodialysis (HD) patients [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>Program &amp; Abstracts</NO>
<PG>353A</PG>
<IDENTIFIERS MODIFIED="2012-03-20 11:19:22 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-30 10:47:57 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB</AU>
<TI>Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2002</YR>
<VL>39</VL>
<NO>6</NO>
<PG>1213-7</PG>
<IDENTIFIERS MODIFIED="2009-01-20 11:43:27 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-20 11:43:27 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12046033"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diepeveen-2005" MODIFIED="2013-07-23 17:49:00 +1000" MODIFIED_BY="[Empty name]" NAME="Diepeveen 2005" YEAR="2001">
<REFERENCE MODIFIED="2013-07-23 17:48:35 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bilo HJ, Diepeveen SJ, Verhoeven GH, van der Palen J, Dikkeschei BD, et al</AU>
<TI>Vitaestat 1: alpha-tocopherol and atorvastatin in HD- and PD- patients: a short-term, prospective randomised placebo-controlled intervention trial [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>Program &amp; Abstracts</NO>
<PG>191A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-08 16:06:05 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Diepeveen SH, Verhoeven GH, van der Palen J, Dikkeschei LD, Denmacker PN, Kolsters G, et al</AU>
<TI>Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial</TI>
<SO>Journal of Internal Medicine</SO>
<YR>2005</YR>
<VL>257</VL>
<NO>5</NO>
<PG>438-45</PG>
<IDENTIFIERS MODIFIED="2009-01-20 11:44:43 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-20 11:44:43 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15836660"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 17:49:00 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diepeveen SH, Verhoeven GH, van der Palen J, Dikkeschei LD, Denmacker PN, Kolsters G, et al</AU>
<TI>Vitaestat 1: a prospective randomised placebo controlled trial with a-tocoferol and atorvastatin in patients in hemo- and peritoneal dialysis [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>6</NO>
<PG>A87</PG>
<IDENTIFIERS MODIFIED="2012-01-06 16:43:16 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dornbrook_x002d_Lavender-2005" MODIFIED="2013-07-23 17:49:31 +1000" MODIFIED_BY="[Empty name]" NAME="Dornbrook-Lavender 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-05-15 11:56:21 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dornbrook-Lavender KA, Joy MS, Denu-Ciocca CJ, Chin H, Hogan SL, Pieper JA</AU>
<TI>Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis</TI>
<SO>Pharmacotherapy</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>3</NO>
<PG>335-44</PG>
<IDENTIFIERS MODIFIED="2009-01-20 12:04:29 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-20 12:04:29 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15843280"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-10-23 12:34:00 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joy MS, Dornbrook-Lavender KA, Chin H, Hogan SL, Denu-Ciocca C</AU>
<TI>Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>2008</YR>
<VL>42</VL>
<NO>1</NO>
<PG>9-15</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="18000162"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 17:49:31 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joy MS, Dornbrook-Lavender KA, Chin H, Hogan SL, Denu-Ciocca CJ</AU>
<TI>Atorvastatin can safely and effectively improve cholesterol and contemporary measures of cardiovascular risks in hemodialysis patients [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>Oct</NO>
<PG>615A</PG>
<IDENTIFIERS MODIFIED="2012-03-20 11:19:39 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Han-2011" MODIFIED="2013-07-23 17:49:51 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Han 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-07-23 17:49:51 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Han SH, Kang EW, Yoon SJ, Lee HC, Yoo TH, Choi KH, et al</AU>
<TI>Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2011</YR>
<VL>26</VL>
<NO>11</NO>
<PG>3722-8</PG>
<IDENTIFIERS MODIFIED="2012-03-20 11:20:17 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2012-03-20 11:20:17 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="21385862"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harris-2002" MODIFIED="2013-07-24 17:53:43 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Harris 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-07-24 17:53:43 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Harris KP, Wheeler DC, Chong CC, Atorvastatin in CAPD Study Investigators</AU>
<TI>A placebo controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD</TI>
<SO>Kidney International</SO>
<YR>2002</YR>
<VL>61</VL>
<NO>4</NO>
<PG>1469-74</PG>
<IDENTIFIERS MODIFIED="2013-07-24 17:53:43 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-24 17:53:43 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11918754"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 17:50:15 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wheeler D, Harris KP, UK CAPD Investigators</AU>
<TI>A placebo-controlled trial examining the efficacy and safety of atorvastatin in dyslipidaemic patients undergoing CAPD [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>6</NO>
<PG>A196</PG>
<IDENTIFIERS MODIFIED="2012-03-20 11:20:23 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ichihara-2002" MODIFIED="2013-07-24 17:56:42 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Ichihara 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-03-20 11:20:28 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T</AU>
<TI>Effects of fluvastatin on leg arterial stiffness in hemodialysis patients with type 2 diabetes mellitus [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>Program &amp; Abstracts</NO>
<PG>148A</PG>
<IDENTIFIERS MODIFIED="2012-03-20 11:20:28 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-24 17:56:42 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T</AU>
<TI>Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>8</NO>
<PG>1513-7</PG>
<IDENTIFIERS MODIFIED="2013-07-24 17:56:42 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-24 17:56:42 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12147804"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lins-2004" MODIFIED="2013-07-24 18:02:12 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Lins 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-07-23 17:50:50 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lins RL, Carpentier YA, Clinical Investigators Study Group</AU>
<TI>Plasma lipids and liporoteins during atorvastatin (ATVS) up-titration in hemodialysis patients with hyperlipidemia: a placebo-controlled study [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>Suppl 1</NO>
<PG>124</PG>
<IDENTIFIERS MODIFIED="2012-03-20 11:20:36 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-24 18:02:12 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lins RL, Matthys KE, Billiouw JM, Dratwa M, Dupont P, Lameire NH et al</AU>
<TI>Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study</TI>
<SO>Clinical Nephrology</SO>
<YR>2004</YR>
<VL>62</VL>
<NO>4</NO>
<PG>287-94</PG>
<IDENTIFIERS MODIFIED="2013-07-24 18:02:12 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2013-07-24 18:02:12 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15524059"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PERFECT-Study-1997" MODIFIED="2013-07-30 18:21:15 +1000" MODIFIED_BY="Gail Y Higgins" NAME="PERFECT Study 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-10-23 12:11:58 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Collins JF, Robson R, MacMahon S, Bailey RR, PERFECT Study Group</AU>
<TI>Safety and efficacy of enalapril and simvastatin in dialysis patients [abstract]</TI>
<SO>6th Asian Pacific Congress of Nephrology; 1995 Dec 5-9; Hong Kong</SO>
<YR>1995</YR>
<PG>144</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 17:51:24 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robson R, Collins J, Johnson R, Kitching R, Searle M, Walker R, et al</AU>
<TI>Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis</TI>
<SO>Journal of Nephrology</SO>
<YR>1997</YR>
<VL>10</VL>
<NO>1</NO>
<PG>33-40</PG>
<IDENTIFIERS MODIFIED="2009-01-20 12:15:45 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-20 12:15:45 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9241623"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 17:51:33 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robson R, Collins J, Kitchings R, Searle M, Walker R, Sharpe N, et al</AU>
<TI>A randomized controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1994</YR>
<VL>5</VL>
<NO>3</NO>
<PG>526</PG>
<IDENTIFIERS MODIFIED="2012-03-20 11:20:41 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 17:51:43 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Robson RA, Collins J, Walker RJ, MacMahon S</AU>
<TI>A randomised controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract]</TI>
<SO>ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid (Spain)</SO>
<YR>1995</YR>
<PG>530</PG>
<IDENTIFIERS MODIFIED="2012-03-20 11:20:46 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 17:53:23 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Walker RJ, Sutherland WH, Walker H, Robson RA, MacMahon SA</AU>
<TI>The effects of simvastatin and enalapril on plasma cholesteryl ester transfer (CET) activity in renal failure (RF) [abstract]</TI>
<SO>6th Asian Pacific Congress of Nephrology; 1995 Dec 5-9; Hong Kong</SO>
<YR>1995</YR>
<PG>28</PG>
<IDENTIFIERS MODIFIED="2012-03-20 11:20:52 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 17:52:37 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Walker RJ, Sutherland WH, Walker H</AU>
<TI>Simvastatin and cholesteryl ester transfer (CET) activity in renal failure (RF) [abstract]</TI>
<SO>ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid (Spain)</SO>
<YR>1995</YR>
<PG>529</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-30 18:21:15 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Walker RJ, Sutherland WH, Walker HL, MacMahon S, Robson RA</AU>
<TI>Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. PERFECT Study Collaborative Group</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>1</NO>
<PG>87-92</PG>
<IDENTIFIERS MODIFIED="2013-07-28 15:26:18 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-28 15:26:18 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9027779"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saltissi-HD-2002" MODIFIED="2013-09-02 14:14:09 +1000" MODIFIED_BY="Narelle S Willis" NAME="Saltissi HD 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-07-28 18:21:49 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Saltissi D, Morgan C, Rigby RJ, Westhuyzen J</AU>
<TI>Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2002</YR>
<VL>39</VL>
<NO>2</NO>
<PG>283-90</PG>
<IDENTIFIERS MODIFIED="2013-07-28 18:21:49 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2013-07-28 18:21:49 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11840368"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-02 14:14:09 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Westhuyzen J, Saltissi C, Morgan C, Rigby RJ</AU>
<TI>Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]</TI>
<SO>Nephrology</SO>
<YR>2002</YR>
<VL>7</VL>
<NO>Suppl 3</NO>
<PG>A38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saltissi-PD-2002" MODIFIED="2013-09-02 14:14:09 +1000" MODIFIED_BY="Narelle S Willis" NAME="Saltissi PD 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-07-28 15:46:00 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Saltissi D, Morgan C, Rigby RJ, Westhuyzen J</AU>
<TI>Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2002</YR>
<VL>39</VL>
<NO>2</NO>
<PG>283-90</PG>
<IDENTIFIERS MODIFIED="2013-07-28 15:46:00 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2013-07-28 15:46:00 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="11840368"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-02 14:14:09 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Westhuyzen J, Saltissi C, Morgan C, Rigby RJ</AU>
<TI>Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]</TI>
<SO>Nephrology</SO>
<YR>2002</YR>
<VL>7</VL>
<NO>Suppl 3</NO>
<PG>A38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SHARP-Study-2010" MODIFIED="2014-05-12 14:43:36 +1000" MODIFIED_BY="[Empty name]" NAME="SHARP Study 2010" YEAR="2011">
<REFERENCE MODIFIED="2013-07-28 18:22:11 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baigent C, Landry M</AU>
<TI>Study of Heart and Renal Protection (SHARP)</TI>
<SO>Kidney International - Supplement</SO>
<YR>2003</YR>
<VL>63</VL>
<NO>Suppl 84</NO>
<PG>S207-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12694346"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-28 15:53:03 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Baigent C, Reith C, Emberson J, Wheeler DC, Tomson CR, Wanner C, et al</AU>
<TI>The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>2011</YR>
<VL>377</VL>
<NO>9784</NO>
<PG>2181-92</PG>
<IDENTIFIERS MODIFIED="2013-07-28 15:53:03 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2013-07-28 15:53:03 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="21663949"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-20 11:22:10 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>SHARP Collaborative Group</AU>
<TI>SHARP: an international randomized placebo-controlled trial of lipid-lowering in chronic kidney disease. 1-year safety and efficacy experience [abstract no: SU-PO1044]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>Abstracts Issue</NO>
<PG>817A</PG>
<IDENTIFIERS MODIFIED="2012-03-20 11:22:10 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2012-03-20 11:22:03 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharp Collaborative Group</AU>
<TI>Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease</TI>
<SO>American Heart Journal</SO>
<YR>2010</YR>
<VL>160</VL>
<NO>5</NO>
<PG>785-94</PG>
<IDENTIFIERS MODIFIED="2012-03-20 11:22:01 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="21095263"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 17:58:48 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="OTHER">
<TI>Study of Heart and Renal Protection (SHARP). Final protocol (Version 5: 12th July 2005)</TI>
<SO>http://www.ctsu.ox.ac.uk/~sharp/download_protocol_en_v5.pdf</SO>
<YR>(accessed 23 July 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-03-19 17:02:19 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2012-03-19 17:02:19 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="CTG" VALUE="NCT00125593"/>
<IDENTIFIER MODIFIED="2012-03-19 17:02:06 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="ISRCTN" VALUE="54137607"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soliemani-2011" MODIFIED="2013-07-23 17:59:29 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Soliemani 2011" YEAR="2011 Jan">
<REFERENCE MODIFIED="2013-07-23 17:59:29 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soliemani A, Nikoueinejad H, Tabatabaizade M, Mianehsaz E, Tamadon M</AU>
<TI>Effect of hydroxymethylglutaryl-CoA reductase inhibitors on low-density lipoprotein cholesterol, interleukin-6, and high-sensitivity C-reactive protein in end-stage renal disease</TI>
<SO>Iranian journal of Kidney Diseases</SO>
<YR>2011</YR>
<VL>5</VL>
<NO>1</NO>
<PG>29-33</PG>
<IDENTIFIERS MODIFIED="2013-07-23 17:59:26 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-23 17:59:26 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="21189431"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stegmayr-2005" MODIFIED="2013-07-28 16:07:27 +1000" MODIFIED_BY="[Empty name]" NAME="Stegmayr 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-07-23 17:59:40 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holmberg B, Brannstrom M, Bucht B, Crougneau V, Dimeny E, Ekspong A, et al</AU>
<TI>Safety and efficacy of atorvastatin in patients with severe renal dysfunction</TI>
<SO>Scandinavian Journal of Urology &amp; Nephrology</SO>
<YR>2005</YR>
<VL>39</VL>
<NO>6</NO>
<PG>503-10</PG>
<IDENTIFIERS MODIFIED="2009-01-30 11:05:12 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="16303728"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-28 16:07:27 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stegmayr BG, Brännström M, Bucht S, Crougneau V, Dimeny E, Ekspong A, et al</AU>
<TI>Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study</TI>
<SO>Scandinavian Journal of Urology &amp; Nephrology</SO>
<YR>2005</YR>
<VL>39</VL>
<NO>6</NO>
<PG>489-97</PG>
<IDENTIFIERS MODIFIED="2013-07-28 16:07:27 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-28 16:07:27 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18161210"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 18:00:05 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Stegmayr BG, Brannstrom M, Bucht S, Dimeny E, Ekspong A, Granroth B, et al</AU>
<TI>Safety and efficacy of atorvastatin in patients with impaired renal function [abstract]</TI>
<SO>38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24-27; Vienna (Austria)</SO>
<YR>2001</YR>
<PG>134</PG>
<IDENTIFIERS MODIFIED="2012-03-20 11:22:21 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 18:00:32 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stegmayr BG, Nasstrom BG, Brannstrom M, Bucht S, Dimeny E, Gosch J, et al</AU>
<TI>Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>Program &amp; Abstracts</NO>
<PG>161A</PG>
<IDENTIFIERS MODIFIED="2012-03-20 11:22:27 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 18:02:31 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stegmayr BG, Nasstrom BG, Brannstrom M, Bucht S, Dimeny E, Granroth B, et al</AU>
<TI>Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>Program &amp; Abstracts</NO>
<PG>268A</PG>
<IDENTIFIERS MODIFIED="2012-03-20 11:22:31 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tse-2008" MODIFIED="2013-07-28 16:26:11 +1000" MODIFIED_BY="[Empty name]" NAME="Tse 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-07-28 16:26:11 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tse KC, Yung S, Tang CS, Tam S, Lai KN, Chan TM</AU>
<TI>Atorvastatin at conventional dose did not reduce C-reactive protein in patients on peritoneal dialysis</TI>
<SO>Journal of Nephrology</SO>
<YR>2008</YR>
<VL>21</VL>
<NO>3</NO>
<PG>283</PG>
<IDENTIFIERS MODIFIED="2013-07-28 16:26:11 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2013-07-28 16:26:11 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18587714"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-UK_x002d_HARP_x002d_I-2005" MODIFIED="2013-07-28 18:25:58 +1000" MODIFIED_BY="Gail Y Higgins" NAME="UK-HARP-I 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-07-28 16:29:14 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, et al</AU>
<TI>First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2005</YR>
<VL>45</VL>
<NO>3</NO>
<PG>473-84</PG>
<IDENTIFIERS MODIFIED="2013-07-28 16:29:14 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2013-07-28 16:29:14 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15754269"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-28 18:25:58 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baigent C, UK-HARP Steering Committee</AU>
<TI>Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>Program &amp; Abstracts</NO>
<PG>437A</PG>
<IDENTIFIERS MODIFIED="2012-03-20 11:22:40 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-den-Akker-2003" MODIFIED="2013-07-30 18:22:52 +1000" MODIFIED_BY="[Empty name]" NAME="van den Akker 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-07-30 18:22:52 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van den Akker JM, Bredie SJ, Diepenveen SH, van Tits LJ, Stalenhoef AF, van Leusen R</AU>
<TI>Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL</TI>
<SO>Journal of Nephrology</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>2</NO>
<PG>238-44</PG>
<IDENTIFIERS MODIFIED="2013-07-28 16:44:26 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-28 16:44:26 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12768071"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vareesangthip-2005" MODIFIED="2013-07-23 18:04:57 +1000" MODIFIED_BY="[Empty name]" NAME="Vareesangthip 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-07-23 18:04:57 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vareesangthip K, Laouthaiwattana P, Hanlakorn P, Suwannaton L, Larpkitkachorn R, Chuawattana D, et al</AU>
<TI>Effects of simvastatin on the kinetics of erythrocyte sodium lithium countertransport and C-reactive protein in hemodialysis patients [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2005</YR>
<VL>16</VL>
<PG>276A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Velickovic-1997" MODIFIED="2011-10-26 05:55:22 +1100" MODIFIED_BY="[Empty name]" NAME="Velickovic 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-10-22 03:18:06 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Velickovic-Radovanovic R, Avramovic M, Malobabic Z, Djordjevic V, Kostic S, Mitic B</AU>
<TI>Therapeutic effects of simvastatin on hyperlipidemia in uraemic patients on CAPD [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>9</NO>
<PG>A187</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vernaglione-2003" MODIFIED="2013-07-23 18:05:48 +1000" MODIFIED_BY="[Empty name]" NAME="Vernaglione 2003" YEAR="2004">
<REFERENCE MODIFIED="2013-04-24 13:13:31 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vernaglione L, Cristofano C, Muscogiuri P, Chimienti S</AU>
<TI>Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis?</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2004</YR>
<VL>43</VL>
<NO>3</NO>
<PG>471-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14981605"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 18:05:36 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vernaglione L, Cristofano C, Muscogiuri P, Pennacchiotti F, Chimienti S</AU>
<TI>Analysis of the impact of atorvastatin (ATO) on c-reactive protein (CRP) levels in haemodialysis patients (HDP) [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>Nov</NO>
<PG>41A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 18:05:48 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vernaglione L, Cristofano C, Pennacchiotti F, Muscogiuri P, Chimienti S</AU>
<TI>Effects of atorvastatin (ATO) on C-reactive protein (CRP) levels in haemodialysis patients (HDP) : a prospective study [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>Suppl 4</NO>
<PG>712-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-2007" MODIFIED="2013-07-23 18:06:00 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Yu 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-07-23 18:06:00 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu MH, Lee JH, Min WK, Chi HS, Chang JW, Yang WS, et al</AU>
<TI>Effects of ezetimibe and ezetimibe plus simvastatin (Vytorin®) on markers for inflammation and thrombogenesis in end-stage renal disease (ESRD) patients [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>Suppl 6</NO>
<PG>vi322</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-09-02 14:14:09 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Akcicek-1996" MODIFIED="2013-07-23 18:06:48 +1000" MODIFIED_BY="[Empty name]" NAME="Akcicek 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-07-23 18:06:48 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akcicek F, Ok E, Duman S, Kursad S, Unsal A, Alev M, et al</AU>
<TI>Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study</TI>
<SO>Advances in Peritoneal Dialysis</SO>
<YR>1996</YR>
<VL>12</VL>
<PG>261-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8865916"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bunio-2004" MODIFIED="2013-07-23 18:07:01 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Bunio 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-07-23 18:07:01 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bunio A, Kwiecinski R, Steciwko A, Migas A</AU>
<TI>Effect of lipid lowering treatment on direct markers of bone metabolism in hemodialysis patients [abstract]</TI>
<SO>41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon (Portugal)</SO>
<YR>2004</YR>
<PG>320-1</PG>
<IDENTIFIERS MODIFIED="2012-03-20 11:22:56 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cappelli-2000" MODIFIED="2013-07-23 18:07:14 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Cappelli 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-07-23 18:07:14 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cappelli P, Di Liberato L, Del Rosso G, Bonomini M</AU>
<TI>Lipid-lowering therapy in patients with chronic renal failure [abstract]</TI>
<SO>37th Congress. European Renal Association. European Dialysis and Transplantation Association. European Kidney Research Organisation; 2000 Sept 17-20; Nice (France)</SO>
<YR>2000</YR>
<PG>181</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-1995" MODIFIED="2013-07-23 18:07:46 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Cheng 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-07-23 18:07:46 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cheng IKP, Li PWC, Janus ED, Tang CSO, Chan TM, Lo CY</AU>
<TI>Comparative efficacy of gemfibrozil (G) and simvastatin (S) in the treatment of hyperlipidaemia in renal transplant recipients (RT) - a randomised prospective study [abstract]</TI>
<SO>ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid (Spain)</SO>
<YR>1995</YR>
<PG>383</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CHORUS-Study-2001" MODIFIED="2013-07-23 18:08:18 +1000" MODIFIED_BY="Suetonia Palmer" NAME="CHORUS Study 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-07-23 18:08:18 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keane WF, Brenner BM, Mazzu A, Agro A</AU>
<TI>The CHORUS (Cerivastatin in Heart Outcomes in Renal Disease: Understanding Survival) protocol: a double-blind, placebo-controlled trial in patients with ESRD</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2001</YR>
<VL>37</VL>
<NO>1 Suppl 2</NO>
<PG>S48-53</PG>
<IDENTIFIERS MODIFIED="2013-07-23 18:08:18 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-23 18:08:18 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11158861"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dogra-2007" MODIFIED="2013-07-30 18:27:15 +1000" MODIFIED_BY="[Empty name]" NAME="Dogra 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-07-30 18:27:15 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dogra G, Irish A, Chan D, Watts G</AU>
<TI>A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2007</YR>
<VL>49</VL>
<NO>6</NO>
<PG>776-85</PG>
<IDENTIFIERS MODIFIED="2012-01-31 14:35:10 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2012-01-31 14:35:10 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="17533020"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-23 18:08:38 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dogra S, Kanganas C, Chan D, Irish A, Watts G</AU>
<TI>Effect of statin and fibrate therapy on vascular function in chronic kidney disease (CKD) [abstract]</TI>
<SO>Nephrology</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>Suppl 3</NO>
<PG>A422</PG>
<IDENTIFIERS MODIFIED="2012-01-31 14:34:31 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-01-31 14:35:50 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2012-01-31 14:35:50 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="OTHER" VALUE="CRG080500011"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fiorini-1992" MODIFIED="2013-07-23 18:09:10 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Fiorini 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-07-23 18:09:10 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fiorini F, Patrone E, Ardu F, Castelluccio A</AU>
<TI>Efficacy and safety of simvastatin in the treatment of hyperlipidemia in uremic patients undergoing hemodialysis treatment</TI>
<SO>Minerva Urologica e Nefrologica</SO>
<YR>1992</YR>
<VL>44</VL>
<NO>2</NO>
<PG>165-8</PG>
<IDENTIFIERS MODIFIED="2013-07-23 18:09:05 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-23 18:09:05 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="1411867"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fiorini-1994" MODIFIED="2013-07-23 18:09:43 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Fiorini 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-07-23 18:09:43 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fiorini F, Patrone E, Castelluccio A</AU>
<TI>Clinical investigation on the hypolipidemic effect of simvastatin versus probucol in hemodialysis patients</TI>
<SO>Clinica Terapeutica</SO>
<YR>1994</YR>
<VL>145</VL>
<NO>9</NO>
<PG>213-7</PG>
<IDENTIFIERS MODIFIED="2013-07-23 18:09:38 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-23 18:09:38 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="7813167"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hufnagel-2000" MODIFIED="2013-04-23 16:46:06 +1000" MODIFIED_BY="[Empty name]" NAME="Hufnagel 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-04-23 16:46:06 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hufnagel G, Michel C, Vrtovsnik F, Queffeulou G, Kossari N, Mignon F</AU>
<TI>Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>5</NO>
<PG>684-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10809811"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khajehdehi-2000" MODIFIED="2013-07-23 18:10:07 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Khajehdehi 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-07-23 18:10:07 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Khajehdehi A, Khajehdehi P</AU>
<TI>Lipid lowering effect of polyunsaturated fatty acids in hemodialysis (HD) patients [abstract]</TI>
<SO>37th Congress. European Renal Association. European Dialysis and Transplantation Association. European Kidney Research Organisation; 2000 Sept 17-20; Nice (France)</SO>
<YR>2000</YR>
<PG>200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2009" MODIFIED="2013-07-23 18:10:25 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Kim 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-07-23 18:10:25 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kim YJ, Lee HK, Jeong JU, Kim SB, Park JS, Moon KH, et al</AU>
<TI>Effects of rosuvastatin and gemfibrozil on small dense LDL-cholesterol in chronic hemodialysis (CHD) patients [abstract]</TI>
<SO>World Congress of Nephrology 2009; May 22-26; Milan (Italy)</SO>
<YR>2009</YR>
<IDENTIFIERS MODIFIED="2012-03-19 17:03:32 +1100" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kishimoto-2010" MODIFIED="2013-07-23 18:10:42 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Kishimoto 2010" YEAR="2010 Nov 5">
<REFERENCE MODIFIED="2013-07-23 18:10:42 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kishimoto N, Hayashi T, Sakuma I, Kano-Hayashi H, Tsunekawa T, Osawa M, et al</AU>
<TI>A hydroxymethylglutaryl coenzyme A reductase inhibitor improves endothelial function within 7 days in patients with chronic hemodialysis</TI>
<SO>International Journal of Cardiology</SO>
<YR>2010</YR>
<VL>145</VL>
<NO>1</NO>
<PG>21-6</PG>
<IDENTIFIERS MODIFIED="2012-03-19 17:04:02 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="19481279"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-1993" MODIFIED="2013-04-23 16:46:21 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Li 1993" YEAR="1992">
<REFERENCE MODIFIED="2012-01-31 14:38:44 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li PK, Mak TW, Chiu K, Mak GY, Leung CB, Lui SF, et al</AU>
<TI>Effect of lovastatin on serum lipid profile in the treatment of dyslipoproteinaemia in uraemic patients on continuous ambulatory peritoneal dialysis</TI>
<SO>Australian &amp; New Zealand Journal of Medicine</SO>
<YR>1993</YR>
<VL>23</VL>
<NO>3</NO>
<PG>252-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8352699"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-04-23 16:46:21 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li PK, Mak TW, Lam CW, Lai KN</AU>
<TI>Lovastatin treatment of dyslipoproteinemia in patients on continuous ambulatory peritoneal dialysis</TI>
<SO>Peritoneal Dialysis International</SO>
<YR>1993</YR>
<VL>13 Suppl 2</VL>
<PG>S428-30</PG>
<IDENTIFIERS MODIFIED="2009-01-20 12:24:35 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-20 12:24:35 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8399631"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lins-2003" MODIFIED="2012-03-20 11:23:29 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Lins 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-03-20 11:23:29 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lins RL, Matthys KE, Verpooten GA, Peeters PC, Dratwa M, Stolear JC, et al</AU>
<TI>Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>5</NO>
<PG>967-76</PG>
<IDENTIFIERS MODIFIED="2012-03-20 11:23:26 +1100" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="12686673"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lynoe-2004" MODIFIED="2011-10-23 12:24:40 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Lynoe 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-10-23 12:23:26 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lynoe N, Nasstrom B, Sandlund M</AU>
<TI>Study of the quality of information given to patients participating in a clinical trial regarding chronic hemodialysis</TI>
<SO>Scandinavian Journal of Urology &amp; Nephrology</SO>
<YR>2004</YR>
<VL>38</VL>
<NO>6</NO>
<PG>517-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15841789"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malyszko-2002" MODIFIED="2013-09-02 14:14:09 +1000" MODIFIED_BY="[Empty name]" NAME="Malyszko 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-09-02 14:14:09 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malyszko J, Malyszko JS, Hryszko T, Brzosko S, Mysliwiec M</AU>
<TI>Simvastatin and markers of endothelial function in patients undergoing continuous ambulatory peritoneal dialysis</TI>
<SO>International Journal of Tissue Reactions</SO>
<YR>2002</YR>
<VL>24</VL>
<NO>3</NO>
<PG>111-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12635864"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nishikawa-1999" MODIFIED="2013-07-23 18:11:28 +1000" MODIFIED_BY="[Empty name]" NAME="Nishikawa 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-07-23 18:11:28 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nishikawa O, Mune M, Miyano M, Nishide T, Nishide I, Maeda A, et al</AU>
<TI>Effect of simvastatin on the lipid profile of hemodialysis patients</TI>
<SO>Kidney International - Supplement</SO>
<YR>1999</YR>
<VL>71</VL>
<PG>219-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10412781"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nishizawa-1995" MODIFIED="2013-07-23 18:11:34 +1000" MODIFIED_BY="[Empty name]" NAME="Nishizawa 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-07-23 18:11:34 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nishizawa Y, Shoji T, Emoto M, Kawaskai K, Konishi T, Tabata T, et al</AU>
<TI>Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients</TI>
<SO>Clinical Nephrology</SO>
<YR>1995</YR>
<VL>43</VL>
<NO>4</NO>
<PG>268-77</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7606882"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rincon-1995" MODIFIED="2013-07-30 18:24:54 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Rincon 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-07-30 18:24:54 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rincon B, Tornero F, Uson J, Garcia-Carzon A, Lozano L</AU>
<TI>Efficacy and side effects of HMG-CoA reductase inhibitors in the treatment of hyperlipemia in hemodialysis patients [abstract]</TI>
<SO>ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid (Spain)</SO>
<YR>1995</YR>
<PG>531</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Samuelsson-2002" MODIFIED="2013-05-08 16:08:55 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Samuelsson 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-10-23 12:35:49 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alaupovic P, Attman PO, Knight-Gibson C, Mulec H, Weiss L, Samuelsson O</AU>
<TI>Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency</TI>
<SO>Kidney International</SO>
<YR>2006</YR>
<VL>69</VL>
<NO>10</NO>
<PG>1865-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16572113"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-08 16:08:55 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Samuelsson O, Attman PO, Knight-Gibson C, Mulec H, Weiss L, Alaupovic P</AU>
<TI>Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2002</YR>
<VL>39</VL>
<NO>1</NO>
<PG>67-75</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11774104"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sezer-2004" MODIFIED="2013-07-28 18:24:28 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Sezer 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-07-28 18:24:28 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Sezer M, Katirci S, Adana S, Erturk J, Kaya S</AU>
<TI>Simvastatin decreases tumor necrosis factor alpha in patients on peritoneal dialysis [abstract]</TI>
<SO>41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon (Portugal)</SO>
<YR>2004</YR>
<PG>181</PG>
<IDENTIFIERS MODIFIED="2013-07-28 18:24:28 +1000" MODIFIED_BY="Narelle S Willis"/>
</REFERENCE>
<REFERENCE MODIFIED="2011-10-23 12:24:50 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sezer MT, Katirci S, Demir M, Erturk J, Adana S, Kaya S</AU>
<TI>Short-term effect of simvastatin treatment on inflammatory parameters in peritoneal dialysis patients</TI>
<SO>Scandinavian Journal of Urology &amp; Nephrology</SO>
<YR>2007</YR>
<VL>41</VL>
<NO>5</NO>
<PG>436-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17853009"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singh-2002" MODIFIED="2013-07-23 18:12:37 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Singh 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-07-23 18:12:37 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singh B, Srinivasan B, Narsipur SS</AU>
<TI>Effect of simvastatin use on autonomic function in patients with end stage renal disease [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>Program &amp; Abstracts</NO>
<PG>217A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tani-1998" MODIFIED="2013-04-23 16:46:56 +1000" MODIFIED_BY="[Empty name]" NAME="Tani 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-04-23 16:46:56 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tani M, Inagaki M, Oguchi K</AU>
<TI>Favorable effects of long-term low-dose pravastatin administration on lipid metabolism in chronic hemodialysis patients with hypercholesterolemia</TI>
<SO>Journal of the Showa Medical Association</SO>
<YR>1999</YR>
<VL>59</VL>
<NO>1</NO>
<PG>22-7</PG>
<IDENTIFIERS MODIFIED="2009-01-20 12:25:10 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-20 12:25:10 +1100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="1999206546"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-UK_x002d_HARP_x002d_II-2006" MODIFIED="2013-05-08 16:09:32 +1000" MODIFIED_BY="Suetonia Palmer" NAME="UK-HARP-II 2006" YEAR="2003">
<REFERENCE MODIFIED="2013-05-08 16:09:32 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Landray M, Baigent C, Leaper C, Adu D, Altmann P, Armitage J, et al</AU>
<TI>The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2006</YR>
<VL>47</VL>
<NO>3</NO>
<PG>385-95</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16490616"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-10-23 12:25:20 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Landray M, Baigent C, Leaper C, the UK-HARP Steering Committee</AU>
<TI>Biochemical safety and efficacy of co-administration of Ezetimibe and Simvastatin among patients with chronic kidney disease: the second UK-heart and renal protection (UK-HARP-II) study [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>Suppl 4</NO>
<PG>119-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CRG060500006"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wanner-1991" MODIFIED="2013-04-23 16:47:02 +1000" MODIFIED_BY="[Empty name]" NAME="Wanner 1991" YEAR="">
<REFERENCE MODIFIED="2013-04-23 16:47:02 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wanner C, Horl WH, Luley CH, Wieland H</AU>
<TI>Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis</TI>
<SO>Kidney International</SO>
<YR>1991</YR>
<VL>39</VL>
<NO>4</NO>
<PG>754-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2051734"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wanner-1992" MODIFIED="2013-04-23 16:47:08 +1000" MODIFIED_BY="[Empty name]" NAME="Wanner 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-04-23 16:47:08 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wanner C, Lubrich-Birkner I, Summ O, Weiland H, Schollmeyer P</AU>
<TI>Effect of simvastatin on qualitative and quantitative changes of lipoprotein metabolism in CAPD patients</TI>
<SO>Nephron</SO>
<YR>1992</YR>
<VL>62</VL>
<NO>1</NO>
<PG>40-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1436290"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yigit-2004" MODIFIED="2011-10-23 12:26:27 +1100" MODIFIED_BY="Suetonia Palmer" NAME="Yigit 2004" YEAR="2004 Nov">
<REFERENCE MODIFIED="2011-10-23 12:26:27 +1100" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yigit F, Muderrisoglu H, Guz G, Bozbas H, Korkmaz ME, Ozin MB, et al</AU>
<TI>Comparison of intermittent with continuous simvastatin treatment in hypercholesterolemic patients with end stage renal failure</TI>
<SO>Japanese Heart Journal</SO>
<YR>2004</YR>
<VL>45</VL>
<NO>6</NO>
<PG>959-68</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15655271"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2000" MODIFIED="2013-07-23 18:13:33 +1000" MODIFIED_BY="[Empty name]" NAME="Zhu 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-07-23 18:13:33 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu XP, Li J, Liu FY, Liu YH</AU>
<TI>Effects of Simvastatin in continuous ambulatory peritoneal dialysis patients with hyperlipidemia</TI>
<SO>Bulletin of Hunan Medical University</SO>
<YR>2000</YR>
<VL>25</VL>
<NO>2</NO>
<PG>154-6</PG>
<IDENTIFIERS MODIFIED="2013-07-23 18:13:33 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-23 18:13:33 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12212206"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-03-02 13:45:51 +1100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2013-07-23 18:22:08 +1000" MODIFIED_BY="Gail Y Higgins">
<STUDY DATA_SOURCE="PUB" ID="STD-Nardi-2005" MODIFIED="2013-07-23 18:14:07 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Nardi 2005" YEAR="2005 Mar">
<REFERENCE MODIFIED="2013-07-23 18:14:07 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nardi H</AU>
<TI>Clinical protocol. Pravastatin for the prevention of the destruction of the nutritional status of hemodialysis patients exhibiting chronic inflammation</TI>
<SO>Nephrologie et Therapeutique</SO>
<YR>2005</YR>
<VL>1</VL>
<NO>1</NO>
<PG>75-6</PG>
<IDENTIFIERS MODIFIED="2013-07-23 18:14:05 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-23 18:14:05 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16895670"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00291863" MODIFIED="2013-07-23 18:22:08 +1000" MODIFIED_BY="Gail Y Higgins" NAME="NCT00291863" YEAR="2010">
<REFERENCE MODIFIED="2013-07-23 18:22:08 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00291863</AU>
<TI>Simvastatin effect on endothelium dependent venodilation in chronic renal failure patients treated by peritoneal dialysis</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT00291863</SO>
<YR>(accessed 23 July 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="CTG" VALUE="NCT00291863"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00858637" MODIFIED="2013-07-23 18:21:58 +1000" MODIFIED_BY="Suetonia Palmer" NAME="NCT00858637" YEAR="2010">
<REFERENCE MODIFIED="2013-07-23 18:21:58 +1000" MODIFIED_BY="Suetonia Palmer" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00858637</AU>
<TI>Efficacy and safety study of MCI-196 versus simvastatin for dyslipidaemia in chronic kidney disease (CKD) subjects on dialysis</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT00858637</SO>
<YR>(accessed 23 July 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="CTG" VALUE="NCT00858637"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00999453" MODIFIED="2013-07-23 18:21:49 +1000" MODIFIED_BY="Gail Y Higgins" NAME="NCT00999453" YEAR="2010">
<REFERENCE MODIFIED="2013-07-23 18:21:49 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="OTHER">
<AU>Kang SW</AU>
<TI>The effects of lowering low-density lipoprotein cholesterol levels to new targets on cardiovascular complications in peritoneal dialysis patients</TI>
<SO>http://www.clinicaltrials.gov/ct2/show/NCT00999453</SO>
<YR>(accessed 23 July 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="CTG" VALUE="NCT00999453"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-09-02 13:14:30 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-09-02 13:14:30 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-ANZDATA-2009" MODIFIED="2013-07-24 16:06:53 +1000" MODIFIED_BY="Suetonia Palmer" NAME="ANZDATA 2009" TYPE="OTHER">
<AU>Australia and New Zealand Transplant Registry (ANZDATA)</AU>
<TI>The 32nd Annual Report 2009 Report - Data to 2008</TI>
<SO>http://www.anzdata.org.au/v1/report_2009.html</SO>
<YR>(accessed 24 July 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baigent-2005" MODIFIED="2013-07-28 18:23:00 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Baigent 2005" TYPE="JOURNAL_ARTICLE">
<AU>Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al</AU>
<TI>Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>366</VL>
<NO>9493</NO>
<PG>1267-78</PG>
<IDENTIFIERS MODIFIED="2013-07-28 18:23:00 +1000" MODIFIED_BY="Suetonia Palmer">
<IDENTIFIER MODIFIED="2013-07-28 18:23:00 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="16214597"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Briel-2006" MODIFIED="2013-07-28 18:23:12 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Briel 2006" TYPE="JOURNAL_ARTICLE">
<AU>Briel M, Schwartz GG, Thompson PL, de Lemos JA, Blazing MA, van Es GA, et al</AU>
<TI>Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>295</VL>
<NO>17</NO>
<PG>2046-56</PG>
<IDENTIFIERS MODIFIED="2013-07-28 18:23:12 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2013-07-28 18:23:12 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="16670413"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-FDA-2011" MODIFIED="2013-07-24 16:11:39 +1000" MODIFIED_BY="Suetonia Palmer" NAME="FDA 2011" TYPE="OTHER">
<AU>Smith JP</AU>
<TI>Clinical Briefing Document. Endocrinologic and Metabolic Drugs Advisory Committee Meeting. November 2, 2011. New Drug Application 21-687/S-039:Vytorin (ezetimibe/simvastatin). New Drug Application 21-445/S-033:Zetia (ezetimibe)</TI>
<SO>http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM277649.pdf</SO>
<YR>(accessed 24 July 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Foley-2007" MODIFIED="2013-07-28 18:23:18 +1000" MODIFIED_BY="[Empty name]" NAME="Foley 2007" TYPE="JOURNAL_ARTICLE">
<AU>Foley RN, Collins AJ</AU>
<TI>End-stage renal disease in the United States: an update from the United States Renal Data System</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>10</NO>
<PG>2644-8</PG>
<IDENTIFIERS MODIFIED="2013-07-28 18:23:18 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-28 18:23:18 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17656472"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ganesh-2001" MODIFIED="2009-01-20 12:33:24 +1100" MODIFIED_BY="[Empty name]" NAME="Ganesh 2001" TYPE="JOURNAL_ARTICLE">
<AU>Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK</AU>
<TI>Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>10</NO>
<PG>2131-8</PG>
<IDENTIFIERS MODIFIED="2009-01-20 12:33:24 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-20 12:33:24 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11562412"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2013-07-28 18:23:28 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7650</NO>
<PG>924-6</PG>
<IDENTIFIERS MODIFIED="2013-07-28 18:23:28 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2013-07-28 18:23:28 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="18436948"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Herzog-1998" MODIFIED="2013-07-28 18:23:31 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Herzog 1998" TYPE="JOURNAL_ARTICLE">
<AU>Herzog C A, Ma J Z, Collins A J</AU>
<TI>Poor long-term survival after acute myocardial infarction among patients on long-term dialysis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>339</VL>
<NO>12</NO>
<PG>799-805</PG>
<IDENTIFIERS MODIFIED="2013-07-28 18:23:31 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2013-07-28 18:23:31 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="9738087"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Herzog-2011" MODIFIED="2013-07-28 18:23:34 +1000" MODIFIED_BY="[Empty name]" NAME="Herzog 2011" TYPE="JOURNAL_ARTICLE">
<AU>Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, et al</AU>
<TI>Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)</TI>
<SO>Kidney International</SO>
<YR>2011</YR>
<VL>80</VL>
<NO>6</NO>
<PG>572-86</PG>
<IDENTIFIERS MODIFIED="2013-07-28 18:23:34 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2013-07-28 18:23:34 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="21750584"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2013-07-28 18:23:38 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS MODIFIED="2013-07-28 18:23:38 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-28 18:23:38 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12958120"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-07-24 16:14:38 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JP, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jungers-1997" MODIFIED="2012-03-20 11:31:30 +1100" MODIFIED_BY="[Empty name]" NAME="Jungers 1997" TYPE="JOURNAL_ARTICLE">
<AU>Jungers P, Massy ZA, Khoa TN, Fumeron C, Labrunie M, Lacour B, et al</AU>
<TI>Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>12</NO>
<PG>2597-602</PG>
<IDENTIFIERS MODIFIED="2009-01-20 12:38:04 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-20 12:38:04 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9430858"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Law-1994" MODIFIED="2009-01-20 13:41:23 +1100" MODIFIED_BY="[Empty name]" NAME="Law 1994" TYPE="JOURNAL_ARTICLE">
<AU>Law MR, Wald NJ, Thompson SG</AU>
<TI>By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>308</VL>
<NO>6925</NO>
<PG>367-72</PG>
<IDENTIFIERS MODIFIED="2009-01-20 13:41:23 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-20 13:41:23 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8043072"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mallamaci-2002" MODIFIED="2012-03-20 11:31:05 +1100" MODIFIED_BY="[Empty name]" NAME="Mallamaci 2002" TYPE="JOURNAL_ARTICLE">
<AU>Mallamaci F, Zoccali C, Tripepi G, Fermo I, Benedetto FA, Cataliotti A, et al</AU>
<TI>Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients</TI>
<SO>Kidney International</SO>
<YR>2002</YR>
<VL>61</VL>
<NO>2</NO>
<PG>609-13</PG>
<IDENTIFIERS MODIFIED="2009-01-20 13:52:57 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-20 13:52:57 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11849403"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Navaneethan-2009b" MODIFIED="2013-09-02 13:07:17 +1000" MODIFIED_BY="Narelle S Willis" NAME="Navaneethan 2009b" TYPE="COCHRANE_REVIEW">
<AU>Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, et al</AU>
<TI>HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-09-02 13:02:44 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2013-09-02 13:02:44 +1000" MODIFIED_BY="Narelle S Willis" TYPE="DOI" VALUE="10.1002/14651858.CD007784"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Navaneethan-2009c" MODIFIED="2013-09-02 13:07:11 +1000" MODIFIED_BY="Narelle S Willis" NAME="Navaneethan 2009c" TYPE="COCHRANE_REVIEW">
<AU>Navaneethan SD, Perkovic V, Johnson DW, Nigwekar SU, Craig JC, Strippoli GF</AU>
<TI>HMG CoA reductase inhibitors (statins) for kidney transplant recipients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-09-02 11:58:25 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2013-09-02 11:58:25 +1000" MODIFIED_BY="Narelle S Willis" TYPE="DOI" VALUE="10.1002/14651858.CD005019.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Palmer-2012" MODIFIED="2013-09-02 13:05:00 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Palmer 2012" TYPE="JOURNAL_ARTICLE">
<AU>Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF</AU>
<TI>Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2012</YR>
<VL>157</VL>
<NO>4</NO>
<PG>263-75</PG>
<IDENTIFIERS MODIFIED="2013-09-02 13:05:00 +1000" MODIFIED_BY="Suetonia Palmer">
<IDENTIFIER MODIFIED="2013-09-02 13:05:00 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="22910937"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Palmer-2013a" MODIFIED="2013-09-02 13:08:43 +1000" MODIFIED_BY="[Empty name]" NAME="Palmer 2013a" TYPE="COCHRANE_REVIEW">
<AU>Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J, et al</AU>
<TI>HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>in press</NO>
<IDENTIFIERS MODIFIED="2013-06-04 09:19:22 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Palmer-2013b" MODIFIED="2013-09-02 13:14:30 +1000" MODIFIED_BY="Narelle S Willis" NAME="Palmer 2013b" TYPE="COCHRANE_REVIEW">
<AU>Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, et al</AU>
<TI>HMG CoA reductase inhibitors (statins) for kidney transplant recipients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>in press</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rossouw-1990" MODIFIED="2009-01-20 13:54:18 +1100" MODIFIED_BY="[Empty name]" NAME="Rossouw 1990" TYPE="JOURNAL_ARTICLE">
<AU>Rossouw JE, Lewis B, Rifkind BM</AU>
<TI>The value of lowering cholesterol after myocardial infarction</TI>
<SO>New England Journal of Medicine</SO>
<YR>1990</YR>
<VL>323</VL>
<NO>16</NO>
<PG>1112-9</PG>
<IDENTIFIERS MODIFIED="2009-01-20 13:54:18 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-20 13:54:18 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="2215579"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Trivedi-2009" MODIFIED="2013-07-28 18:23:53 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Trivedi 2009" TYPE="JOURNAL_ARTICLE">
<AU>Trivedi H, Xiang Q, Klein J P</AU>
<TI>Risk factors for non-fatal myocardial infarction and cardiac death in incident dialysis patients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2009</YR>
<VL>24</VL>
<NO>1</NO>
<PG>258-66</PG>
<IDENTIFIERS MODIFIED="2013-07-28 18:23:53 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2013-07-28 18:23:53 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="18682489"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-USRDS-2011" MODIFIED="2013-07-24 16:17:24 +1000" MODIFIED_BY="[Empty name]" NAME="USRDS 2011" TYPE="OTHER">
<AU>United States Renal Data System</AU>
<TI>USRDS 2011 Annual Data Report. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD</TI>
<SO>http://www.usrds.org/2011/pdf/v2_ch04_11.pdf</SO>
<YR>(accessed 24 July 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weiner-2006" MODIFIED="2013-07-28 18:24:02 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Weiner 2006" TYPE="JOURNAL_ARTICLE">
<AU>Weiner D E, Tabatabai S, Tighiouart H, Elsayed E, Bansal N, Griffith J, et al</AU>
<TI>Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2006</YR>
<VL>48</VL>
<NO>3</NO>
<PG>392-401</PG>
<IDENTIFIERS MODIFIED="2013-07-28 18:24:02 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2013-07-28 18:24:02 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="16931212"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wetmore-2009" MODIFIED="2013-07-28 18:24:06 +1000" MODIFIED_BY="Suetonia Palmer" NAME="Wetmore 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wetmore JB, Shireman TI</AU>
<TI>The ABCs of cardioprotection in dialysis patients: a systematic review</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2009</YR>
<VL>53</VL>
<NO>3</NO>
<PG>457-66</PG>
<IDENTIFIERS MODIFIED="2013-07-28 18:24:06 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2013-07-28 18:24:06 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="19022545"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-09-02 13:07:21 +1000" MODIFIED_BY="Narelle S Willis">
<REFERENCE ID="REF-Navaneethan-2003" MODIFIED="2009-01-21 17:35:50 +1100" MODIFIED_BY="Narelle S Willis" NAME="Navaneethan 2003" TYPE="COCHRANE_PROTOCOL">
<AU>Navaneethan SD, Shrivastava R</AU>
<TI>HGM CoA reductase inhibitors (statins) for lowering cholesterol in dialysis patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2009-01-21 17:35:45 +1100" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2009-01-21 17:35:45 +1100" MODIFIED_BY="Narelle S Willis" TYPE="DOI" VALUE="10.1002/14651858.CD004289"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Navaneethan-2004" MODIFIED="2013-07-24 16:21:16 +1000" MODIFIED_BY="Narelle S Willis" NAME="Navaneethan 2004" TYPE="COCHRANE_REVIEW">
<AU>Navaneethan SD, Shrivastava R</AU>
<TI>HMG CoA reductase inhibitors (statins) for dialysis patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-07-24 16:21:16 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2013-07-24 16:21:16 +1000" MODIFIED_BY="Narelle S Willis" TYPE="DOI" VALUE="10.1002/14651858.CD004289.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Navaneethan-2009a" MODIFIED="2013-09-02 13:07:21 +1000" MODIFIED_BY="[Empty name]" NAME="Navaneethan 2009a" TYPE="COCHRANE_REVIEW">
<AU>Navaneethan SD, Nigwekar SU, Perkovic V, Johnson DW, Craig JC, Strippoli GF</AU>
<TI>HMG CoA reductase inhibitors (statins) for dialysis patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>3</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD004289.pub4"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2008-07-21 16:15:40 +1000" MODIFIED_BY="Narelle S Willis"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-05-07 11:10:10 +1000" MODIFIED_BY="Gail Y Higgins">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-05-07 11:10:10 +1000" MODIFIED_BY="Gail Y Higgins" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-08-30 09:39:10 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x0034_D-Study-2004">
<CHAR_METHODS MODIFIED="2013-07-23 16:58:02 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: March 1998 to March 2004</LI>
<LI>Follow-up period: 3.96 years (atorvastatin group); 3.91 years (placebo group)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-23 17:07:08 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Germany</LI>
<LI>Setting: multicentre</LI>
<LI>Inclusion criteria: patients with type 2 DM aged 18 to 80 years who had been receiving maintenance HD &lt; 2 years</LI>
<LI>Number (treatment/control): 619/636</LI>
<LI>Age (mean ± SD) years: treatment group (65.7 ± 8.3); control group (65.7 ± 8.3)</LI>
<LI>Sex (M/F): treatment group (333/286); control group (344/292)</LI>
<LI>Exclusion criteria: Levels of fasting serum LDL &lt; 80 mg/dL or &gt; 190 mg/dL, TG levels &gt; 1000 mg/dL; liver function values &gt; 3 x ULN or equal to those in patient with symptomatic hepatobiliary cholestatic disease; haematopoietic disease or systemic disease unrelated to ESKD; vascular intervention, CHF or MI within the 3 months preceding the period of enrolment; unsuccessful kidney transplantation; hypertension resistant to therapy</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-23 16:58:58 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Atorvastatin</LI>
<UL>
<LI>Dose: 20 mg/d</LI>
<LI>Treatment duration: 6 months</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-01-21 16:59:35 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Primary outcome</LI>
<UL>
<LI>Composite of death from cardiac causes, fatal stroke, nonfatal MI, or nonfatal stroke</LI>
</UL>
<LI>Death from all causes</LI>
<UL>
<LI>All cardiac events combined, and all cerebrovascular events combined</LI>
</UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-30 09:37:44 +1000" MODIFIED_BY="Narelle S Willis">
<P>Industry funding received</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-02 13:16:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ahmadi-2005">
<CHAR_METHODS MODIFIED="2013-07-28 17:04:39 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: NR</LI>
<LI>Follow-up period: 3 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-02 13:16:22 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Iran</LI>
<LI>Setting: multicentre</LI>
<LI>Inclusion criteria: chronic HD patients CRP &gt; 10 mg/L</LI>
<LI>Number (treatment/control): 14/13</LI>
<LI>Age (mean ± SD) years: treatment group (57 ± 8); control group (56 ± 9)</LI>
<LI>Sex (M/F): unclear</LI>
<LI>Exclusion criteria: patients with illnesses or drugs that may affect CRP levels</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-23 17:05:08 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Lovastatin</LI>
<UL>
<LI>20 mg daily</LI>
<LI>Treatment duration: 3 months</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>No medications</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-23 17:07:24 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Hb levels</LI>
<LI>CRP levels</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-30 10:44:15 +1000" MODIFIED_BY="[Empty name]">
<P>Abstract only</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-30 10:44:21 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Angel-2007">
<CHAR_METHODS MODIFIED="2013-07-28 17:04:46 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Study design: double-blinded cross-over RCT</LI>
<LI>Time frame: NR</LI>
<LI>Follow-up period: 2 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-23 17:10:49 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Country: Mexico</LI>
<LI>Setting: NR</LI>
<LI>Inclusion criteria: CAPD patients without present or past (3 months) evidence of inflammation or anti-inflammatory drug intake (including statins or NSAIDs)</LI>
<LI>Age (mean ± SD) years: 54 ± 12 years</LI>
<LI>Sex: NR</LI>
<LI>Exclusion criteria: NR</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-23 17:21:37 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Treatment group</P>
<UL>
<LI>Pravastatin</LI>
<UL>
<LI>Dose: 20 mg daily</LI>
<LI>Treatment duration: 2 months</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-28 17:03:30 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>BMI</LI>
<LI>Creatinine</LI>
<LI>TC, LDL</LI>
<LI>TG</LI>
<LI>IL-6, CRP</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-30 10:44:21 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Abstract only publication</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-30 09:45:11 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Arabul-2008">
<CHAR_METHODS MODIFIED="2013-07-23 17:15:15 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Study design: placebo-controlled RCT</LI>
<LI>Time frame: NR</LI>
<LI>Follow-up period: 8 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-29 15:57:35 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Country: Turkey</LI>
<LI>Inclusion criteria: aged &#8805; 18 years receiving either HD or PD; duration of dialysis of at least 6 months and presence of renal anaemia and dyslipidaemia</LI>
<LI>Setting: NR</LI>
<LI>Number (treatment/control): 22/18</LI>
<LI>Age (mean ± SD) years: treatment group (48.7 ± 11.3); control group (43.6 ± 14.4)</LI>
<LI>Sex (M/F): treatment group (12/10); control group (10/8)</LI>
<LI>Exclusion criteria: pregnancy, malignancy, presence of acute inflammatory disorders, current drug use (statins, NSAIDs, immunosuppression), liver or thyroid disease, and haemodynamic instability</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-23 17:15:42 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Treatment group</P>
<UL>
<LI>Fluvastatin</LI>
<UL>
<LI>Dose: 40 mg twice daily</LI>
<LI>Treatment duration: 8 weeks</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-28 17:03:34 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>TC, LDL, HDL</LI>
<LI>TG</LI>
<LI>hs-CRP</LI>
<LI>Prohepcidin</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-30 09:43:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-AURORA-Study-2005">
<CHAR_METHODS MODIFIED="2013-07-24 16:28:41 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: January 2003 to December 2008</LI>
<LI>Follow-up period: mean 3.2 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-23 17:19:17 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: International</LI>
<LI>Setting: multicentre</LI>
<LI>Inclusion criteria: patients treated with HD or HF for at least 3 months and aged 50 to 80 years</LI>
<LI>Number (treatment/control): 1389/1384</LI>
<LI>Age (mean ± SD) years: treatment group (64.1 ± 8.6); control group (64.3 ± 8.7)</LI>
<LI>Sex (M/F): treatment group (851/538); control group (812/512)</LI>
<LI>Exclusion criteria: statins therapy 6 months,<B> </B>expected kidney transplantation within 1 year, and serious haematologic, neoplastic, gastrointestinal, infectious, or metabolic disease (excluding diabetes) predicted to limit life expectancy to &lt; 1 year; history of malignant condition, active liver disease (indicated by an AST level &gt; 3 x ULN), uncontrolled hypothyroidism, and an unexplained elevation in CK level &gt; 3 x ULN</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-23 17:19:39 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Rosuvastatin</LI>
<UL>
<LI>Dose: 10 mg</LI>
<LI>Treatment duration: mean 3.2 years, maximum 5.6 months</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-30 18:12:06 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Primary endpoint: Time to a major cardiovascular event defined as non-fatal MI, non-fatal stroke or death from cardiovascular causes</LI>
<LI>Secondary endpoints: all-cause mortality, cardiovascular event&#8211;free survival (i.e. freedom from non-fatal MI, non-fatal stroke, cardiovascular cause mortality, and all-cause mortality), procedures performed for stenosis or thrombosis of the vascular access for long-term HD (arteriovenous fistulas and grafts only), and coronary or peripheral revascularisation, death from cardiovascular causes, and death from non-cardiovascular causes</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-30 09:43:41 +1000" MODIFIED_BY="[Empty name]">
<P>Industry funding received</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-30 09:43:55 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burmeister-2006">
<CHAR_METHODS MODIFIED="2013-07-28 17:05:03 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: double-blind placebo controlled RCT</LI>
<LI>Time frame: NR</LI>
<LI>Follow-up period: 3 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-24 16:35:41 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Brazil</LI>
<LI>Setting: single centre</LI>
<LI>Inclusion criteria: patients undergoing regular 4 hour HD sessions 3 x week for at least 3 months</LI>
<LI>Number (treatment/control): 28/31</LI>
<LI>Age (mean ± SD) years: treatment group (53.7 ± 16.6); control group (60.1 ± 13.8)</LI>
<LI>Sex (M/F): treatment group (16/12); control group (21/10)</LI>
<LI>Exclusion criteria: uncontrolled DM (HbA1C &gt; 9%), fasting LDL-C &gt; 190 mg/dL, TG &gt; 400 mg/dL, impaired hepatic function (aminotransferases &gt; 3 x ULN reference value, or symptomatic hepatobiliary cholestatic disease), elevated SCr phosphokinase levels, use of beta-blockers, any active infectious disease, past or present malignancies, acute myocardial insufficiency, or any other systemic disease not related to CRF, and previous usage of any lipid-lowering drug for the last 3 months</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-24 16:36:06 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Rosuvastatin</LI>
<UL>
<LI>Dose: 10 mg/d</LI>
<LI>Treatment duration: 3 months</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-29 16:04:45 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Serum lipids (TC, LDL, HDL, TG)</LI>
<LI>Apo B</LI>
<LI>hs-CRP</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-30 09:43:55 +1000" MODIFIED_BY="[Empty name]">
<P>Industry funding received</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-30 09:44:15 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chang-2002">
<CHAR_METHODS MODIFIED="2013-07-24 16:46:07 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: 2000 to 2001</LI>
<LI>Follow-up period: 8 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-24 16:47:34 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: South Korea</LI>
<LI>Setting: single centre</LI>
<LI>Inclusion criteria: HD patients with TC &gt; 200 mg/dL</LI>
<LI>Number (treatment/control): 31/31</LI>
<LI>Age (mean ± SD) years: treatment group (63 ± 11); control group (60 ± 12)</LI>
<LI>Sex (M/F): treatment group (8/23); control group (10/21)</LI>
<LI>Exclusion criteria: active inflammation; infection; on other hypolipidaemic agents; other intercurrent illnesses</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-24 16:47:46 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Simvastatin</LI>
<UL>
<LI>Dose: 20 mg</LI>
<LI>Treatment duration: 2 months</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-24 16:47:57 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Lipoprotein profiles and CRP levels</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-30 09:44:15 +1000" MODIFIED_BY="[Empty name]">
<P>Industry funding received</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-02 11:43:25 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Diepeveen-2005">
<CHAR_METHODS MODIFIED="2013-07-24 16:54:06 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: placebo controlled RCT</LI>
<LI>Time frame: NR</LI>
<LI>Study duration: 12 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-24 17:08:18 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Netherlands</LI>
<LI>Setting: single centre</LI>
<LI>Inclusion criteria: clinically stable non-diabetic patients on dialysis therapy; without manifest CVD</LI>
<LI>Number (group 1/group 2/group 3/control): 13/10/11/10</LI>
<UL>
<LI>HD (23); PD (21)</LI>
</UL>
<LI>Age (mean ± SD) years group 1 (46 ± 15); group 2 (47 ± 16); group 3 (51 ± 20); control group (51 ± 18)</LI>
<LI>Sex (M/F): group 1 (9/4); group 2 (8/2); group 3 (5/6); control group (8/2)</LI>
<LI>Exclusion criteria: NR</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-02 11:43:25 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>Atrovastatin + alfa-tocopherol placebo</LI>
<UL>
<LI>Dose: 40 mg, once/d</LI>
</UL>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Alfa-tocopherol + atorvastatin placebo</LI>
<UL>
<LI>Dose: 800 IU, once/d</LI>
</UL>
</UL>
<P>Treatment group 3</P>
<UL>
<LI>Alfa-tocopherol</LI>
<UL>
<LI>Dose: 800 IU, once/d</LI>
</UL>
<LI>Atorvastatin</LI>
<UL>
<LI>Dose: 40 mg, once/d</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Alfa-tocopherol placebo + atorvastatin placebo</LI>
</UL>
<P>Treatment duration: 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-01-20 15:02:24 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-30 09:44:31 +1000" MODIFIED_BY="[Empty name]">
<P>Study included 4 arms and we compared treatment group 1 and the control group (see interventions)</P>
<P>Industry funding received</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-30 09:44:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dornbrook_x002d_Lavender-2005">
<CHAR_METHODS MODIFIED="2013-07-24 17:37:16 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: unblinded parallel RCT</LI>
<LI>Time frame: June 2001 to October 2002</LI>
<LI>Follow-up period: 20 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-24 17:36:42 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: USA</LI>
<LI>Setting: two centres</LI>
<LI>Inclusion criteria: HD patients with normal liver function, CK levels and LDL &gt; 100 mg/dL</LI>
<LI>Number (treatment/control): 9/10</LI>
<LI>Age (mean ± SD) years: treatment group (70 ± 15); control group (62 ± 15)</LI>
<LI>Sex (M/F): treatment group (3/6); control group (4/6)</LI>
<LI>Exclusion criteria: pregnancy; known allergies to statin; history of alcohol use</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-24 17:36:57 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Atorvastatin</LI>
<UL>
<LI>Dose: 10 mg</LI>
</UL>
<LI>Treatment duration: 20 weeks</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No treatment</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-01-20 15:17:14 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Lipoprotein profiles and CRP levels</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-30 09:44:35 +1000" MODIFIED_BY="[Empty name]">
<P>Industry funding received</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-30 09:45:15 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Han-2011">
<CHAR_METHODS MODIFIED="2013-07-24 17:41:23 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: open-label prospective RCT</LI>
<LI>Time frame: January 2008 to December 2008</LI>
<LI>Follow-up period: 6 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-24 17:43:42 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Korea</LI>
<LI>Setting: single centre</LI>
<LI>Inclusion criteria: aged &gt; 20 years and maintained on PD &gt; 3 months</LI>
<LI>Number (treatment/control): 57/57</LI>
<LI>Age (mean ± SD) years: 48.8 ± 11.0</LI>
<LI>Sex (M/F): 55/69</LI>
<LI>Exclusion criteria: patients with overt infection during 3 months prior to study and history of malignancy or other chronic inflammatory disease, such as systemic lupus erythematosus or rheumatoid arthritis</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-24 17:45:00 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Rosuvastatin</LI>
<UL>
<LI>Dose: 10 mg/d</LI>
</UL>
<LI>Valsartan</LI>
<UL>
<LI>Dose: 80 mg/d</LI>
</UL>
<LI>Treatment duration: 6 months</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Valsartan</LI>
<UL>
<LI>Dose: 80 mg/d</LI>
<LI>Treatment duration: 6 months</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-08 15:41:38 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Clinical adverse events along with ALT, AST, CK monitoring</LI>
<LI>All-cause mortality</LI>
<LI>Inflammatory markers, oxidative stress and pulse wave velocity</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-30 10:37:04 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harris-2002">
<CHAR_METHODS MODIFIED="2013-07-24 17:54:21 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: RCT</LI>
<LI>Time frame: November 1998 to February 2000</LI>
<LI>Follow-up period: 16 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-24 17:51:21 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: UK/Ireland</LI>
<LI>Setting: 33 centres</LI>
<LI>Inclusion criteria: CAPD or APD for at least 3 months, TC &gt; 200 mg/dL, LDL &gt; 135 mg/dL, dyslipidaemia uncontrolled by other lipid-lowering therapy for at least 4 weeks</LI>
<LI>Number (treatment/control): 82/94</LI>
<LI>Age (mean ± SD) years: treatment group (56.7 ± 15.4); control group (57.5 ± 13.5)</LI>
<LI>Sex (M/F): treatment group (47/35); control group (42/52)</LI>
<LI>Exclusion criteria: active liver disease or Increased ALT or AST (&gt; 3 x ULN), concurrent therapy with immunosuppressants, uncontrolled DM, patient receiving other lipid-lowering agents, patients with history of PTCA, CABG within 3 months, alcohol abuse, clinical evidence of inflammatory muscle disease and TC &gt; 310 mg/dL)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-24 17:55:32 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Atorvastatin</LI>
<UL>
<LI>Dose: 10 mg; dose increased to 40 mg as needed to achieve LDL &lt; 135 mg/dL</LI>
<LI>Treatment duration: 16 weeks</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-01-20 17:43:55 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Clinical adverse events along with ALT, AST, CK monitoring</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-24 18:01:18 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ichihara-2002">
<CHAR_METHODS MODIFIED="2013-07-24 17:59:29 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: RCT</LI>
<LI>Time frame: NR</LI>
<LI>Follow-up period: 6 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-24 18:01:04 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Japan</LI>
<LI>Setting: single centre</LI>
<LI>Inclusion criteria: HD for at least 6 months, with no pre-existing CVD, secondary hyperparathyroidism and fasting blood glucose &gt; 110 mg/dL</LI>
<LI>Number (treatment/control): 12/10</LI>
<LI>Age (mean ± SD) years: treatment group (65.8 ± 3.0); control group (64.3 ± 3.7)</LI>
<LI>Sex (M/F): treatment group (8/4); control group (6/4)</LI>
<LI>Exclusion criteria: premenopausal women, patients on HRT, alcohol consumption</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-24 18:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Fluvastatin</LI>
<UL>
<LI>Dose: 10 mg</LI>
<LI>Treatment duration: 6 months</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-01-20 17:46:28 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Pulse wave velocity, CRP levels</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-30 10:36:16 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lins-2004">
<CHAR_METHODS MODIFIED="2013-07-24 18:05:14 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: placebo-controlled RCT</LI>
<LI>Time frame: March 1998 to October 1999</LI>
<LI>Follow-up period: 12 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-30 15:18:30 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Belgium</LI>
<LI>Setting: multicentre (10 HD centres)</LI>
<LI>Inclusion criteria: TC &gt; 210 mg/dL and total TG &gt; 500 mg/d</LI>
<LI>Number (treatment/control): 23/19</LI>
<LI>Age (mean ± SD) years: treatment group (63.8 ± 12.3); control group (65.2 ± 9.3)</LI>
<LI>Sex (male): treatment group (92%); control group (73%)</LI>
<LI>Exclusion criteria: pregnancy, breastfeeding, LFT &gt; 3 x ULN, HbA1C &gt; 10%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-24 18:09:02 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Atorvastatin</LI>
<UL>
<LI>Dose: forced 4 weekly titration of 10 to 20 mg and up to 40 mg once daily</LI>
<LI>Treatment duration: 12 weeks</LI>
</UL>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-28 15:38:04 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, TG, LDL, HDL) and Apo (A-I, A-II, B, E, CIII)</LI>
<LI>Adverse events (specific details unknown)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-30 10:36:16 +1000" MODIFIED_BY="[Empty name]">
<P>Industry funding received</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-02 11:18:26 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PERFECT-Study-1997">
<CHAR_METHODS MODIFIED="2013-07-28 15:33:29 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Duration: NR</LI>
<LI>Follow-up: 6 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-28 15:38:16 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: New Zealand</LI>
<LI>Setting: multicentre</LI>
<LI>Inclusion criteria: HD and CAPD patients</LI>
<LI>Number (treatment/control): simvastatin (24); placebo (29)</LI>
<LI>Age (mean ± SD) years: 50 ± 15</LI>
<LI>Sex<B> </B>(M/F): 32/21</LI>
<LI>Exclusion criteria: definite indication for statin or ACEi, known allergy to either drug, planned transplant from living related donor in next 12 months, CHF, severe valve disease, supine systolic BP &gt; 100 mm Hg or significant postural hypotension, uncontrolled hypertension, hepatitis B or C positive, AST or ALT &gt; 2 X ULN, treatment with cyclosporin or a fibrate, life threatening illness or serious debilitating disease other than CKD</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-28 15:35:13 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group (B)</P>
<UL>
<LI>Simvastatin</LI>
<UL>
<LI>Dose: 10 mg/d</LI>
</UL>
<LI>Placebo enalapril</LI>
<LI>Treatment duration: 6 months</LI>
</UL>
<P>Control group (D)</P>
<UL>
<LI>Placebo simvastatin</LI>
<LI>Placebo enalapril</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-28 15:37:42 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Apo A, Apo B</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-02 11:18:26 +1000" MODIFIED_BY="[Empty name]">
<P>Study had four arms</P>
<UL>
<LI>Group A: simvastatin plus enalapril</LI>
<LI>Group B: simvastatin plus placebo enalapril</LI>
<LI>Group C: placebo simvastatin plus enalapril</LI>
<LI>Group D: placebo simvastatin plus placebo enalapril</LI>
</UL>
<P>Industry funding received</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-02 11:45:03 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saltissi-HD-2002">
<CHAR_METHODS MODIFIED="2013-07-28 15:46:52 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: stratified, placebo-controlled RCT</LI>
<LI>Time frame: NR</LI>
<LI>Follow-up period: 24 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-02 11:45:03 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Australia</LI>
<LI>Setting: single centre</LI>
<LI>Inclusion criteria: HD or CAPD for 9 months, non-HDL &gt; 135 mg/dL, LDL &gt; 116 mg/dL, TG &lt; 600 mg/dL</LI>
<LI>Number (treatment/control): 22/12</LI>
<LI>Age (mean ± SD) years: treatment group (59.5 ± 13.9); control group (62.8 ± 9.6)</LI>
<LI>Sex (M/F): treatment group (6/16); control group (5/7)</LI>
<LI>Exclusion criteria: impaired hepatic function; elevated creatine phosphokinase; myocardial insufficiency; uncontrolled DM; active infection; malignancy; treatment with other lipid-lowering agents</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-28 15:43:07 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Simvastatin</LI>
<UL>
<LI>Dose: 5 mg and dose was increased to 20 mg as needed to achieve non-HDL &lt; 135 mg/dL</LI>
</UL>
<LI>Treatment duration: 24 weeks</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-28 15:37:49 +1000" MODIFIED_BY="[Empty name]">
<P>Lipid parameters (TC, LDL, HDL, TG, Lp (a), Apo A1)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-30 10:39:07 +1000" MODIFIED_BY="Narelle S Willis">
<P>This is the same study as <LINK REF="STD-Saltissi-PD-2002" TYPE="STUDY">Saltissi PD 2002</LINK>
</P>
<P>Industry funding received</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-02 11:45:15 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saltissi-PD-2002">
<CHAR_METHODS MODIFIED="2013-07-28 15:47:13 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: stratified, placebo-controlled RCT</LI>
<LI>Time frame: NR</LI>
<LI>Follow-up period: 24 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-02 11:45:15 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Australia</LI>
<LI>Setting: single centre</LI>
<LI>Inclusion criteria: HD or CAPD for 9 months, non-HDL &gt; 135 mg/dL, LDL &gt; 116 mg/dL, TG &lt; 600 mg/dL</LI>
<LI>Number (treatment/control): 16/7</LI>
<LI>Age (mean ± SD) years: treatment group (55.3 ± 13.3); control group (61.0 ± 7.6)</LI>
<LI>Sex (M/F): treatment group (4/12); control group (1/6)</LI>
<LI>Exclusion criteria: impaired hepatic function; elevated creatine phosphokinase; myocardial insufficiency; uncontrolled DM; active infection; malignancy; treatment with other lipid-lowering agents</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-28 15:49:50 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Simvastatin</LI>
<UL>
<LI>Dose: 5 mg and dose was increased to 20 mg as needed to achieve non-HDL &lt; 135 mg/dL</LI>
</UL>
<LI>Treatment duration: 24 weeks</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-28 15:37:52 +1000" MODIFIED_BY="[Empty name]">
<P>Lipid parameters (TC, LDL, HDL, TG, Lp (a), Apo A1)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-30 10:40:02 +1000" MODIFIED_BY="Narelle S Willis">
<P>This is the same study as <LINK REF="STD-Saltissi-HD-2002" TYPE="STUDY">Saltissi HD 2002</LINK>
</P>
<P>Industry funding received</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-07 11:10:10 +1000" MODIFIED_BY="Gail Y Higgins" STUDY_ID="STD-SHARP-Study-2010">
<CHAR_METHODS MODIFIED="2013-07-28 17:06:18 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: double blind RCT</LI>
<LI>Time frame: August 2003 to August 2010</LI>
<LI>Follow-up period: 4.9 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-02 13:17:33 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: multinational</LI>
<LI>Setting: multicentre</LI>
<LI>Inclusion criteria: predialysis (SCr &#8805;1.7 mg/dL (&#8805; 150 &#956;mol/L) in men or &#8805; 1.5 mg/dL (&#8805; 130 &#956;mol/L) in women at both the most recent routine clinic visit and the study screening visit) or dialysis (HD or PD); men or women aged &#8805; 40 years</LI>
<LI>Number (treatment/control): 1533/1490 (dialysis patients only)</LI>
<LI>Age (mean ± SD) years: treatment group (62 ± 12); control group (62 ± 12)</LI>
<LI>Sex (M): treatment group (2915, 63%); control group (2885, 62%)</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Confirmed history of MI or coronary revascularisation procedure</LI>
<LI>Functioning renal transplant or living donor renal transplant planned</LI>
<LI>&lt; 2 months since presentation as an acute uraemic emergency</LI>
<LI>Confirmed history of chronic liver disease or abnormal liver function (i.e. ALT N1.5 x ULN or, if ALT not available, AST N1.5 x ULN) (patients with history of hepatitis were eligible if these limits not exceeded)</LI>
<LI>Evidence of active inflammatory muscle disease (e.g. dermatomyositis, polymyositis) or CK N3 x ULN</LI>
<LI>Confirmed previous adverse reaction to a statin or to ezetimibe</LI>
<LI>Concurrent treatment with a contraindicated drug:</LI>
</UL>
<UL>
<UL>
<LI>Hydroxymethylglutaryl&#8211;coenzyme A reductase inhibitor (statin)</LI>
<LI>Ezetimibe</LI>
<LI>Fibric acid derivative (fibrate)</LI>
<LI>Nicotinic acid</LI>
<LI>Cyclosporin</LI>
<LI>Macrolide antibiotic (erythromycin, clarithromycin)</LI>
<LI>Systemic use of imidazole or triazole antifungals (e.g. itraconazole, ketoconazole)</LI>
<LI>Protease-inhibitors (e.g. antiretroviral drugs for HIV infection)</LI>
<LI>Nefazodone</LI>
</UL>
</UL>
<UL>
<LI>Childbearing potential (i.e. premenopausal woman not using a reliable method of contraception)</LI>
<LI>Known to be poorly compliant with clinic visits or prescribed medication</LI>
<LI>Medical history that might limit the individual's ability to participate in trial treatments for the duration of the study (e.g. severe respiratory disease, history of cancer other than non-melanoma skin cancer, or recent history of alcohol or substance misuse)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-28 15:59:25 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Simvastatin</LI>
<UL>
<LI>Dose: 20 mg/d</LI>
</UL>
<LI>Ezetimibe</LI>
<UL>
<LI>Dose: 10 mg/d</LI>
</UL>
<LI>Treatment duration: 4.9 years</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-28 15:59:55 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Major atherosclerotic events (defined as non-fatal MI or coronary death, non-haemorrhagic stroke, or arterial revascularisation excluding dialysis access procedures)</LI>
<LI>Lipid profile</LI>
<LI>Kidney function: SCr</LI>
<LI>Adverse events: CK, ALT, AST</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-07 11:10:10 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Only dialysis patients data from the <LINK REF="STD-SHARP-Study-2010" TYPE="STUDY">SHARP Study 2010</LINK> trial have been included in this review</P>
<P>Industry funding received</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-29 16:06:49 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Soliemani-2011">
<CHAR_METHODS MODIFIED="2013-07-28 16:01:47 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Study design: double-blinded RCT</LI>
<LI>Time frame: 2009</LI>
<LI>Follow-up period: 2 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-28 16:04:45 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Country: Iran</LI>
<LI>Setting: single centre</LI>
<LI>Inclusion criteria: HD patients aged &lt; 70 years</LI>
<LI>Number (treatment 1/treatment 2/treatment 3): 31/32/32</LI>
<LI>Age (mean ± SD) years: treatment group 1 (49.8 ± 12.3); treatment group 2 (47.2 ± 9.4); treatment group 3 (51.6 ± 14.2)</LI>
<LI>Sex (M/F): treatment group 1 (21/10); treatment group 2 (19/13); treatment group 3 (22/10)</LI>
<LI>Exclusion criteria: infectious, inflammatory or rheumatic diseases during the past 2 months (based on physician's records); MI, CVA, or any indisposition during the past 3 months; and having been receiving statins, NSAIDs, corticosteroid, or other immunological inhibitors (e.g. cyclosporin) within the past 3 months</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-28 16:06:17 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Treatment group 1</P>
<UL>
<LI>Atorvastatin</LI>
<UL>
<LI>Dose: 10 mg/d</LI>
</UL>
<LI>Treatment duration: 2 months</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Simvastatin</LI>
<UL>
<LI>Dose: 20 mg/d</LI>
</UL>
<LI>Treatment duration: 2 months</LI>
</UL>
<P>Treatment group 3</P>
<UL>
<LI>Lovastatin</LI>
<UL>
<LI>Dose: 40 mg/d</LI>
</UL>
<LI>Treatment duration: 2 months</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-29 16:06:49 +1000" MODIFIED_BY="Suetonia Palmer">
<OL>
<LI>CRP</LI>
<LI>IL-6</LI>
<LI>TC, LDL, HDL</LI>
<LI>TG</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-28 16:20:13 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stegmayr-2005">
<CHAR_METHODS MODIFIED="2013-07-28 16:08:53 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: open RCT</LI>
<LI>Time frame: from February 1998</LI>
<LI>Follow-up period: 5 years</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-28 16:18:02 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Sweden</LI>
<LI>Setting: multicentre</LI>
<LI>Inclusion criteria: GFR &lt; 30 mL/min/1.73 m²</LI>
<LI>Number (treatment/control): 70/73</LI>
<LI>Age (mean ± SD) years: treatment group (67.8 ± 12.4); control group (69.4 ± 10.2)</LI>
<LI>Sex (M/F): treatment group (48/22); control group (51/22)</LI>
<LI>Exclusion criteria: aged &lt; 18 years; fertile women not taking oral contraceptives; pregnant or lactating women; active liver disease; history of adverse reactions to statins; patients with functioning kidney transplant not on dialysis; patients on waiting list for transplantation; those on protein-restricted diet &lt; 40 g protein/day; poor compliance to medication and follow-up; history of progressive malignancy and life expectancy &lt; 6 months</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-28 16:18:16 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Atorvastatin</LI>
<UL>
<LI>Dose: 10 mg/d</LI>
</UL>
<LI>Treatment duration: 35 ± 20.1 months (range 1 to 67 months)</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
<LI>Treatment duration: 31 ± 21.4 months (range 0.5 to 69 months)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-28 16:20:13 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>All-cause mortality</LI>
<LI>AMI</LI>
<LI>need for PTCA</LI>
<LI>CABG</LI>
<LI>Lipid profile</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-30 18:13:36 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tse-2008">
<CHAR_METHODS MODIFIED="2013-07-28 16:22:04 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: RCT</LI>
<LI>Time frame: NR</LI>
<LI>Follow-up period: 12 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-29 16:05:14 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Hong Kong</LI>
<LI>Setting: single centre</LI>
<LI>Inclusion criteria: dialysis patients with elevated baseline hs-CRP (&#8805;1.50 mg/L) without concomitant infection or inflammatory conditions</LI>
<LI>Number (treatment/control): NR</LI>
<LI>Age: NR</LI>
<LI>Sex (M/F): NR</LI>
<LI>Exclusion criteria: NR</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-30 18:13:36 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Atorvastatin</LI>
<UL>
<LI>Dose: 10 mg/d</LI>
</UL>
<LI>Treatment duration: 12 weeks</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-29 16:35:02 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>hs-CRP</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-28 16:27:50 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Letter to the editor</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-30 10:40:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-UK_x002d_HARP_x002d_I-2005">
<CHAR_METHODS MODIFIED="2013-07-28 16:32:33 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: RCT</LI>
<LI>Time frame: October 1999 to March 2001</LI>
<LI>Follow-up: 1 year</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-28 16:39:04 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: UK</LI>
<LI>Setting: multicentre</LI>
<LI>Inclusion criteria: Adult patients on dialysis (subset of study)</LI>
<LI>Number of dialysis patients (treatment/control): 38/35</LI>
<UL>
<LI>HD patients (treatment/control): 17/17</LI>
<LI>PD patients (treatment/control): 21/18</LI>
</UL>
<LI>Age: NR</LI>
<LI>Sex: NR</LI>
<LI>Exclusion criteria: Patients on statins; recent history of acute uraemia; chronic liver disease</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-28 16:39:36 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Simvastatin</LI>
<UL>
<LI>Dose 20 mg/d</LI>
</UL>
<LI>Treatment duration: 12 months</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-01-20 17:31:55 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Safety outcomes (hepatic and muscle toxicity)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-30 10:40:17 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study included predialysis, dialysis (HD and PD) and kidney transplant recipients</LI>
<LI>Data for age and sex were only reported for the complete randomised groups</LI>
<LI>Industry funding received</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-30 12:13:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-den-Akker-2003">
<CHAR_METHODS MODIFIED="2013-07-28 16:40:53 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: RCT</LI>
<LI>Time frame: NR</LI>
<LI>Follow-up period: 5 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-30 15:20:21 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Netherlands</LI>
<LI>Setting: single centre</LI>
<LI>Inclusion criteria: HD patients</LI>
<LI>Number (treatment 1/treatment 2): 28/10</LI>
<LI>Age (years): treatment group 1 (65.8); treatment group 2 (66)</LI>
<LI>Sex (M/F): NR</LI>
<LI>Exclusion criteria: DM, hypothyroidism or familial dyslipidaemia; patients using beta blockers</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-30 12:13:22 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group 1</P>
<UL>
<LI>Simvastatin</LI>
<UL>
<LI>Dose: 10 mg to 40 mg</LI>
</UL>
<LI>Treatment duration: 18 weeks</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Atorvastatin</LI>
<UL>
<LI>Dose: 10 to 40 mg</LI>
</UL>
<LI>Treatment duration: 18 weeks</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-29 16:05:21 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid profile (TC, LDL, HDL, TG)</LI>
<LI>Lipoproteins</LI>
<LI>LDL particle heterogeneity</LI>
<LI>hs-CRP</LI>
<LI>Markers of in vivo LDL oxidation</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-02 13:18:40 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vareesangthip-2005">
<CHAR_METHODS MODIFIED="2013-07-28 16:49:25 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: RCT</LI>
<LI>Time frame: NR</LI>
<LI>Follow-up period: 4 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-28 16:50:29 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Thailand</LI>
<LI>Setting: single centre</LI>
<LI>Inclusion criteria: HD patients</LI>
<LI>Number (treatment/control): 10/10</LI>
<LI>Age: NR</LI>
<LI>Sex (M/F): NR</LI>
<LI>Exclusion criteria: NR</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-28 17:06:46 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Simvastatin</LI>
<UL>
<LI>Dose: 10 mg</LI>
</UL>
<LI>Treatment duration: 4 months</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-02 13:18:40 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>CRP</LI>
<LI>ESR</LI>
<LI>Lipid parameters</LI>
<LI>Erythrocyte sodium lithium countertransport</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-08 15:22:24 +1000" MODIFIED_BY="[Empty name]">
<P>Abstract only</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-30 18:14:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Velickovic-1997">
<CHAR_METHODS MODIFIED="2013-07-28 16:51:56 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: cross-over RCT</LI>
<LI>Time frame: Unclear</LI>
<LI>Follow-up period: 24 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-30 18:14:17 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Yugoslavia</LI>
<LI>Setting: single centre</LI>
<LI>Inclusion criteria: CAPD patients</LI>
<LI>Number: 13</LI>
<LI>Age (mean ± SD) years: 55.2 ± 8.0</LI>
<LI>Sex (M/F): NR</LI>
<LI>Exclusion criteria: NR</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-28 16:53:20 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Simvastatin</LI>
<UL>
<LI>Dose: 20 mg</LI>
</UL>
<LI>Treatment duration: 24 weeks</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-28 16:53:28 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Adverse events: Liver and muscle enzymes</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-08 15:23:12 +1000" MODIFIED_BY="[Empty name]">
<P>Abstract only</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-30 18:14:34 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vernaglione-2003">
<CHAR_METHODS MODIFIED="2013-07-28 16:55:41 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Study design: prospective RCT</LI>
<LI>Time frame: NR</LI>
<LI>Follow-up period: 6 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-30 18:14:34 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Country: Italy</LI>
<LI>Setting: single centre</LI>
<LI>Inclusion criteria: serum CRP levels &#8805; 3 mg/L (42.2% of the entire population) undergoing HD treatment for at least 6 months, had patent autologous vascular access, and treated with the same dialyser in the last 3 months</LI>
<LI>Number (treatment/control): 16/17</LI>
<LI>Age (mean ± SD) years: treatment group (65.2 ± 11.8); control group (65.5 ± 10.2)</LI>
<LI>Sex (M/F): treatment group (4/12); control group (8/9)</LI>
<LI>Exclusion criteria: patients with liver diseases, neoplasms, recent surgical interventions or trauma, sepsis, chronic inflammatory diseases, and those who had received prolonged treatments with NSAIDs and/or steroids and/or vitamins E or C</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-28 16:58:05 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment group</P>
<UL>
<LI>Atorvastatin</LI>
<UL>
<LI>Dose: 10 mg/d</LI>
</UL>
<LI>Treatment duration: 6 months</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-30 14:20:15 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Lipid parameters (TC, LDL, HDL, TG)</LI>
<LI>Serum CRP</LI>
<LI>Serum albumin</LI>
<LI>Serum urea, SCr</LI>
<LI>Adverse events: Serum ALT, AST, glutamyltransferase, CK, lactate dehydrogenase</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-10-22 03:18:11 +1100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-07-30 18:17:23 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Yu-2007">
<CHAR_METHODS MODIFIED="2013-07-28 17:04:16 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Study design: RCT</LI>
<LI>Time frame: NR</LI>
<LI>Follow-up period: 8 weeks</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-28 17:01:43 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>Country: South Korea</LI>
<LI>Setting: NR</LI>
<LI>Inclusion criteria: HD or PD therapy and TC &gt; 170 mg/dL</LI>
<LI>Number (treatment 1/treatment 2): NR</LI>
<LI>Age: NR</LI>
<LI>Sex (M/F): NR</LI>
<LI>Exclusion criteria: NR</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-28 17:02:38 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Treatment group 1</P>
<UL>
<LI>Simvastatin</LI>
<UL>
<LI>Dose: 10 mg/d</LI>
</UL>
<LI>Ezetimibe</LI>
<UL>
<LI>Dose: 10 mg/d</LI>
</UL>
<LI>Treatment duration: 8 weeks</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>Ezetimibe</LI>
<UL>
<LI>Dose: 10 mg/d</LI>
</UL>
<LI>Treatment duration: 8 weeks</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-30 18:17:23 +1000" MODIFIED_BY="Suetonia Palmer">
<UL>
<LI>CRP</LI>
<LI>TC, LDL</LI>
<LI>Fibrinogen, Von Willebrand factor, D-dimer</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-30 12:35:45 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Abstract publication only</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ALT - alanine aminotransferase; APD - automated peritoneal dialysis; Apo - apoprotein; AST - aspartate aminotransferase; AMI - acute myocardial infarction; BP - blood pressure; CABG - coronary artery bypass graft; CAPD - continuous ambulatory peritoneal dialysis; CHF - chronic heart failure; CK - creatine kinase; CKD - chronic kidney disease; CRP - C-reactive protein; CVA - cerebrovascular accident; CVD - cardiovascular disease; DM - diabetes mellitus; ESKD - end-stage kidney disease; ESR - erythrocyte sedimentation rate; HD - haemodialysis; HDL - high-density lipoprotein; HRT - hormone replacement therapy; hs-CRP - highly-sensitive CRP; IL-6 - interleukin 6; ITT - intention-to-treat; LDL - low-density lipoprotein; LFT - liver function test; MI - myocardial infarction; NR - not reported; NSAIDs - non-steroidal anti-inflammatory drugs; PD - peritoneal dialysis; PTCA - percutaneous transluminal coronary angioplasty; SCr - serum creatinine; TC - total cholesterol; TG - triglycerides; ULN - upper limit of normal</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-07-28 17:57:23 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-07-28 17:57:23 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Akcicek-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-28 17:57:23 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT (prospective cohort study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-28 17:53:48 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Bunio-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-28 17:53:48 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Active comparator (not statin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-08 15:59:13 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Cappelli-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-08 15:59:13 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Active comparator (not statin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-08 15:59:19 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Cheng-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-08 15:59:19 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Active comparator (not statin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 13:24:06 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-CHORUS-Study-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 13:24:06 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Study discontinued</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-02 13:46:47 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Dogra-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-02 13:46:47 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Short duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-28 17:57:17 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Fiorini-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-28 17:57:17 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-08 15:59:28 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Fiorini-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-08 15:59:28 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Active comparator (not statin)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-28 17:57:11 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Hufnagel-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-28 17:57:11 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT (prospective cohort study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 13:24:53 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Khajehdehi-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 13:24:53 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-02 13:47:00 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Kim-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-02 13:47:00 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not dialysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-28 17:57:04 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Kishimoto-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-28 17:57:04 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-30 12:48:39 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-30 12:48:39 +1000" MODIFIED_BY="[Empty name]">
<P>Study duration &lt; 8 weeks</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-30 12:10:30 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Lins-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-30 12:10:30 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Study duration 2 weeks</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 13:27:09 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Lynoe-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 13:27:09 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-28 17:56:59 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Malyszko-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-28 17:56:59 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT (prospective cohort study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-28 17:56:51 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Nishikawa-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-28 17:56:51 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT (prospective cohort study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-28 17:56:40 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Nishizawa-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-28 17:56:40 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT (prospective cohort study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-28 17:56:44 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Rincon-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-28 17:56:44 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 13:27:39 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Samuelsson-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 13:27:39 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not dialysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-30 12:12:19 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Sezer-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-30 12:12:19 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Duration 1 month</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-30 12:13:03 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Singh-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-30 12:13:03 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Duration 4 weeks</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-28 17:56:33 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Tani-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-28 17:56:33 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT (prospective cohort study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-23 13:28:06 +1100" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-UK_x002d_HARP_x002d_II-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-23 13:28:06 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Not appropriate intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-28 17:56:28 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Wanner-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-28 17:56:28 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT (prospective cohort study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-28 17:56:23 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Wanner-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-28 17:56:23 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT (prospective cohort study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-28 17:55:52 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Yigit-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-28 17:55:52 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-28 17:56:06 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Zhu-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-28 17:56:06 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT (prospective cohort study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-03-02 13:45:51 +1100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-07-29 16:37:28 +1000" MODIFIED_BY="Gail Y Higgins" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2013-07-29 16:37:28 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-Nardi-2005">
<CHAR_STUDY_NAME MODIFIED="2011-10-23 13:29:47 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Prévention par la pravastatine de la dégradation de l&#8217;état nutritionnel des patients hémodialysés présentant un état inflammatoire chronique</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-10-23 13:31:15 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Randomised trial, multicentre, double-blinded, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-04 13:00:06 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Haemodialysis &gt; 3 months, aged &gt; 18 years and &lt; 80 years, serum albumin &lt; 40 g/L, and existence of chronic inflammation defined as CRP 10 to 50 mg/L on two separate occasions, without an identifiable cause</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-08 16:00:51 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Pravastatin 20 to 40 mg/d or placebo for 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-23 13:32:58 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Inflammation</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-10-23 13:33:47 +1100" MODIFIED_BY="Suetonia Palmer">
<P>2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-07-29 16:37:28 +1000" MODIFIED_BY="Suetonia Palmer">
<P>CHU de Bordeaux, hôpital Pellegrin, Département de Néphrologie&#8211;Hémodialyse, 1, place Amélie-Raba-Léon, 33076 Bordeaux Cedex, France</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-10-23 12:23:57 +1100" MODIFIED_BY="Suetonia Palmer"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-07-28 17:34:39 +1000" MODIFIED_BY="Gail Y Higgins" STUDY_ID="STD-NCT00291863">
<CHAR_STUDY_NAME MODIFIED="2013-07-28 17:34:39 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Simvastatin effect on end stage renal failure patients treated by peritoneal dialysis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-05-08 16:01:11 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Randomised, parallel group, double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-28 17:34:16 +1000" MODIFIED_BY="Gail Y Higgins">
<P>18 to 80 years, ESKD, LDL cholesterol &gt; 100 mg/dL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-10-23 13:35:26 +1100" MODIFIED_BY="Gail Y Higgins">
<P>Simvastatin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-23 13:36:01 +1100" MODIFIED_BY="Gail Y Higgins">
<P>Endothelial venodilation, inflammatory markers, lipoproteins, oxidative stress</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-10-23 13:36:13 +1100" MODIFIED_BY="Suetonia Palmer">
<P>February 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-05-08 16:01:43 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Maristela Bohlke</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-05-08 16:01:52 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Recruitment status of this study is unknown because the information has not been verified recently</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-07-29 16:15:16 +1000" MODIFIED_BY="Suetonia Palmer" STUDY_ID="STD-NCT00858637">
<CHAR_STUDY_NAME MODIFIED="2013-07-28 17:35:14 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Efficacy and safety study of MCI-196 versus simvastatin for dyslipidaemia in chronic kidney disease (CKD) subjects on dialysis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-07-28 17:35:42 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Phase III, multicentre, double-blind, double-dummy, randomised, flexible-dose, comparative study of MCI-196 versus simvastatin</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-08 16:02:21 +1000" MODIFIED_BY="Suetonia Palmer">
<P>&gt; 18 years, male or female, stable dialysis, negative pregnancy test and appropriate contraception</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-10-23 13:38:56 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Simvastatin, MCl-196, or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-29 16:15:16 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Change in LDL cholesterol, change in total cholesterol, HDL cholesterol, triglycerides and additional lipid parameters, change in phosphorus (P), Calcium (Ca), calcium-phosphorus ion product (PxCa) and parathyroid hormone (PTH), vital signs, adverse events, and laboratory values</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-10-23 13:39:46 +1100" MODIFIED_BY="Suetonia Palmer">
<P>March 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-10-23 13:40:20 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Mitsubishi Tanabe Pharma Corporation</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-10-23 13:40:28 +1100" MODIFIED_BY="Suetonia Palmer">
<P>Unclear contact information</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-07-28 17:37:11 +1000" MODIFIED_BY="Gail Y Higgins" STUDY_ID="STD-NCT00999453">
<CHAR_STUDY_NAME MODIFIED="2013-07-28 17:36:51 +1000" MODIFIED_BY="Suetonia Palmer">
<P>The effects of lowering low-density lipoprotein cholesterol levels to new targets on cardiovascular complications in peritoneal dialysis patients</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-10-23 13:41:25 +1100" MODIFIED_BY="Gail Y Higgins">
<P>Randomised, parallel group, open label</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-08 16:03:15 +1000" MODIFIED_BY="Gail Y Higgins">
<P>20 to 70 years, treated with peritoneal dialysis for 3 or more months, LDL cholesterol 100 mg/dL or higher within 3 months and total cholesterol level 220 mg/dL or higher</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-28 17:37:11 +1000" MODIFIED_BY="Gail Y Higgins">
<P>Either aggressive targets of LDL cholesterol of 70 mg/dL or current standard targets of LDL cholesterol of 100 mg/dL</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-10-23 13:42:32 +1100" MODIFIED_BY="Gail Y Higgins">
<P>Cardiovascular complication including acute coronary syndrome, cerebrovascular infarction and cardiovascular death</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-10-23 13:42:37 +1100" MODIFIED_BY="Suetonia Palmer">
<P>October 2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-05-08 16:03:46 +1000" MODIFIED_BY="Suetonia Palmer">
<P>Shin-Wook Kang</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-05-08 16:03:38 +1000" MODIFIED_BY="Gail Y Higgins">
<P>This study is currently recruiting participants</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>LDL - low density lipoprotein; HDL - high density lipoprotein</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-09-02 13:19:22 +1000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-09-02 13:16:34 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 16:18:58 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0034_D-Study-2004">
<DESCRIPTION>
<P>Computer-generated randomisation code</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:12 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-AURORA-Study-2005">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-02 13:16:34 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Ahmadi-2005">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:27:36 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Angel-2007">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:27:59 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Arabul-2008">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:33 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Burmeister-2006">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:35 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Chang-2002">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:37 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Diepeveen-2005">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:39 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Dornbrook_x002d_Lavender-2005">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:41 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Han-2011">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:43 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Harris-2002">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:45 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Ichihara-2002">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:48 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Lins-2004">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-02 11:43:58 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-PERFECT-Study-1997">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 17:23:01 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SHARP-Study-2010">
<DESCRIPTION>
<P>Allocated by local study laptop computer with minimised randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:54 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Saltissi-HD-2002">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:56 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Saltissi-PD-2002">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:28:02 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Soliemani-2011">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:58 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Stegmayr-2005">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:59 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Tse-2008">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-28 16:31:15 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-UK_x002d_HARP_x002d_I-2005">
<DESCRIPTION>
<P>Minimised randomisation used to balance the treatment groups; 2 x 2 factorial design</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:30:05 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Vareesangthip-2005">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:30:10 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Velickovic-1997">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:30:13 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Vernaglione-2003">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:28:10 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Yu-2007">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:30:03 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-van-den-Akker-2003">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-09-02 13:16:38 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-04 12:22:07 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0034_D-Study-2004">
<DESCRIPTION>
<P>Randomisation code prepared by a central unit that was independent of local study personnel</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:15 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-AURORA-Study-2005">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-02 13:16:38 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Ahmadi-2005">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:27:39 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Angel-2007">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:28:00 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Arabul-2008">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:34 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Burmeister-2006">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:36 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chang-2002">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:37 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Diepeveen-2005">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:39 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dornbrook_x002d_Lavender-2005">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:41 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Han-2011">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:44 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harris-2002">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:46 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Ichihara-2002">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lins-2004">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-30 10:39:02 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PERFECT-Study-1997">
<DESCRIPTION>
<P>"...the code identifying the treatment received by individual patients was maintained by a person remote from the investigators."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 17:25:23 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SHARP-Study-2010">
<DESCRIPTION>
<P>Local laptop computer that was synchronised regularly with central database and double-dummy treatment to ensure blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:55 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saltissi-HD-2002">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:57 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saltissi-PD-2002">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:28:02 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Soliemani-2011">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-08 15:54:30 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stegmayr-2005">
<DESCRIPTION>
<P>Randomisation by means of a telephone call to the study data centre where sealed envelopes were drawn</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:30:00 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Tse-2008">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 17:56:48 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-UK_x002d_HARP_x002d_I-2005">
<DESCRIPTION>
<P>Randomisation was by telephone to the Clinical Trial Service Unit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:30:06 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Vareesangthip-2005">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:30:11 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Velickovic-1997">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:30:14 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vernaglione-2003">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:28:11 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Yu-2007">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:30:04 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-van-den-Akker-2003">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-08-30 09:45:03 +1000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-30 15:09:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0034_D-Study-2004">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-03 16:45:24 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AURORA-Study-2005">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-03 16:44:44 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ahmadi-2005">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-30 11:33:25 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="YES" STUDY_ID="STD-Angel-2007">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-30 11:51:41 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="YES" STUDY_ID="STD-Arabul-2008">
<DESCRIPTION>
<P>Double blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-03 16:49:20 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burmeister-2006">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-03 17:02:22 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chang-2002">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-03 17:07:16 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Diepeveen-2005">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-03 17:08:14 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dornbrook_x002d_Lavender-2005">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-08-30 09:45:03 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="NO" STUDY_ID="STD-Han-2011">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-03 17:15:51 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Harris-2002">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-03 17:18:20 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ichihara-2002">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-03 17:18:43 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lins-2004">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-03 17:19:05 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PERFECT-Study-1997">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-21 14:32:36 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SHARP-Study-2010">
<DESCRIPTION>
<P>Double-dummy 2 x 2 factorial design</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-03 17:20:21 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saltissi-HD-2002">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-03 17:20:48 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saltissi-PD-2002">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-30 12:30:08 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Soliemani-2011">
<DESCRIPTION>
<P>Double blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-03 17:54:58 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stegmayr-2005">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-24 16:30:00 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Tse-2008">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-03 18:00:00 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-UK_x002d_HARP_x002d_I-2005">
<DESCRIPTION>
<P>Matching placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-24 16:30:07 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Vareesangthip-2005">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-03 18:03:28 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Velickovic-1997">
<DESCRIPTION>
<P>Investigators not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-24 16:30:14 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Vernaglione-2003">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-05-30 12:36:31 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="NO" STUDY_ID="STD-Yu-2007">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-24 16:30:04 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-van-den-Akker-2003">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-07-30 15:09:04 +1000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-30 15:09:04 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0034_D-Study-2004">
<DESCRIPTION>
<P>All analyses of primary and secondary endpoints were based on the classification by the endpoint committee that was agreed by consensus or majority vote. All committee members were blinded to treatment assignments until 13 August 2004</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-04 12:28:34 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AURORA-Study-2005">
<DESCRIPTION>
<P>All MIs, strokes, and deaths were reviewed and adjudicated by a clinical endpoint committee whose members were unaware of the randomised treatment assignments to ensure consistency of the event diagnosis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-03 16:44:48 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ahmadi-2005">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 16:27:41 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Angel-2007">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 16:28:01 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Arabul-2008">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 16:29:34 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Burmeister-2006">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-03 17:02:26 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chang-2002">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 16:29:38 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Diepeveen-2005">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 16:29:40 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Dornbrook_x002d_Lavender-2005">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 16:29:42 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Han-2011">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 16:29:44 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Harris-2002">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 16:29:46 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Ichihara-2002">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 16:29:50 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Lins-2004">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 16:29:53 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-PERFECT-Study-1997">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-03 17:51:02 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SHARP-Study-2010">
<DESCRIPTION>
<P>Central adjudication by trained clinicians who were masked to study treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 16:29:56 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Saltissi-HD-2002">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 16:29:58 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Saltissi-PD-2002">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 16:28:03 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Soliemani-2011">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-03 17:55:01 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stegmayr-2005">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 16:30:01 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Tse-2008">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-03 17:59:58 +1100" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-UK_x002d_HARP_x002d_I-2005">
<DESCRIPTION>
<P>All events were coded centrally according to a standard protocol. Otherwise unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 16:30:08 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Vareesangthip-2005">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-03 18:03:26 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Velickovic-1997">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 16:30:15 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Vernaglione-2003">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 16:28:11 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Yu-2007">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-07-24 16:30:05 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-van-den-Akker-2003">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-09-02 13:19:22 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-30 15:09:14 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0034_D-Study-2004">
<DESCRIPTION>
<P>All participants included in ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-24 16:29:21 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AURORA-Study-2005">
<DESCRIPTION>
<P>No patients were lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-02 13:19:22 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Ahmadi-2005">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-24 16:27:58 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Angel-2007">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-30 11:51:54 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="YES" STUDY_ID="STD-Arabul-2008">
<DESCRIPTION>
<P>None</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-30 09:44:03 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burmeister-2006">
<DESCRIPTION>
<P>3/59 (5%) lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-30 09:44:20 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chang-2002">
<DESCRIPTION>
<P>4/62 (6.5%) patients did not complete study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-03 17:07:51 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Diepeveen-2005">
<DESCRIPTION>
<P>Complete follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-08 15:40:39 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dornbrook_x002d_Lavender-2005">
<DESCRIPTION>
<P>6/19 (32%) did not complete study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-30 09:44:57 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="NO" STUDY_ID="STD-Han-2011">
<DESCRIPTION>
<P>36/114 patients (32%) withdrawn</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-08 15:06:01 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Harris-2002">
<DESCRIPTION>
<P>130/153 (85%) completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-24 16:29:47 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Ichihara-2002">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-24 16:29:50 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Lins-2004">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-24 16:29:54 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-PERFECT-Study-1997">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-03 17:51:37 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SHARP-Study-2010">
<DESCRIPTION>
<P>All participants included in analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-30 14:17:19 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Saltissi-HD-2002">
<DESCRIPTION>
<P>42/57 patients (74%) completed study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-30 14:17:34 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Saltissi-PD-2002">
<DESCRIPTION>
<P>42/57 patients (74%) completed study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-30 12:30:30 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Soliemani-2011">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-03 17:55:13 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stegmayr-2005">
<DESCRIPTION>
<P>All patients analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-24 16:30:01 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Tse-2008">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-30 15:19:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-UK_x002d_HARP_x002d_I-2005">
<DESCRIPTION>
<P>442/448 (98.7%) patients completed follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-24 16:30:08 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Vareesangthip-2005">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-24 16:30:11 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Velickovic-1997">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-24 16:30:15 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vernaglione-2003">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-30 12:36:04 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Yu-2007">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-30 10:40:36 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-den-Akker-2003">
<DESCRIPTION>
<P>2/28 patients (7%) discontinued therapy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-08-30 09:43:28 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 09:51:46 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0034_D-Study-2004">
<DESCRIPTION>
<P>Published reports included all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 11:15:31 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AURORA-Study-2005">
<DESCRIPTION>
<P>Published reports included all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 11:14:58 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ahmadi-2005">
<DESCRIPTION>
<P>Published reports did not include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 11:33:56 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="NO" STUDY_ID="STD-Angel-2007">
<DESCRIPTION>
<P>Published reports did not include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-30 09:43:28 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="NO" STUDY_ID="STD-Arabul-2008">
<DESCRIPTION>
<P>Published reports did not include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 11:15:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burmeister-2006">
<DESCRIPTION>
<P>Published reports included all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 11:16:44 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chang-2002">
<DESCRIPTION>
<P>Published reports did not include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 11:16:59 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Diepeveen-2005">
<DESCRIPTION>
<P>Published reports did not include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 11:17:08 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dornbrook_x002d_Lavender-2005">
<DESCRIPTION>
<P>Published reports did not include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 11:17:20 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Han-2011">
<DESCRIPTION>
<P>Published reports did not include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 11:17:31 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Harris-2002">
<DESCRIPTION>
<P>Published reports did not include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 11:17:39 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ichihara-2002">
<DESCRIPTION>
<P>Published reports did not include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 11:18:28 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lins-2004">
<DESCRIPTION>
<P>Published reports included all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 11:18:45 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-PERFECT-Study-1997">
<DESCRIPTION>
<P>Published reports did not include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 11:19:44 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SHARP-Study-2010">
<DESCRIPTION>
<P>Published reports included all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 11:19:21 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saltissi-HD-2002">
<DESCRIPTION>
<P>Published reports included all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 11:19:29 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saltissi-PD-2002">
<DESCRIPTION>
<P>Published reports included all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 12:30:53 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="NO" STUDY_ID="STD-Soliemani-2011">
<DESCRIPTION>
<P>Published reports did not include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 11:20:00 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stegmayr-2005">
<DESCRIPTION>
<P>Published reports included all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 11:20:26 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tse-2008">
<DESCRIPTION>
<P>Published reports did not include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 11:20:39 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-UK_x002d_HARP_x002d_I-2005">
<DESCRIPTION>
<P>Published reports included all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 11:23:35 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vareesangthip-2005">
<DESCRIPTION>
<P>Published reports did not include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 11:23:59 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Velickovic-1997">
<DESCRIPTION>
<P>Published reports did not include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 11:24:07 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vernaglione-2003">
<DESCRIPTION>
<P>Published reports did not include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 12:36:35 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="NO" STUDY_ID="STD-Yu-2007">
<DESCRIPTION>
<P>Publication reports did not provide all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 11:23:12 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-van-den-Akker-2003">
<DESCRIPTION>
<P>Published reports did not include all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2013-09-02 13:16:42 +1000" MODIFIED_BY="[Empty name]" NO="9">
<NAME>ITT analysis</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-08 15:30:04 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x0034_D-Study-2004">
<DESCRIPTION>
<P>ITT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 16:48:39 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-AURORA-Study-2005">
<DESCRIPTION>
<P>Conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-02 13:16:42 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Ahmadi-2005">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:27:58 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Angel-2007">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:28:01 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Arabul-2008">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 17:02:02 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Burmeister-2006">
<DESCRIPTION>
<P>Not conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 17:06:50 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chang-2002">
<DESCRIPTION>
<P>Not conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 17:07:54 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Diepeveen-2005">
<DESCRIPTION>
<P>Conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 17:08:21 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dornbrook_x002d_Lavender-2005">
<DESCRIPTION>
<P>Not conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:43 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Han-2011">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 17:16:17 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Harris-2002">
<DESCRIPTION>
<P>Not conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:48 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Ichihara-2002">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:29:51 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Lins-2004">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 17:19:22 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PERFECT-Study-1997">
<DESCRIPTION>
<P>Conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 17:52:12 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SHARP-Study-2010">
<DESCRIPTION>
<P>Conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 17:20:41 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Saltissi-HD-2002">
<DESCRIPTION>
<P>Not conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 17:20:48 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Saltissi-PD-2002">
<DESCRIPTION>
<P>Not conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-30 12:30:56 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Soliemani-2011">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 17:55:16 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stegmayr-2005">
<DESCRIPTION>
<P>Conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:30:02 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Tse-2008">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 17:58:41 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-UK_x002d_HARP_x002d_I-2005">
<DESCRIPTION>
<P>Conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:30:09 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Vareesangthip-2005">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:30:12 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Velickovic-1997">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:30:16 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Vernaglione-2003">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-24 16:28:12 +1000" MODIFIED_BY="Suetonia Palmer" RESULT="UNKNOWN" STUDY_ID="STD-Yu-2007">
<DESCRIPTION>
<P>NR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-03 18:02:02 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-van-den-Akker-2003">
<DESCRIPTION>
<P>Not conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-09-02 11:17:45 +1000" MODIFIED_BY="Suetonia Palmer">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-09-02 11:17:45 +1000" MODIFIED_BY="Suetonia Palmer" NO="1">
<TITLE MODIFIED="2012-03-01 19:03:09 +1100" MODIFIED_BY="Suetonia Palmer">Summary of findings</TITLE>
<TABLE COLS="6" ROWS="10">
<TR>
<TD COLSPAN="6">
<P>
<B>Statin versus placebo or no treatment for dialysis patients</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population: </B>adults with chronic kidney disease</P>
<P>
<B>Settings: </B>dialysis</P>
<P>
<B>Intervention: </B>statin therapy</P>
<P>
<B>Comparison: </B>placebo or no treatment</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk/year/1000 treated</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk/year/1000 treated</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Placebo or no treatment</P>
</TH>
<TH VALIGN="TOP">
<P>Statin</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Major cardiovascular events </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>150 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>143 per 1000 (7 fewer)</B>
<BR/>(132 to 155) (18 fewer to 5 more)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.95</B> (0.88 to 1.03)</P>
</TD>
<TD VALIGN="TOP">
<P>7804 (4)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>All-cause mortality</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>200 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>192 per 1000 (8 fewer)</B>
<BR/>(176 to 208) (24 fewer to 8 more)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.96</B> (0.90 to 1.02)</P>
</TD>
<TD VALIGN="TOP">
<P>4705 (13)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;</P>
<P>
<B>moderate</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Cardiovascular mortality</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>94 per 1000 (6 fewer)</B>
<BR/>(82 to 105) (18 fewer to 5 more)</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.94 </B>(0.84 to 1.06)</P>
</TD>
<TD VALIGN="TOP">
<P>4627 (13)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;<BR/>
<B>moderate</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk Ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Absolute approximate events rates of outcomes per year were derived from previously observational cohort studies. Absolute numbers of people on dialysis with cardiovascular or mortality events avoided or incurred per 1000 treated were estimated using these assumed risks together with the estimated relative risks and 95% confidence intervals (<LINK REF="REF-Herzog-1998" TYPE="REFERENCE">Herzog 1998</LINK>; <LINK REF="REF-Trivedi-2009" TYPE="REFERENCE">Trivedi 2009</LINK>; <LINK REF="REF-Weiner-2006" TYPE="REFERENCE">Weiner 2006</LINK>; <LINK REF="REF-Wetmore-2009" TYPE="REFERENCE">Wetmore 2009</LINK>)</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2012-03-01 19:02:51 +1100" MODIFIED_BY="Gail Y Higgins"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-09-02 10:58:31 +1000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-09-02 10:58:31 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Statin versus placebo or no treatment</NAME>
<DICH_OUTCOME CHI2="1.3593275704351693" CI_END="1.0270628044304235" CI_START="0.876482212527155" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9487899025767097" ESTIMABLE="YES" EVENTS_1="852" EVENTS_2="899" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.011597001322311416" LOG_CI_START="-0.057256893123739355" LOG_EFFECT_SIZE="-0.02282994590071397" METHOD="IV" MODIFIED="2012-03-01 11:56:46 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7150958151352647" P_Q="1.0" P_Z="0.19369217381657786" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3557" TOTAL_2="3527" WEIGHT="99.99999999999999" Z="1.2997339393621976">
<NAME>Major cardiovascular events</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Statin better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control better</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.099426132832591" CI_START="0.010939162996078491" EFFECT_SIZE="0.21176470588235294" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6127230653081122" LOG_CI_START="-1.9610159065300856" LOG_EFFECT_SIZE="-0.6741464206109866" MODIFIED="2011-10-31 17:01:50 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="266" O_E="0.0" SE="1.5118270122711395" STUDY_ID="STD-Vernaglione-2003" TOTAL_1="16" TOTAL_2="17" VAR="2.28562091503268" WEIGHT="0.07156950630126697"/>
<DICH_DATA CI_END="1.071782965419624" CI_START="0.7704896952621891" EFFECT_SIZE="0.9087341362650417" ESTIMABLE="YES" EVENTS_1="230" EVENTS_2="246" LOG_CI_END="0.030106850222941583" LOG_CI_START="-0.11323316527871628" LOG_EFFECT_SIZE="-0.04156315752788737" MODIFIED="2011-10-31 17:01:50 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="264" O_E="0.0" SE="0.08419863465019393" STUDY_ID="STD-SHARP-Study-2010" TOTAL_1="1533" TOTAL_2="1490" VAR="0.007089410076956839" WEIGHT="23.07395942751794"/>
<DICH_DATA CI_END="1.1029130564666376" CI_START="0.8279345121008624" EFFECT_SIZE="0.9555834779313509" ESTIMABLE="YES" EVENTS_1="226" EVENTS_2="243" LOG_CI_END="0.04254127800226902" LOG_CI_START="-0.08200401364749972" LOG_EFFECT_SIZE="-0.019731367822615347" MODIFIED="2011-10-31 17:01:50 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="263" O_E="0.0" SE="0.07315852082421077" STUDY_ID="STD-_x0034_D-Study-2004" TOTAL_1="619" TOTAL_2="636" VAR="0.005352169169186481" WEIGHT="30.563451062516194"/>
<DICH_DATA CI_END="1.0865978043767526" CI_START="0.8607339065472543" EFFECT_SIZE="0.96709439715411" ESTIMABLE="YES" EVENTS_1="396" EVENTS_2="408" LOG_CI_END="0.03606882314568282" LOG_CI_START="-0.06513108870817125" LOG_EFFECT_SIZE="-0.014531132781244205" MODIFIED="2011-10-31 17:01:50 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="265" O_E="0.0" SE="0.05944532917059675" STUDY_ID="STD-AURORA-Study-2005" TOTAL_1="1389" TOTAL_2="1384" VAR="0.003533747160200601" WEIGHT="46.29102000366459"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.497364297686694" CI_END="1.0210654859666382" CI_START="0.896901322023727" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9569717781817167" ESTIMABLE="YES" EVENTS_1="938" EVENTS_2="988" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.009053596427682612" LOG_CI_START="-0.04725533583883514" LOG_EFFECT_SIZE="-0.01910086970557629" METHOD="IV" MODIFIED="2013-02-27 11:39:46 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8687626180906801" P_Q="1.0" P_Z="0.18361686466629734" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="WEIGHT" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2352" TOTAL_2="2353" WEIGHT="100.0" Z="1.3297008197252709">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Statin better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control better</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-02-27 11:39:43 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="94" O_E="0.0" SE="0.0" STUDY_ID="STD-Harris-2002" TOTAL_1="82" TOTAL_2="94" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-01 12:01:51 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="89" O_E="0.0" SE="0.0" STUDY_ID="STD-Saltissi-PD-2002" TOTAL_1="16" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-01 12:02:32 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="92" O_E="0.0" SE="0.0" STUDY_ID="STD-Saltissi-HD-2002" TOTAL_1="22" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-02-27 11:39:44 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="90" O_E="0.0" SE="0.0" STUDY_ID="STD-Diepeveen-2005" TOTAL_1="13" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-01 12:02:18 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="91" O_E="0.0" SE="0.0" STUDY_ID="STD-Ichihara-2002" TOTAL_1="12" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-02-27 11:39:43 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="93" O_E="0.0" SE="0.0" STUDY_ID="STD-Chang-2002" TOTAL_1="28" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.450659942619297" CI_START="0.011961643384324708" EFFECT_SIZE="0.2777777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8096041479339453" LOG_CI_START="-1.9222091494685196" LOG_EFFECT_SIZE="-0.5563025007672873" MODIFIED="2013-02-27 11:39:45 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="273" O_E="0.0" SE="1.6046806535881213" STUDY_ID="STD-Lins-2004" TOTAL_1="23" TOTAL_2="19" VAR="2.575" WEIGHT="0.04248665647574637"/>
<DICH_DATA CI_END="72.08425860083103" CI_START="0.15107320532078622" EFFECT_SIZE="3.3" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8578404360205125" LOG_CI_START="-0.8208125562647377" LOG_EFFECT_SIZE="0.5185139398778874" MODIFIED="2013-02-27 11:39:45 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="272" O_E="0.0" SE="1.573454027214515" STUDY_ID="STD-Dornbrook_x002d_Lavender-2005" TOTAL_1="9" TOTAL_2="10" VAR="2.4757575757575756" WEIGHT="0.04418976296238125"/>
<DICH_DATA CI_END="3.9959083298702427" CI_START="0.009649540105241232" EFFECT_SIZE="0.19636363636363635" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6016155165188679" LOG_CI_START="-2.015493384533456" LOG_EFFECT_SIZE="-0.7069389340072941" MODIFIED="2011-10-31 17:01:54 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="267" O_E="0.0" SE="1.5373027233761292" STUDY_ID="STD-PERFECT-Study-1997" TOTAL_1="54" TOTAL_2="53" VAR="2.3632996632996632" WEIGHT="0.04629253840467151"/>
<DICH_DATA CI_END="5.778086808041854" CI_START="0.05303508526457441" EFFECT_SIZE="0.5535714285714286" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7617840622520969" LOG_CI_START="-1.2754367285959523" LOG_EFFECT_SIZE="-0.2568263331719277" MODIFIED="2013-02-27 11:39:46 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="270" O_E="0.0" SE="1.1966735769496981" STUDY_ID="STD-Burmeister-2006" TOTAL_1="28" TOTAL_2="31" VAR="1.4320276497695852" WEIGHT="0.07639736596053157"/>
<DICH_DATA CI_END="4.7475155054503135" CI_START="0.210636489517931" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6764663918230654" LOG_CI_START="-0.6764663918230656" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-01-03 19:28:32 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="268" O_E="0.0" SE="0.7947194142390263" STUDY_ID="STD-Han-2011" TOTAL_1="57" TOTAL_2="57" VAR="0.631578947368421" WEIGHT="0.17322163900632429"/>
<DICH_DATA CI_END="1.067337109378236" CI_START="0.8520091639488117" EFFECT_SIZE="0.9536147011308562" ESTIMABLE="YES" EVENTS_1="297" EVENTS_2="320" LOG_CI_END="0.02830160932136095" LOG_CI_START="-0.06955573407015642" LOG_EFFECT_SIZE="-0.020627062374397726" MODIFIED="2011-10-31 17:01:54 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="268" O_E="0.0" SE="0.057481887909839394" STUDY_ID="STD-_x0034_D-Study-2004" TOTAL_1="619" TOTAL_2="636" VAR="0.0033041674376793405" WEIGHT="33.11065267984284"/>
<DICH_DATA CI_END="1.0396101033815215" CI_START="0.886795656872191" EFFECT_SIZE="0.960167550232345" ESTIMABLE="YES" EVENTS_1="636" EVENTS_2="660" LOG_CI_END="0.01687049151146999" LOG_CI_START="-0.0521764425321328" LOG_EFFECT_SIZE="-0.01765297551033139" MODIFIED="2012-03-01 11:56:41 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="269" O_E="0.0" SE="0.0405585108450481" STUDY_ID="STD-AURORA-Study-2005" TOTAL_1="1389" TOTAL_2="1384" VAR="0.0016449928019678845" WEIGHT="66.5067593573475"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.2979777666605608" CI_END="1.0565110359376313" CI_START="0.8418637402118883" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9431003829336466" ESTIMABLE="YES" EVENTS_1="446" EVENTS_2="477" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.023874037897355958" LOG_CI_START="-0.07475819551087066" LOG_EFFECT_SIZE="-0.025442078806757376" METHOD="IV" MODIFIED="2013-02-27 11:41:21 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6541513659146745" P_Q="1.0" P_Z="0.3119488604399018" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2315" TOTAL_2="2312" WEIGHT="100.0" Z="1.011141214793075">
<NAME>Cardiovascular mortality</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Statin better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control better</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-01 12:09:45 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="100" O_E="0.0" SE="0.0" STUDY_ID="STD-Saltissi-HD-2002" TOTAL_1="22" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-02-27 11:41:19 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="97" O_E="0.0" SE="0.0" STUDY_ID="STD-Dornbrook_x002d_Lavender-2005" TOTAL_1="13" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-01 12:09:49 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="99" O_E="0.0" SE="0.0" STUDY_ID="STD-Ichihara-2002" TOTAL_1="12" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-02-27 11:41:18 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="95" O_E="0.0" SE="0.0" STUDY_ID="STD-Chang-2002" TOTAL_1="28" TOTAL_2="32" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-01 12:09:39 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="101" O_E="0.0" SE="0.0" STUDY_ID="STD-Saltissi-PD-2002" TOTAL_1="16" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-02-27 11:41:19 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="98" O_E="0.0" SE="0.0" STUDY_ID="STD-Harris-2002" TOTAL_1="82" TOTAL_2="94" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-02-27 11:41:20 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="96" O_E="0.0" SE="0.0" STUDY_ID="STD-Diepeveen-2005" TOTAL_1="13" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.858106453551668" CI_START="0.013630184148004135" EFFECT_SIZE="0.32727272727272727" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.895317907891022" LOG_CI_START="-1.8654982766728974" LOG_EFFECT_SIZE="-0.48509018439093776" MODIFIED="2011-10-31 17:01:58 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="280" O_E="0.0" SE="1.6217170930733664" STUDY_ID="STD-PERFECT-Study-1997" TOTAL_1="54" TOTAL_2="53" VAR="2.62996632996633" WEIGHT="0.1276329332178925"/>
<DICH_DATA CI_END="6.450659942619297" CI_START="0.011961643384324708" EFFECT_SIZE="0.2777777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8096041479339453" LOG_CI_START="-1.9222091494685196" LOG_EFFECT_SIZE="-0.5563025007672873" MODIFIED="2013-02-27 11:41:21 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="279" O_E="0.0" SE="1.6046806535881213" STUDY_ID="STD-Lins-2004" TOTAL_1="23" TOTAL_2="19" VAR="2.575" WEIGHT="0.13035740464384404"/>
<DICH_DATA CI_END="8.082984457423786" CI_START="0.015411074301155481" EFFECT_SIZE="0.35294117647058826" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9075717437049503" LOG_CI_START="-1.812167085694211" LOG_EFFECT_SIZE="-0.45229767099463025" MODIFIED="2011-10-31 17:01:58 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="278" O_E="0.0" SE="1.5975880513134" STUDY_ID="STD-Vernaglione-2003" TOTAL_1="16" TOTAL_2="17" VAR="2.5522875816993467" WEIGHT="0.13151743532537374"/>
<DICH_DATA CI_END="15.208600307956246" CI_START="0.06575227040958258" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1820892464985915" LOG_CI_START="-1.1820892464985915" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-02-27 11:41:21 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="277" O_E="0.0" SE="1.3887301496588271" STUDY_ID="STD-Burmeister-2006" TOTAL_1="28" TOTAL_2="28" VAR="1.9285714285714284" WEIGHT="0.17405127545965104"/>
<DICH_DATA CI_END="1.032245119720476" CI_START="0.6744477323106284" EFFECT_SIZE="0.8343832334030857" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="149" LOG_CI_END="0.013782838281079629" LOG_CI_START="-0.17105170121613578" LOG_EFFECT_SIZE="-0.07863443146752806" MODIFIED="2011-10-31 17:01:58 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="275" O_E="0.0" SE="0.10857272344639092" STUDY_ID="STD-_x0034_D-Study-2004" TOTAL_1="619" TOTAL_2="636" VAR="0.011788036276566485" WEIGHT="28.475507631850405"/>
<DICH_DATA CI_END="1.1401904935652962" CI_START="0.8707435638900249" EFFECT_SIZE="0.9964002879769619" ESTIMABLE="YES" EVENTS_1="324" EVENTS_2="324" LOG_CI_END="0.056977415716222585" LOG_CI_START="-0.06010972694997569" LOG_EFFECT_SIZE="-0.0015661556168765497" MODIFIED="2012-03-01 09:53:36 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="276" O_E="0.0" SE="0.0687775671928286" STUDY_ID="STD-AURORA-Study-2005" TOTAL_1="1389" TOTAL_2="1384" VAR="0.004730353748964052" WEIGHT="70.96093331950284"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4246731462834406" CI_END="1.0651839893892505" CI_START="0.7131085415201501" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8715456391514924" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="187" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.027424630004833344" LOG_CI_START="-0.14684436159892209" LOG_EFFECT_SIZE="-0.059709865797044404" METHOD="IV" MODIFIED="2013-07-28 18:18:35 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8086925737431594" P_Q="1.0" P_Z="0.1792438865609958" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2017" TOTAL_2="2030" WEIGHT="99.99999999999999" Z="1.3430867466086276">
<NAME>Fatal and non-fatal myocardial infarction</NAME>
<GROUP_LABEL_1>Statins</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Statin better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control better</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.009362066759007" CI_START="0.016785911702309583" EFFECT_SIZE="0.36666666666666664" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9035979265811878" LOG_CI_START="-1.7750550657040625" LOG_EFFECT_SIZE="-0.4357285695614374" MODIFIED="2011-10-31 17:01:41 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="262" O_E="0.0" SE="1.573454027214515" STUDY_ID="STD-Dornbrook_x002d_Lavender-2005" TOTAL_1="9" TOTAL_2="10" VAR="2.4757575757575756" WEIGHT="0.42326009370144063"/>
<DICH_DATA CI_END="1.2314966799812899" CI_START="0.6730410994487467" EFFECT_SIZE="0.9104108300443754" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="79" LOG_CI_END="0.09043324535275157" LOG_CI_START="-0.1719584146485289" LOG_EFFECT_SIZE="-0.04076258464788869" MODIFIED="2011-10-31 17:01:41 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="261" O_E="0.0" SE="0.15413015994441687" STUDY_ID="STD-_x0034_D-Study-2004" TOTAL_1="619" TOTAL_2="636" VAR="0.023756106204491523" WEIGHT="44.11031734228737"/>
<DICH_DATA CI_END="1.109400979219118" CI_START="0.6472832565670016" EFFECT_SIZE="0.8474058523916218" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="107" LOG_CI_END="0.045088544875493644" LOG_CI_START="-0.18890562683747883" LOG_EFFECT_SIZE="-0.07190854098099259" MODIFIED="2011-10-31 17:01:41 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="260" O_E="0.0" SE="0.13744933475403062" STUDY_ID="STD-AURORA-Study-2005" TOTAL_1="1389" TOTAL_2="1384" VAR="0.018892319624325568" WEIGHT="55.46642256401118"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4768360438906198" CI_END="1.7187722579735003" CI_START="0.9636797731656567" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2869910876487554" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="78" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.23521833529214378" LOG_CI_START="-0.01606725639924938" LOG_EFFECT_SIZE="0.10957553944644721" METHOD="IV" MODIFIED="2013-07-28 18:18:38 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.4898590037913436" P_Q="1.0" P_Z="0.08739114966845558" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="WEIGHT" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2008" TOTAL_2="2010" WEIGHT="99.99999999999997" Z="1.7093229218278372">
<NAME>Fatal and non-fatal stroke</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Statin better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo better</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2164985834516626" CI_START="0.9359825378776534" EFFECT_SIZE="1.440348558280707" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="33" LOG_CI_END="0.34566745808095545" LOG_CI_START="-0.028732253584672064" LOG_EFFECT_SIZE="0.15846760224814171" MODIFIED="2011-10-26 05:04:01 +1100" MODIFIED_BY="[Empty name]" ORDER="1395" O_E="0.0" SE="0.21992424394085208" STUDY_ID="STD-_x0034_D-Study-2004" TOTAL_1="619" TOTAL_2="626" VAR="0.04836667307295542" WEIGHT="45.04682267261427"/>
<DICH_DATA CI_END="1.7337483935394007" CI_START="0.7943434682148796" EFFECT_SIZE="1.173538116950644" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="45" LOG_CI_END="0.23898607167194147" LOG_CI_START="-0.09999167125480385" LOG_EFFECT_SIZE="0.06949720020856882" MODIFIED="2011-10-26 05:04:13 +1100" MODIFIED_BY="[Empty name]" ORDER="1396" O_E="0.0" SE="0.19911720416205958" STUDY_ID="STD-AURORA-Study-2005" TOTAL_1="1389" TOTAL_2="1384" VAR="0.03964766099331532" WEIGHT="54.95317732738571"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9859197305979575" CI_END="2.8264361768392883" CI_START="0.5521132123142173" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2492048498928647" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.45123918319452416" LOG_CI_START="-0.2579718598758003" LOG_EFFECT_SIZE="0.09663366165936198" METHOD="IV" MODIFIED="2013-07-28 18:18:38 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.610815839355985" P_Q="1.0" P_Z="0.5932651578451571" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="WEIGHT" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1538" TOTAL_2="1529" WEIGHT="99.99999999999999" Z="0.5341103988641587">
<NAME>Elevated creatine kinase</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-01 12:11:36 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="102" O_E="0.0" SE="0.0" STUDY_ID="STD-Burmeister-2006" TOTAL_1="28" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-01 12:11:43 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="103" O_E="0.0" SE="0.0" STUDY_ID="STD-Lins-2004" TOTAL_1="23" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.043438183395884" CI_START="0.031671747801753206" EFFECT_SIZE="0.4375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.7812840841924895" LOG_CI_START="-1.4993279694758255" LOG_EFFECT_SIZE="-0.3590219426416679" MODIFIED="2011-10-31 18:10:19 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="351" O_E="0.0" SE="1.3396428095365038" STUDY_ID="STD-Saltissi-PD-2002" TOTAL_1="16" TOTAL_2="7" VAR="1.7946428571428572" WEIGHT="9.670482602875992"/>
<DICH_DATA CI_END="7.750685170103297" CI_START="0.4709614992105888" EFFECT_SIZE="1.910569105691057" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8893400963698015" LOG_CI_START="-0.32701459470512473" LOG_EFFECT_SIZE="0.2811627508323383" MODIFIED="2011-10-31 18:13:13 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="329" O_E="0.0" SE="0.7144927665902387" STUDY_ID="STD-Harris-2002" TOTAL_1="82" TOTAL_2="94" VAR="0.5104999135097734" WEIGHT="33.996210516582984"/>
<DICH_DATA CI_END="3.4351950036203327" CI_START="0.3899744259940189" EFFECT_SIZE="1.1574274058075353" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5359513954254009" LOG_CI_START="-0.40896387249619176" LOG_EFFECT_SIZE="0.06349376146460461" MODIFIED="2011-10-31 18:13:04 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="330" O_E="0.0" SE="0.555047905783156" STUDY_ID="STD-AURORA-Study-2005" TOTAL_1="1389" TOTAL_2="1378" VAR="0.3080781777142672" WEIGHT="56.33330688054101"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.952527838803935" CI_END="2.911338986870425" CI_START="0.41177435297908455" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.094903981005345" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.46409277622411255" LOG_CI_START="-0.3853407065439353" LOG_EFFECT_SIZE="0.0393760348400886" METHOD="IV" MODIFIED="2012-03-01 11:58:46 +1100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.8127366305846762" P_Q="1.0" P_Z="0.8558097060863311" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1522" TOTAL_2="1522" WEIGHT="100.00000000000001" Z="0.1817107794928828">
<NAME>Elevated liver function enzymes</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Statin better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control better</GRAPH_LABEL_2>
<DICH_DATA CI_END="78.098188794083" CI_START="0.14031545477219828" EFFECT_SIZE="3.310344827586207" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8926409620993694" LOG_CI_START="-0.8528944918181446" LOG_EFFECT_SIZE="0.5198732351406123" MODIFIED="2011-10-31 18:13:44 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="334" O_E="0.0" SE="1.6127411162508312" STUDY_ID="STD-Burmeister-2006" TOTAL_1="28" TOTAL_2="31" VAR="2.600933908045977" WEIGHT="9.572042964786846"/>
<DICH_DATA CI_END="58.055939483573674" CI_START="0.10765479045892236" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.76384665737327" LOG_CI_START="-0.9679666400291949" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2011-10-31 18:14:24 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="353" O_E="0.0" SE="1.6046806535881213" STUDY_ID="STD-Lins-2004" TOTAL_1="23" TOTAL_2="19" VAR="2.575" WEIGHT="9.668447035490116"/>
<DICH_DATA CI_END="18.03862517679177" CI_START="0.07284916327405619" EFFECT_SIZE="1.146341463414634" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2562034344872057" LOG_CI_START="-1.137575432055242" LOG_EFFECT_SIZE="0.05931400121598193" MODIFIED="2011-10-31 18:13:50 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="335" O_E="0.0" SE="1.4061175556035277" STUDY_ID="STD-Harris-2002" TOTAL_1="82" TOTAL_2="94" VAR="1.97716658017644" WEIGHT="12.591883438655604"/>
<DICH_DATA CI_END="2.7025689404117372" CI_START="0.2529034013471481" EFFECT_SIZE="0.8267338612910967" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.43177678127789776" LOG_CI_START="-0.5970453297051644" LOG_EFFECT_SIZE="-0.08263427421363338" MODIFIED="2011-10-31 17:02:23 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="333" O_E="0.0" SE="0.6043352007430349" STUDY_ID="STD-AURORA-Study-2005" TOTAL_1="1389" TOTAL_2="1378" VAR="0.36522103485712437" WEIGHT="68.16762656106745"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.9839771913147772" CI_END="1.2452126806029726" CI_START="0.8684266919678323" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0398922679837737" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="182" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.09524353466375209" LOG_CI_START="-0.06126683653476368" LOG_EFFECT_SIZE="0.01698834906449422" METHOD="IV" MODIFIED="2012-03-01 11:58:47 +1100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.8585662195289896" P_Q="1.0" P_Z="0.6704818077710863" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="913" TOTAL_2="919" WEIGHT="100.0" Z="0.42548684880403864">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Statin better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control better</GRAPH_LABEL_2>
<DICH_DATA CI_END="70.72295808196499" CI_START="0.12267165733203719" EFFECT_SIZE="2.9454545454545453" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8495604173303466" LOG_CI_START="-0.9112557672335727" LOG_EFFECT_SIZE="0.46915232504838705" MODIFIED="2011-10-31 17:02:27 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="339" O_E="0.0" SE="1.6217170930733664" STUDY_ID="STD-PERFECT-Study-1997" TOTAL_1="54" TOTAL_2="53" VAR="2.62996632996633" WEIGHT="0.32137438493756093"/>
<DICH_DATA CI_END="27.285371978396153" CI_START="0.3298470699657666" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.435929878847171" LOG_CI_START="-0.4816873694078459" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-10-31 17:02:27 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="348" O_E="0.0" SE="1.1264178639834665" STUDY_ID="STD-Chang-2002" TOTAL_1="31" TOTAL_2="31" VAR="1.2688172043010753" WEIGHT="0.6661352075258169"/>
<DICH_DATA CI_END="10.522727533272967" CI_START="0.1637081492942723" EFFECT_SIZE="1.3125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.0221283252850193" LOG_CI_START="-0.7859297011290303" LOG_EFFECT_SIZE="0.11809931207799448" MODIFIED="2011-10-31 17:02:27 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="342" O_E="0.0" SE="1.0620622347471878" STUDY_ID="STD-Saltissi-PD-2002" TOTAL_1="16" TOTAL_2="7" VAR="1.1279761904761905" WEIGHT="0.7493099755435523"/>
<DICH_DATA CI_END="5.324634285066367" CI_START="0.12816272878107046" EFFECT_SIZE="0.8260869565217391" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7262897842362329" LOG_CI_START="-0.8922382543657607" LOG_EFFECT_SIZE="-0.08297423506476391" MODIFIED="2011-10-31 17:02:27 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="343" O_E="0.0" SE="0.9507313817178155" STUDY_ID="STD-Lins-2004" TOTAL_1="23" TOTAL_2="19" VAR="0.9038901601830664" WEIGHT="0.9350735840826534"/>
<DICH_DATA CI_END="4.239597396625859" CI_START="0.1578974192540249" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.6273246167989693" LOG_CI_START="-0.8016249682367697" LOG_EFFECT_SIZE="-0.08715017571890014" MODIFIED="2011-10-31 17:02:27 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="345" O_E="0.0" SE="0.8393720596645176" STUDY_ID="STD-Saltissi-HD-2002" TOTAL_1="22" TOTAL_2="12" VAR="0.7045454545454545" WEIGHT="1.19964411983144"/>
<DICH_DATA CI_END="9.367991071897338" CI_START="0.527143073369529" EFFECT_SIZE="2.2222222222222223" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9716464681629865" LOG_CI_START="-0.2780714957136739" LOG_EFFECT_SIZE="0.3467874862246563" MODIFIED="2011-10-31 17:02:27 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="347" O_E="0.0" SE="0.7340905181848413" STUDY_ID="STD-Dornbrook_x002d_Lavender-2005" TOTAL_1="9" TOTAL_2="10" VAR="0.5388888888888889" WEIGHT="1.568419444390683"/>
<DICH_DATA CI_END="2.857532378509588" CI_START="0.6423003766266009" EFFECT_SIZE="1.3547671840354767" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.4559911600571284" LOG_CI_START="-0.19226182332794103" LOG_EFFECT_SIZE="0.13186466836459368" MODIFIED="2011-10-31 17:02:27 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="344" O_E="0.0" SE="0.3807870113444101" STUDY_ID="STD-Harris-2002" TOTAL_1="82" TOTAL_2="94" VAR="0.1449987480086079" WEIGHT="5.829042135241386"/>
<DICH_DATA CI_END="2.43536718805871" CI_START="0.7021771419039123" EFFECT_SIZE="1.3076923076923077" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.38656445044814164" LOG_CI_START="-0.1535533123052674" LOG_EFFECT_SIZE="0.11650556907143717" MODIFIED="2012-01-03 19:30:53 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="269" O_E="0.0" SE="0.31726784746739783" STUDY_ID="STD-Han-2011" TOTAL_1="57" TOTAL_2="57" VAR="0.10065888703659603" WEIGHT="8.396713261812017"/>
<DICH_DATA CI_END="1.1892503372654588" CI_START="0.795524978774004" EFFECT_SIZE="0.9726655896607431" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="150" LOG_CI_END="0.07527328325570383" LOG_CI_START="-0.09934617934436153" LOG_EFFECT_SIZE="-0.012036448044328869" MODIFIED="2011-10-31 17:02:27 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="346" O_E="0.0" SE="0.10257233671155884" STUDY_ID="STD-_x0034_D-Study-2004" TOTAL_1="619" TOTAL_2="636" VAR="0.010521084258469402" WEIGHT="80.3342878866349"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.0785385173245025E-4" CI_END="1.1141557216874503" CI_START="0.7249781791964303" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8987427810281718" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="162" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.046945894915997044" LOG_CI_START="-0.13967506487341522" LOG_EFFECT_SIZE="-0.046364584978709066" METHOD="IV" MODIFIED="2012-05-24 13:21:36 +1000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.9884971871505577" P_Q="1.0" P_Z="0.33011769934717927" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="WEIGHT" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2008" TOTAL_2="2004" WEIGHT="99.99999999999999" Z="0.9738768551931127">
<NAME>Cancer</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Statin better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control better</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3594840945886604" CI_START="0.5910403059577012" EFFECT_SIZE="0.8963871346746952" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="44" LOG_CI_END="0.13337413088432415" LOG_CI_START="-0.2283829014230772" LOG_EFFECT_SIZE="-0.04750438526937654" MODIFIED="2011-10-31 17:02:31 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="349" O_E="0.0" SE="0.21249787150355795" STUDY_ID="STD-_x0034_D-Study-2004" TOTAL_1="619" TOTAL_2="626" VAR="0.04515534539354263" WEIGHT="26.612573433583236"/>
<DICH_DATA CI_END="1.156037020589904" CI_START="0.7000446523945139" EFFECT_SIZE="0.8995985405913289" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="118" LOG_CI_END="0.06297174202609622" LOG_CI_START="-0.15487425759994491" LOG_EFFECT_SIZE="-0.04595125778692433" MODIFIED="2011-10-31 17:02:31 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="350" O_E="0.0" SE="0.1279638185354262" STUDY_ID="STD-AURORA-Study-2005" TOTAL_1="1389" TOTAL_2="1378" VAR="0.016374738854167487" WEIGHT="73.38742656641675"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="42.877732497570655" CI_END="-34.52658334902022" CI_START="-55.19153380993448" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="MD" EFFECT_SIZE="-44.85905857947735" ESTIMABLE="YES" I2="69.681232558796" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2013-09-02 10:57:49 +1000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="4.701933040651696E-5" P_Q="1.0" P_Z="1.7498541890735823E-17" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="WEIGHT" STUDIES="14" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="218.97906556600714" TOTALS="YES" TOTAL_1="905" TOTAL_2="898" UNITS="mg/dL" WEIGHT="100.0" Z="8.509300746928412">
<NAME>Total cholesterol</NAME>
<GROUP_LABEL_1>Statins</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statins</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-57.809761859195156" CI_START="-154.19023814080484" EFFECT_SIZE="-106.0" ESTIMABLE="YES" MEAN_1="204.0" MEAN_2="310.0" MODIFIED="2012-03-14 07:35:51 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="281" SD_1="38.0" SD_2="60.0" SE="24.587307991842344" STUDY_ID="STD-Saltissi-PD-2002" TOTAL_1="16" TOTAL_2="7" WEIGHT="3.3747465781841846"/>
<CONT_DATA CI_END="33.78632317834495" CI_START="-41.78632317834495" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="150.0" MEAN_2="154.0" MODIFIED="2012-03-14 07:35:51 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="286" SD_1="31.0" SD_2="54.0" SE="19.27909057329555" STUDY_ID="STD-Ichihara-2002" TOTAL_1="12" TOTAL_2="10" WEIGHT="4.705147459136495"/>
<CONT_DATA CI_END="-16.227301336861224" CI_START="-87.77269866313878" EFFECT_SIZE="-52.0" ESTIMABLE="YES" MEAN_1="137.0" MEAN_2="189.0" MODIFIED="2012-03-14 07:35:51 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="287" SD_1="30.0" SD_2="35.0" SE="18.25171224844398" STUDY_ID="STD-Dornbrook_x002d_Lavender-2005" TOTAL_1="5" TOTAL_2="8" WEIGHT="5.033749719882175"/>
<CONT_DATA CI_END="3.1891349745147473" CI_START="-59.189134974514744" EFFECT_SIZE="-28.0" ESTIMABLE="YES" MEAN_1="197.0" MEAN_2="225.0" MODIFIED="2013-05-30 12:00:44 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="309" SD_1="40.0" SD_2="57.0" SE="15.913116373836797" STUDY_ID="STD-Arabul-2008" TOTAL_1="22" TOTAL_2="18" WEIGHT="5.885464594637886"/>
<CONT_DATA CI_END="3.226353989950649" CI_START="-57.22635398995065" EFFECT_SIZE="-27.0" ESTIMABLE="YES" MEAN_1="198.0" MEAN_2="225.0" MODIFIED="2012-03-14 07:35:51 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="283" SD_1="61.0" SD_2="49.0" SE="15.421892559441027" STUDY_ID="STD-PERFECT-Study-1997" TOTAL_1="24" TOTAL_2="29" WEIGHT="6.083777390949538"/>
<CONT_DATA CI_END="7.057192988888026" CI_START="-53.057192988888026" EFFECT_SIZE="-23.0" ESTIMABLE="YES" MEAN_1="156.0" MEAN_2="179.0" MODIFIED="2012-03-14 07:35:51 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="290" SD_1="55.0" SD_2="28.0" SE="15.33558434031203" STUDY_ID="STD-Vernaglione-2003" TOTAL_1="16" TOTAL_2="17" WEIGHT="6.11933790647221"/>
<CONT_DATA CI_END="-48.64886892251273" CI_START="-107.35113107748727" EFFECT_SIZE="-78.0" ESTIMABLE="YES" MEAN_1="163.0" MEAN_2="241.0" MODIFIED="2012-03-14 07:35:51 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="292" SD_1="35.0" SD_2="57.0" SE="14.975342051693422" STUDY_ID="STD-Lins-2004" TOTAL_1="23" TOTAL_2="19" WEIGHT="6.270088647508509"/>
<CONT_DATA CI_END="-34.96025495107181" CI_START="-89.03974504892818" EFFECT_SIZE="-62.0" ESTIMABLE="YES" MEAN_1="127.0" MEAN_2="189.0" MODIFIED="2012-03-14 07:35:51 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="282" SD_1="35.0" SD_2="31.0" SE="13.796041795774947" STUDY_ID="STD-Diepeveen-2005" TOTAL_1="13" TOTAL_2="10" WEIGHT="6.789853184858257"/>
<CONT_DATA CI_END="-12.071155645139452" CI_START="-65.92884435486054" EFFECT_SIZE="-39.0" ESTIMABLE="YES" MEAN_1="170.0" MEAN_2="209.0" MODIFIED="2012-03-14 07:35:51 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="291" SD_1="25.0" SD_2="42.0" SE="13.739458769279352" STUDY_ID="STD-Saltissi-HD-2002" TOTAL_1="22" TOTAL_2="11" WEIGHT="6.8157975861748135"/>
<CONT_DATA CI_END="0.05013206151975069" CI_START="-46.05013206151975" EFFECT_SIZE="-23.0" ESTIMABLE="YES" MEAN_1="142.0" MEAN_2="165.0" MODIFIED="2012-03-14 07:35:51 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="289" SD_1="43.0" SD_2="45.0" SE="11.760487561677792" STUDY_ID="STD-Burmeister-2006" TOTAL_1="27" TOTAL_2="29" WEIGHT="7.778466248163838"/>
<CONT_DATA CI_END="-20.584868918872427" CI_START="-57.41513108112757" EFFECT_SIZE="-39.0" ESTIMABLE="YES" MEAN_1="151.0" MEAN_2="190.0" MODIFIED="2012-03-14 07:35:51 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="284" SD_1="34.0" SD_2="45.0" SE="9.395647688622738" STUDY_ID="STD-UK_x002d_HARP_x002d_I-2005" TOTAL_1="38" TOTAL_2="35" WEIGHT="9.045038271345112"/>
<CONT_DATA CI_END="-45.37437956616375" CI_START="-78.62562043383625" EFFECT_SIZE="-62.0" ESTIMABLE="YES" MEAN_1="165.0" MEAN_2="227.0" MODIFIED="2012-03-14 07:35:51 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="288" SD_1="39.0" SD_2="23.0" SE="8.482615275064756" STUDY_ID="STD-Chang-2002" TOTAL_1="28" TOTAL_2="30" WEIGHT="9.55252852357957"/>
<CONT_DATA CI_END="-47.82840295145022" CI_START="-76.17159704854978" EFFECT_SIZE="-62.0" ESTIMABLE="YES" MEAN_1="136.0" MEAN_2="198.0" MODIFIED="2012-03-14 07:35:51 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="270" SD_1="26.0" SD_2="48.0" SE="7.230539520283805" STUDY_ID="STD-Han-2011" TOTAL_1="57" TOTAL_2="57" WEIGHT="10.245358951835112"/>
<CONT_DATA CI_END="-30.830544611572915" CI_START="-41.16945538842708" EFFECT_SIZE="-36.0" ESTIMABLE="YES" MEAN_1="163.0" MEAN_2="199.0" MODIFIED="2012-03-14 07:35:51 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="293" SD_1="43.0" SD_2="49.0" SE="2.6375257041471625" STUDY_ID="STD-_x0034_D-Study-2004" TOTAL_1="602" TOTAL_2="618" WEIGHT="12.3006449372723"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="88.6901787559345" CI_END="-27.52345752290752" CI_START="-52.46092658858875" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="MD" EFFECT_SIZE="-39.992192055748134" ESTIMABLE="YES" I2="87.597273842157" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2013-09-02 10:58:04 +1000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="3.0309088572266774E-14" P_Q="1.0" P_Z="3.2494513683791523E-10" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="WEIGHT" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="370.77578789130683" TOTALS="YES" TOTAL_1="876" TOTAL_2="871" UNITS="mg/dL" WEIGHT="99.99999999999997" Z="6.286384226532892">
<NAME>LDL cholesterol</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Statin better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control better</GRAPH_LABEL_2>
<CONT_DATA CI_END="-57.45420553686762" CI_START="-138.54579446313238" EFFECT_SIZE="-98.0" ESTIMABLE="YES" MEAN_1="111.0" MEAN_2="209.0" MODIFIED="2011-10-31 17:02:06 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="294" SD_1="20.0" SD_2="53.0" SE="20.687009956791265" STUDY_ID="STD-Saltissi-PD-2002" TOTAL_1="15" TOTAL_2="7" WEIGHT="5.066984481729152"/>
<CONT_DATA CI_END="10.738239846241804" CI_START="-52.738239846241804" EFFECT_SIZE="-21.0" ESTIMABLE="YES" MEAN_1="116.0" MEAN_2="137.0" MODIFIED="2013-05-30 12:01:38 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="310" SD_1="44.0" SD_2="56.0" SE="16.193277068654826" STUDY_ID="STD-Arabul-2008" TOTAL_1="22" TOTAL_2="18" WEIGHT="6.39361130997086"/>
<CONT_DATA CI_END="-40.44346172566187" CI_START="-91.55653827433812" EFFECT_SIZE="-66.0" ESTIMABLE="YES" MEAN_1="50.0" MEAN_2="116.0" MODIFIED="2011-10-31 17:02:06 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="297" SD_1="31.0" SD_2="31.0" SE="13.039289739977287" STUDY_ID="STD-Diepeveen-2005" TOTAL_1="13" TOTAL_2="10" WEIGHT="7.483638557636384"/>
<CONT_DATA CI_END="-14.756584408004692" CI_START="-63.24341559199531" EFFECT_SIZE="-39.0" ESTIMABLE="YES" MEAN_1="96.0" MEAN_2="135.0" MODIFIED="2011-10-31 17:02:06 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="303" SD_1="18.0" SD_2="39.0" SE="12.36931687685298" STUDY_ID="STD-Saltissi-HD-2002" TOTAL_1="22" TOTAL_2="11" WEIGHT="7.726862008922729"/>
<CONT_DATA CI_END="-12.07605202033158" CI_START="-59.92394797966842" EFFECT_SIZE="-36.0" ESTIMABLE="YES" MEAN_1="115.0" MEAN_2="151.0" MODIFIED="2011-10-31 17:27:47 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="295" SD_1="46.0" SD_2="42.0" SE="12.206320201992213" STUDY_ID="STD-PERFECT-Study-1997" TOTAL_1="24" TOTAL_2="29" WEIGHT="7.786411141925987"/>
<CONT_DATA CI_END="-4.149391907372593" CI_START="-49.85060809262741" EFFECT_SIZE="-27.0" ESTIMABLE="YES" MEAN_1="78.0" MEAN_2="105.0" MODIFIED="2011-10-31 17:02:06 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="299" SD_1="17.0" SD_2="25.0" SE="11.658687747769902" STUDY_ID="STD-Dornbrook_x002d_Lavender-2005" TOTAL_1="5" TOTAL_2="8" WEIGHT="7.987244806730136"/>
<CONT_DATA CI_END="-34.704523763844094" CI_START="-75.2954762361559" EFFECT_SIZE="-55.0" ESTIMABLE="YES" MEAN_1="73.0" MEAN_2="128.0" MODIFIED="2011-10-31 17:02:06 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="302" SD_1="25.0" SD_2="39.0" SE="10.35502509038127" STUDY_ID="STD-Lins-2004" TOTAL_1="23" TOTAL_2="19" WEIGHT="8.466785539241357"/>
<CONT_DATA CI_END="37.88947341295993" CI_START="2.1105265870400665" EFFECT_SIZE="20.0" ESTIMABLE="YES" MEAN_1="89.0" MEAN_2="69.0" MODIFIED="2011-10-31 17:26:57 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="301" SD_1="36.0" SD_2="32.0" SE="9.127450072587974" STUDY_ID="STD-Burmeister-2006" TOTAL_1="27" TOTAL_2="29" WEIGHT="8.91272149717097"/>
<CONT_DATA CI_END="-49.31085150779056" CI_START="-78.68914849220944" EFFECT_SIZE="-64.0" ESTIMABLE="YES" MEAN_1="95.0" MEAN_2="159.0" MODIFIED="2011-10-31 17:02:06 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="298" SD_1="29.0" SD_2="28.0" SE="7.494601231489746" STUDY_ID="STD-Chang-2002" TOTAL_1="28" TOTAL_2="30" WEIGHT="9.479311845552832"/>
<CONT_DATA CI_END="-17.46968483576782" CI_START="-42.53031516423218" EFFECT_SIZE="-30.0" ESTIMABLE="YES" MEAN_1="80.0" MEAN_2="110.0" MODIFIED="2011-10-31 17:02:06 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="296" SD_1="24.0" SD_2="30.0" SE="6.393135416298314" STUDY_ID="STD-UK_x002d_HARP_x002d_I-2005" TOTAL_1="38" TOTAL_2="35" WEIGHT="9.831563733807233"/>
<CONT_DATA CI_END="-43.95540104573108" CI_START="-66.04459895426892" EFFECT_SIZE="-55.0" ESTIMABLE="YES" MEAN_1="66.0" MEAN_2="121.0" MODIFIED="2012-01-03 19:31:59 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="271" SD_1="21.0" SD_2="37.0" SE="5.635103012803961" STUDY_ID="STD-Han-2011" TOTAL_1="57" TOTAL_2="57" WEIGHT="10.054260523824778"/>
<CONT_DATA CI_END="-27.285310301385596" CI_START="-34.71468969861441" EFFECT_SIZE="-31.0" ESTIMABLE="YES" MEAN_1="79.0" MEAN_2="110.0" MODIFIED="2011-10-31 17:02:06 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="300" SD_1="30.0" SD_2="36.0" SE="1.8952846725324557" STUDY_ID="STD-_x0034_D-Study-2004" TOTAL_1="602" TOTAL_2="618" WEIGHT="10.810604553487563"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="17.13052758563781" CI_END="-3.043247874637226" CI_START="-32.99532708917403" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="-18.01928748190563" ESTIMABLE="YES" I2="29.949618072120746" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2013-09-02 10:58:18 +1000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.14475303564787434" P_Q="1.0" P_Z="0.018361623015156217" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="WEIGHT" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="195.61781075188782" TOTALS="YES" TOTAL_1="844" TOTAL_2="848" UNITS="mg/dL" WEIGHT="99.99999999999999" Z="2.358243929487727">
<NAME>Triglycerides</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Statin better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control better</GRAPH_LABEL_2>
<CONT_DATA CI_END="120.50051434322968" CI_START="-104.50051434322968" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="212.0" MEAN_2="204.0" MODIFIED="2011-10-31 17:02:14 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="323" SD_1="168.0" SD_2="106.0" SE="57.39927632886083" STUDY_ID="STD-Diepeveen-2005" TOTAL_1="13" TOTAL_2="10" WEIGHT="1.672767861620535"/>
<CONT_DATA CI_END="82.35462215168393" CI_START="-102.35462215168393" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="251.0" MEAN_2="261.0" MODIFIED="2011-10-31 17:02:14 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="326" SD_1="135.0" SD_2="87.0" SE="47.12057103098088" STUDY_ID="STD-Saltissi-PD-2002" TOTAL_1="16" TOTAL_2="7" WEIGHT="2.4166121534102967"/>
<CONT_DATA CI_END="74.08001722592375" CI_START="-106.08001722592375" EFFECT_SIZE="-16.0" ESTIMABLE="YES" MEAN_1="105.0" MEAN_2="121.0" MODIFIED="2011-10-31 17:02:14 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="322" SD_1="56.0" SD_2="109.0" SE="45.96003698867093" STUDY_ID="STD-Dornbrook_x002d_Lavender-2005" TOTAL_1="5" TOTAL_2="8" WEIGHT="2.5297216339733164"/>
<CONT_DATA CI_END="33.60849448124398" CI_START="-101.60849448124398" EFFECT_SIZE="-34.0" ESTIMABLE="YES" MEAN_1="156.0" MEAN_2="190.0" MODIFIED="2011-10-31 17:02:14 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="325" SD_1="104.0" SD_2="178.0" SE="34.49476368674688" STUDY_ID="STD-UK_x002d_HARP_x002d_I-2005" TOTAL_1="38" TOTAL_2="35" WEIGHT="4.213948271726802"/>
<CONT_DATA CI_END="72.90989217345563" CI_START="-48.90989217345563" EFFECT_SIZE="12.0" ESTIMABLE="YES" MEAN_1="218.0" MEAN_2="206.0" MODIFIED="2013-05-30 12:03:55 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="312" SD_1="95.0" SD_2="100.0" SE="31.077046646726718" STUDY_ID="STD-Arabul-2008" TOTAL_1="22" TOTAL_2="18" WEIGHT="5.027079082016687"/>
<CONT_DATA CI_END="11.253517184157175" CI_START="-101.25351718415718" EFFECT_SIZE="-45.0" ESTIMABLE="YES" MEAN_1="150.0" MEAN_2="195.0" MODIFIED="2011-10-31 17:02:14 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="318" SD_1="88.0" SD_2="76.0" SE="28.701301466699256" STUDY_ID="STD-Vernaglione-2003" TOTAL_1="16" TOTAL_2="17" WEIGHT="5.727440644763479"/>
<CONT_DATA CI_END="5.221046794545394" CI_START="-105.2210467945454" EFFECT_SIZE="-50.0" ESTIMABLE="YES" MEAN_1="166.0" MEAN_2="216.0" MODIFIED="2011-10-31 17:02:14 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="320" SD_1="80.0" SD_2="109.0" SE="28.174521180043083" STUDY_ID="STD-Lins-2004" TOTAL_1="19" TOTAL_2="26" WEIGHT="5.900875538847948"/>
<CONT_DATA CI_END="39.71446387400507" CI_START="-53.71446387400507" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="180.0" MEAN_2="187.0" MODIFIED="2011-10-31 17:02:14 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="324" SD_1="85.0" SD_2="88.0" SE="23.834348101537987" STUDY_ID="STD-PERFECT-Study-1997" TOTAL_1="24" TOTAL_2="29" WEIGHT="7.645016410733072"/>
<CONT_DATA CI_END="17.58448953042288" CI_START="-73.58448953042287" EFFECT_SIZE="-28.0" ESTIMABLE="YES" MEAN_1="147.0" MEAN_2="175.0" MODIFIED="2011-10-31 17:02:14 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="315" SD_1="75.0" SD_2="101.0" SE="23.25781998546275" STUDY_ID="STD-Chang-2002" TOTAL_1="28" TOTAL_2="30" WEIGHT="7.926821545756229"/>
<CONT_DATA CI_END="25.52182331708989" CI_START="-63.52182331708989" EFFECT_SIZE="-19.0" ESTIMABLE="YES" MEAN_1="177.0" MEAN_2="196.0" MODIFIED="2011-10-31 17:02:14 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="319" SD_1="68.0" SD_2="58.0" SE="22.715633383201094" STUDY_ID="STD-Saltissi-HD-2002" TOTAL_1="22" TOTAL_2="11" WEIGHT="8.2044782608285"/>
<CONT_DATA CI_END="3.978470111121929" CI_START="-69.97847011112194" EFFECT_SIZE="-33.0" ESTIMABLE="YES" MEAN_1="135.0" MEAN_2="168.0" MODIFIED="2011-10-31 17:02:14 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="316" SD_1="49.0" SD_2="88.0" SE="18.86691306718051" STUDY_ID="STD-Burmeister-2006" TOTAL_1="27" TOTAL_2="29" WEIGHT="10.58499529640161"/>
<CONT_DATA CI_END="40.03543498403736" CI_START="-4.035434984037359" EFFECT_SIZE="18.0" ESTIMABLE="YES" MEAN_1="87.0" MEAN_2="69.0" MODIFIED="2011-10-31 17:02:14 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="321" SD_1="24.0" SD_2="28.0" SE="11.242775458044157" STUDY_ID="STD-Ichihara-2002" TOTAL_1="12" TOTAL_2="10" WEIGHT="18.130838305806368"/>
<CONT_DATA CI_END="-13.794166118630756" CI_START="-52.205833881369244" EFFECT_SIZE="-33.0" ESTIMABLE="YES" MEAN_1="216.0" MEAN_2="249.0" MODIFIED="2011-10-31 17:02:14 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="317" SD_1="162.0" SD_2="180.0" SE="9.799074897734044" STUDY_ID="STD-_x0034_D-Study-2004" TOTAL_1="602" TOTAL_2="618" WEIGHT="20.019404994115153"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="24.159340267432444" CI_END="5.52187763862932" CI_START="-0.3871385736262125" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="2.5673695325015538" ESTIMABLE="YES" I2="50.329769492189406" I2_Q="0.0" ID="CMP-001.13" MODIFIED="2013-09-02 10:58:31 +1000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.01934926278175586" P_Q="1.0" P_Z="0.08854118270266709" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="11.375623323452654" TOTALS="YES" TOTAL_1="888" TOTAL_2="881" UNITS="mg/dL" WEIGHT="100.0" Z="1.703143683468668">
<NAME>HDL cholesterol</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Statin better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control better</GRAPH_LABEL_2>
<CONT_DATA CI_END="61.97741260995873" CI_START="2.02258739004127" EFFECT_SIZE="32.0" ESTIMABLE="YES" MEAN_1="49.0" MEAN_2="17.0" MODIFIED="2011-10-31 17:58:13 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="307" SD_1="50.0" SD_2="16.0" SE="15.294879317383755" STUDY_ID="STD-Ichihara-2002" TOTAL_1="12" TOTAL_2="10" WEIGHT="0.9263194527549448"/>
<CONT_DATA CI_END="7.925575810238271" CI_START="-51.92557581023827" EFFECT_SIZE="-22.0" ESTIMABLE="YES" MEAN_1="38.0" MEAN_2="60.0" MODIFIED="2011-10-31 17:02:10 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="310" SD_1="20.0" SD_2="35.0" SE="15.26843148460247" STUDY_ID="STD-Dornbrook_x002d_Lavender-2005" TOTAL_1="5" TOTAL_2="8" WEIGHT="0.9293819189392798"/>
<CONT_DATA CI_END="39.62616186857669" CI_START="10.373838131423312" EFFECT_SIZE="25.0" ESTIMABLE="YES" MEAN_1="42.0" MEAN_2="17.0" MODIFIED="2011-10-31 17:57:35 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="305" SD_1="38.0" SD_2="8.0" SE="7.4624646085060675" STUDY_ID="STD-Burmeister-2006" TOTAL_1="27" TOTAL_2="29" WEIGHT="3.3883224067965654"/>
<CONT_DATA CI_END="1.6629424921275309" CI_START="-21.66294249212753" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="39.0" MEAN_2="49.0" MODIFIED="2011-10-31 17:02:10 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="314" SD_1="13.0" SD_2="13.0" SE="5.9505902068218255" STUDY_ID="STD-Saltissi-PD-2002" TOTAL_1="15" TOTAL_2="7" WEIGHT="4.856978601356892"/>
<CONT_DATA CI_END="9.892853525550244" CI_START="-9.892853525550244" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="36.0" MEAN_2="36.0" MODIFIED="2011-10-31 17:02:10 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="313" SD_1="12.0" SD_2="12.0" SE="5.04746699612024" STUDY_ID="STD-Diepeveen-2005" TOTAL_1="13" TOTAL_2="10" WEIGHT="6.1660449733233005"/>
<CONT_DATA CI_END="12.026938465499478" CI_START="-4.026938465499478" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="40.0" MEAN_2="36.0" MODIFIED="2011-10-31 17:02:10 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="306" SD_1="13.0" SD_2="10.0" SE="4.095452023003966" STUDY_ID="STD-Saltissi-HD-2002" TOTAL_1="22" TOTAL_2="11" WEIGHT="8.072745069369676"/>
<CONT_DATA CI_END="4.982244468523405" CI_START="-10.982244468523405" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="33.0" MEAN_2="36.0" MODIFIED="2011-10-31 17:58:44 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="311" SD_1="14.0" SD_2="20.0" SE="4.072648544303023" STUDY_ID="STD-UK_x002d_HARP_x002d_I-2005" TOTAL_1="38" TOTAL_2="35" WEIGHT="8.126519249453072"/>
<CONT_DATA CI_END="10.892130409568015" CI_START="-4.892130409568014" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="42.0" MEAN_2="39.0" MODIFIED="2011-10-31 17:02:10 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="312" SD_1="17.0" SD_2="11.0" SE="4.026671138765881" STUDY_ID="STD-PERFECT-Study-1997" TOTAL_1="24" TOTAL_2="29" WEIGHT="8.236205081128169"/>
<CONT_DATA CI_END="10.48106920735955" CI_START="-4.481069207359549" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="37.0" MEAN_2="34.0" MODIFIED="2011-10-31 17:02:10 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="309" SD_1="15.0" SD_2="14.0" SE="3.816942181779496" STUDY_ID="STD-Chang-2002" TOTAL_1="28" TOTAL_2="30" WEIGHT="8.758425149804655"/>
<CONT_DATA CI_END="8.852091896934784" CI_START="-4.852091896934783" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="43.0" MODIFIED="2013-05-30 12:02:33 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="311" SD_1="11.0" SD_2="11.0" SE="3.496029493900505" STUDY_ID="STD-Arabul-2008" TOTAL_1="22" TOTAL_2="18" WEIGHT="9.629457826833223"/>
<CONT_DATA CI_END="13.416075287830473" CI_START="0.5839247121695257" EFFECT_SIZE="7.0" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="38.0" MODIFIED="2011-10-31 17:02:10 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="308" SD_1="13.0" SD_2="8.0" SE="3.2735679524928303" STUDY_ID="STD-Lins-2004" TOTAL_1="23" TOTAL_2="19" WEIGHT="10.285885881250255"/>
<CONT_DATA CI_END="7.507023377394012" CI_START="-3.5070233773940123" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="50.0" MEAN_2="48.0" MODIFIED="2012-01-03 19:32:20 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="272" SD_1="15.0" SD_2="15.0" SE="2.809757434745082" STUDY_ID="STD-Han-2011" TOTAL_1="57" TOTAL_2="57" WEIGHT="11.791915487513231"/>
<CONT_DATA CI_END="3.629137174352814" CI_START="0.3708628256471862" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="39.0" MEAN_2="37.0" MODIFIED="2011-10-31 17:02:10 +1100" MODIFIED_BY="Suetonia Palmer" ORDER="304" SD_1="15.0" SD_2="14.0" SE="0.8312077095310118" STUDY_ID="STD-_x0034_D-Study-2004" TOTAL_1="602" TOTAL_2="618" WEIGHT="18.83179890147673"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-09-02 10:57:19 +1000" MODIFIED_BY="Suetonia Palmer" NO="2">
<NAME>Statin versus another statin</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2013-09-02 10:54:31 +1000" MODIFIED_BY="Suetonia Palmer" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="WEIGHT" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="13" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Elevated liver function enzymes</NAME>
<GROUP_LABEL_1>Atorvastatin</GROUP_LABEL_1>
<GROUP_LABEL_2>Simvastatin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours atorvastatin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours simvastatin</GRAPH_LABEL_2>
<DICH_DATA CI_END="109.22351794710269" CI_START="0.29895632221170326" EFFECT_SIZE="5.714285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.038316160483808" LOG_CI_START="-0.524392257856397" LOG_EFFECT_SIZE="0.7569619513137056" MODIFIED="2013-08-30 11:51:36 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="108" O_E="0.0" SE="1.5053476105442982" STUDY_ID="STD-van-den-Akker-2003" TOTAL_1="13" TOTAL_2="15" VAR="2.2660714285714283" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2013-09-02 10:55:03 +1000" MODIFIED_BY="Suetonia Palmer" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="50.0" SORT_BY="WEIGHT" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="31" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawal due to adverse events</NAME>
<GROUP_LABEL_1>Atorvastatin</GROUP_LABEL_1>
<GROUP_LABEL_2>Simvastatin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours atorvastatin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours simvastatin</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.627941066970436" CI_START="0.19707039305481966" EFFECT_SIZE="2.064516129032258" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3350151775151826" LOG_CI_START="-0.7053786172159535" LOG_EFFECT_SIZE="0.3148182801496145" MODIFIED="2013-08-30 11:51:59 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="109" O_E="0.0" SE="1.1985374151372459" STUDY_ID="STD-Soliemani-2011" TOTAL_1="31" TOTAL_2="32" VAR="1.436491935483871" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2013-09-02 10:57:19 +1000" MODIFIED_BY="Suetonia Palmer" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="WEIGHT" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="13" TOTAL_2="15" UNITS="mg/dL" WEIGHT="0.0" Z="0.0">
<NAME>Total cholesterol</NAME>
<GROUP_LABEL_1>Atorvastatin</GROUP_LABEL_1>
<GROUP_LABEL_2>Simvastatin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours atorvastatin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours simvastatin</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8094031768197196" CI_START="-0.34940317681971966" EFFECT_SIZE="0.22999999999999998" ESTIMABLE="YES" MEAN_1="3.55" MEAN_2="3.32" MODIFIED="2013-08-30 11:52:38 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="110" SD_1="0.89" SD_2="0.63" SE="0.29561929779831564" STUDY_ID="STD-van-den-Akker-2003" TOTAL_1="13" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2013-09-02 10:56:59 +1000" MODIFIED_BY="Suetonia Palmer" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="WEIGHT" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="13" TOTAL_2="15" UNITS="mg/dL" WEIGHT="0.0" Z="0.0">
<NAME>LDL cholesterol</NAME>
<GROUP_LABEL_1>Atorvastatin</GROUP_LABEL_1>
<GROUP_LABEL_2>Simvastatin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours atorvastatin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours simvastatin</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5183862428100965" CI_START="-0.3983862428100964" EFFECT_SIZE="0.06000000000000005" ESTIMABLE="YES" MEAN_1="1.85" MEAN_2="1.79" MODIFIED="2013-08-30 11:55:52 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="111" SD_1="0.67" SD_2="0.55" SE="0.23387482955084307" STUDY_ID="STD-van-den-Akker-2003" TOTAL_1="13" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2013-09-02 10:56:44 +1000" MODIFIED_BY="Suetonia Palmer" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="WEIGHT" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="13" TOTAL_2="15" UNITS="mg/dL" WEIGHT="0.0" Z="0.0">
<NAME>Triglycerides</NAME>
<GROUP_LABEL_1>Atorvastatin</GROUP_LABEL_1>
<GROUP_LABEL_2>Simvastatin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours atorvastatin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours simvastatin</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5418499141706653" CI_START="-0.5818499141706653" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.52" MODIFIED="2013-08-30 11:56:43 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="113" SD_1="0.55" SD_2="0.94" SE="0.28666338698183524" STUDY_ID="STD-van-den-Akker-2003" TOTAL_1="13" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2013-09-02 10:56:31 +1000" MODIFIED_BY="Suetonia Palmer" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="WEIGHT" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="13" TOTAL_2="15" UNITS="mg/dL" WEIGHT="0.0" Z="0.0">
<NAME>HDL cholesterol</NAME>
<GROUP_LABEL_1>Atorvastatin</GROUP_LABEL_1>
<GROUP_LABEL_2>Simvastatin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours atorvastatin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours simvastatin</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.32848291048520883" CI_START="-0.12848291048520888" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="0.9" MODIFIED="2013-08-30 12:00:38 +1000" MODIFIED_BY="Suetonia Palmer" ORDER="112" SD_1="0.35" SD_2="0.25" SE="0.11657505560686467" STUDY_ID="STD-van-den-Akker-2003" TOTAL_1="13" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-09-02 13:19:23 +1000" MODIFIED_BY="Narelle S Willis">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-07-28 17:50:51 +1000" MODIFIED_BY="Narelle S Willis" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study selection flow diagram</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArwAAALgCAYAAAB29qTPAACAAElEQVR42uy9AeSW1////2Hm42Mm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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-09-02 13:19:23 +1000" MODIFIED_BY="Suetonia Palmer" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-09-02 13:19:23 +1000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAXsAAARhCAIAAABMKbIGAABQzElEQVR42u2dv04kOdeHS0JCBAQE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=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-07-30 18:26:50 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-07-30 18:26:50 +1000" MODIFIED_BY="Narelle S Willis" NO="1">
<TITLE MODIFIED="2009-01-21 13:39:46 +1100" MODIFIED_BY="Narelle S Willis">Electronic search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2013-07-30 18:26:50 +1000" MODIFIED_BY="Narelle S Willis">
<TABLE COLS="2" ROWS="4">
<TR>
<TH VALIGN="TOP">
<P>Database</P>
</TH>
<TH VALIGN="TOP">
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CENTRAL</P>
</TD>
<TD VALIGN="TOP">
<OL>
<LI>MeSH descriptor Renal Dialysis explode all trees</LI>
<LI>MeSH descriptor Hemofiltration explode all trees</LI>
<LI>MeSH descriptor Kidney Failure, Chronic, this term only</LI>
<LI>(dialysis):ti,ab,kw in Clinical Trials</LI>
<LI>(hemodialysis or haemodialysis):ti,ab,kw in Clinical Trials</LI>
<LI>(hemofiltration or haemofiltration):ti,ab,kw in Clinical Trials</LI>
<LI>(hemodiafiltration or haemodiafiltration):ti,ab,kw in Clinical Trials</LI>
<LI>(CAPD or CCPD or APD):ti,ab,kw in Clinical Trials</LI>
<LI>(end-stage kidney or end-stage renal or endstage kidney or endstage renal):ti,ab,kw in Clinical Trials</LI>
<LI>(ESKD or ESKF or ESRD or ESRF):ti,ab,kw</LI>
<LI>(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10)</LI>
<LI>MeSH descriptor Hydroxymethylglutaryl-CoA Reductase Inhibitors explode all trees</LI>
<LI>"hydroxymethylglutaryl-CoA reductase inhibitor":ti,ab,kw or "hydroxymethylglutaryl-CoA reductase inhibitors":ti,ab,kw in Clinical Trials</LI>
<LI>"HMG CoA reductase inhibitors":ti,ab,kw in Clinical Trials</LI>
<LI>"HMG CoA reductase inhibitor":ti,ab,kw in Clinical Trials</LI>
<LI>(statin*):ti,ab,kw in Clinical Trials</LI>
<LI>(atorvastatin):ti,ab,kw or (cerivastatin):ti,ab,kw or (dalvastatin):ti,ab,kw or (fluindostatin):ti,ab,kw or (fluvastatin):ti,ab,kw in Clinical Trials</LI>
<LI>(lovastatin):ti,ab,kw or (pitavastatin):ti,ab,kw or (pravastatin):ti,ab,kw or (rosuvastatin):ti,ab,kw or (simvastatin):ti,ab,kw in Clinical Trials</LI>
<LI>(rosuvastatin):ti,ab,kw in Clinical Trials</LI>
<LI>(meglutol or mevinolin or monacolin or pravachol or lipex):ti,ab,kw in Clinical Trials</LI>
<LI>(lipitor or zocor or mevacor or lescol or baycol):ti,ab,kw in Clinical Trials</LI>
<LI>(#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21)</LI>
<LI>(#11 AND #22)</LI>
</OL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MEDLINE</P>
</TD>
<TD VALIGN="TOP">
<OL>
<LI>exp Renal Dialysis/</LI>
<LI>exp Hemofiltration/</LI>
<LI>Kidney Failure, Chronic/</LI>
<LI>dialysis.tw.</LI>
<LI>(hemodialysis or haemodialysis).tw.</LI>
<LI>(hemofiltration or haemofiltration).tw.</LI>
<LI>(hemodiafiltration or haemodiafiltration).tw.</LI>
<LI>(CAPD or CCPD or APD).tw.</LI>
<LI>(end-stage kidney or end-stage renal or endstage kidney or endstage renal).tw.</LI>
<LI>(ESKD or ESKF or ESRD or ESRF).tw.</LI>
<LI>or/1-10</LI>
<LI>exp Hydroxymethylglutaryl-CoA Reductase Inhibitors/</LI>
<LI>"hydroxymethylglutaryl-CoA reductase inhibitor$".tw.</LI>
<LI>"HMG CoA reductase inhibitor$".tw.</LI>
<LI>"HMG Co A reductase inhibitor$".tw.</LI>
<LI>statin$.tw.</LI>
<LI>atorvastatin.tw.</LI>
<LI>cerivastatin.tw.</LI>
<LI>dalvastatin.tw.</LI>
<LI>fluindostatin.tw.</LI>
<LI>fluvastatin.tw.</LI>
<LI>lovastatin.tw.</LI>
<LI>pitavastatin.tw.</LI>
<LI>pravastatin.tw.</LI>
<LI>rosuvastatin.tw.</LI>
<LI>simvastatin.tw.</LI>
<LI>rosuvastatin.tw.</LI>
<LI>(meglutol or mevinolin$ or monacolin$ or pravachol or lipex or lipitor or zocor or mevacor or lescol or baycol).tw.</LI>
<LI>or/12-28</LI>
<LI>and/11,29</LI>
</OL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>EMBASE</P>
</TD>
<TD>
<OL>
<LI>exp Renal Replacement Therapy/</LI>
<LI>(hemodialysis or haemodialysis).tw.</LI>
<LI>(hemofiltration or haemofiltration).tw.</LI>
<LI>(hemodiafiltration or haemodiafiltration).tw.</LI>
<LI>dialysis.tw.</LI>
<LI>(CAPD or CCPD or APD).tw.</LI>
<LI>Chronic Kidney Disease/</LI>
<LI>Kidney Failure/</LI>
<LI>Chronic Kidney Failure/</LI>
<LI>(end-stage renal or end-stage kidney or endstage renal or endstage kidney).tw.</LI>
<LI>(ESRF or ESKF or ESRD or ESKD).tw.</LI>
<LI>or/1-11</LI>
<LI>exp Hydroxymethylglutaryl Coenzyme a Reductase Inhibitor/</LI>
<LI>hydroxymethylglutaryl-CoA reductase inhibitor$.tw.</LI>
<LI>HMG CoA reductase inhibitor$.tw.</LI>
<LI>HMG Co A reductase inhibitor$.tw.</LI>
<LI>statin$.tw.</LI>
<LI>atorvastatin.tw.</LI>
<LI>cerivastatin.tw.</LI>
<LI>dalvastatin.tw.</LI>
<LI>fluindostatin.tw.</LI>
<LI>fluvastatin.tw.</LI>
<LI>lovastatin.tw.</LI>
<LI>pitavastatin.tw.</LI>
<LI>pravastatin.tw.</LI>
<LI>rosuvastatin.tw.</LI>
<LI>simvastatin.tw.</LI>
<LI>(meglutol or mevinolin$ or monacolin$ or pravachol or lipex or lipitor or zocor or mevacor or lescol or baycol).tw.</LI>
<LI>or/13-28</LI>
<LI>and/12,29</LI>
</OL>
<P/>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-04-23 16:44:35 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2013-04-23 16:44:31 +1000" MODIFIED_BY="[Empty name]">Risk of bias assessment tool</TITLE>
<APPENDIX_BODY MODIFIED="2013-04-23 16:44:35 +1000" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="22">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Potential source of bias</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Assessment criteria</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Random sequence generation</B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>Random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimization (minimization may be implemented without a random element, and this is considered to be equivalent to being random).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Sequence generated by odd or even date of birth; date (or day) of admission; sequence generated by hospital or clinic record number; allocation by judgement of the clinician; by preference of the participant; based on the results of a laboratory test or a series of tests; by availability of the intervention.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information about the sequence generation process to permit judgement.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Allocation concealment</B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study (e.g. central allocation, including telephone, web-based, and pharmacy-controlled, randomisation; sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear</I>: Randomisation stated but no information on method used is available.</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>
<B>Blinding of participants and personnel</B>
</P>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</TD>
<TD>
<P>
<I>Low risk of bias</I>:<I> </I>No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias</I>: No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear</I>: Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Blinding of outcome assessment</B>
</P>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors.</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Incomplete outcome data</B>
</P>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data.</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>No missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; missing data have been imputed using appropriate methods.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; &#8216;as-treated&#8217; analysis done with substantial departure of the intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Selective reporting</B>
</P>
<P>Reporting bias due to selective outcome reporting</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>The study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way; the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Not all of the study&#8217;s pre-specified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified; one or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Other bias</B>
</P>
<P>Bias due to problems not covered elsewhere in the table</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>The study appears to be free of other sources of bias.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias:</I> Had a potential source of bias related to the specific study design used; stopped early due to some data-dependent process (including a formal-stopping rule); had extreme baseline imbalance; has been claimed to have been fraudulent; had some other problem.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to assess whether an important risk of bias exists; insufficient rationale or evidence that an identified problem will introduce bias.</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="AFF_4552_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="4552">
<ADDRESS>
<DEPARTMENT>Cochrane Renal Group, Centre for Kidney Research</DEPARTMENT>
<ORGANISATION>The Children's Hospital at Westmead</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Westmead</CITY>
<ZIP>2145</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 2 98451469</PHONE_1>
<PHONE_2/>
<FAX_1>+61 2 98451491</FAX_1>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16154_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16154">
<ADDRESS>
<DEPARTMENT>Department of Emergency and Organ Transplantation</DEPARTMENT>
<ORGANISATION>University of Bari</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Bari</CITY>
<ZIP>70100</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16154_2" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16154">
<ADDRESS>
<DEPARTMENT>Department of Clinical Pharmacology and Epidemiology</DEPARTMENT>
<ORGANISATION>Mario Negri Sud Consortium</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Santa Maria Imbaro</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16154_3" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16154">
<ADDRESS>
<DEPARTMENT>Sydney School of Public Health</DEPARTMENT>
<ORGANISATION>The University of Sydney</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Sydney</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16154_4" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="16154">
<ADDRESS>
<DEPARTMENT>Medical-Scientific Office</DEPARTMENT>
<ORGANISATION>Diaverum</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Lund</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="SE">Sweden</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;b&gt;Comparisons&lt;/b&gt;&lt;br&gt;Statins versus placebo: 23 studies (8166 participants)&lt;br&gt;Two or more statin regimens: 2 studies (123 participants)&lt;/p&gt;" WIDTH="400">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;b&gt;Total included studies: 25 (75 reports)&lt;/b&gt;&lt;br&gt;2009 update: 11 (48 reports)&lt;br&gt;2013 update: 14 new studies (27 reports)&lt;/p&gt;" WIDTH="279">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;b&gt;Ineligible studies: 3 (reassessed 2013)&lt;/b&gt;&lt;br&gt;Dogra 2007 (short duration &amp;lt; 6 weeks); Joy 2008 (duplicate; 2 reports); Fiorini 1994 (wrong intervention)&lt;br&gt;&lt;b&gt;Included studies: 11 (30 reports)&lt;/b&gt;&lt;br&gt;&lt;b&gt;Excluded studies: 12 (12 reports)&lt;/b&gt;&lt;/p&gt;" WIDTH="320">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;b&gt;Included studies&lt;/b&gt;&lt;br&gt;2005 review: 6 (7 reports; 357 participants)&lt;br&gt;2009 update: 14 (32 reports; 2086 participants)&lt;/p&gt;&lt;p&gt;&lt;b&gt;Excluded studies&lt;/b&gt;&lt;br&gt;2005 review: 10 (10 reports)&lt;br&gt;2009 update: 10 (10 reports)&lt;/p&gt;&lt;p&gt;&lt;b&gt;Ongoing studies&lt;/b&gt;&lt;br&gt;2005 review: 4 (4 reports)&lt;br&gt;2009 update: 2 (3 reports)&lt;/p&gt;" WIDTH="320">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;b&gt;MEDLINE, EMBASE, CENTRAL, Renal Register&lt;/b&gt;&lt;br&gt;2004 review: 88 reports&lt;br&gt;2009 update: 115 reports&lt;/p&gt;" WIDTH="320"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;b&gt;New included studies&lt;/b&gt;&lt;br&gt;- 14 (27 reports)&lt;/p&gt;&lt;p&gt;&lt;b&gt;Existing included studies&lt;/b&gt;&lt;br&gt;- 6 (18 new reports)&lt;/p&gt;&lt;p&gt;&lt;b&gt;New ongoing studies&lt;/b&gt;&lt;br&gt;- 4 (4 reports)&lt;/p&gt;&lt;p&gt;&lt;b&gt;Excluded studies&lt;/b&gt;&lt;br&gt;- 16 (20 reports) (wrong intervention; new reports of previously excluded studies)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="320">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;b&gt;2013 review update&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Renal Register: 71 reports identified&lt;/p&gt;" WIDTH="320"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Excluded studies: 28 (33 reports)&lt;/p&gt;" WIDTH="140"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>